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ABSTRACT 
 
 
Substance use, stress, and early childhood trauma are among the most detrimental 
catalysts for chronic psychological, behavioral and health related problems. The Institute of 
Medicine recently released a report on the health and well-being of emerging adults, calling for a 
more comprehensive investigation of the risks, health, safety, and development of marginalized 
emerging adults. In a recent meta-analysis on mindfulness based interventions for substance use 
disorders only one study utilized an emerging adult population – however this study recruited 
college attending emerging adults. While important, no study has assessed the efficacy of 
mindfulness based relapse prevention (MBRP) with a sample of emerging adults recruited from a 
not for profit treatment facility.  The current study used a randomized controlled design to assign 
individuals (N = 79) to receive MBRP or treatment as usual (TAU). Participants were followed 
for six months with assessments occurring on a bi-monthly basis (two week intervals). At each 
time point we measured substance use, craving, and stress. Results indicated significant 
decreases in substance use, stress, and craving for individuals assigned to MBRP versus TAU. 
Further, mediation models revealed a significant indirect effect for reductions in stress during the 
treatment phase and both substance use and craving during the post-treatment phase. This study 
provides further support for the use of mindfulness based interventions and is the first to 
investigate its utility among a sample of marginalized emerging adults. Further, this study 
provides support for reductions in perceived stress to act as a mechanism between reductions in 
both substance use and craving.  
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Chapter 1: Introduction 
Substance use, stress, and early childhood trauma are among the most detrimental 
catalysts for chronic psychological, behavioral and health related problems (Andersen & Teicher, 
2009; Horgan, Skwara, & Strickler, 2001; Lupien, McEwen, Gunnar, & Heim, 2009; Shonkoff, 
Boyce, & McEwen, 2009; Shonkoff & Garner, 2012; Teicher et al., 2003). The American 
Psychological Association defines substance use disorders as the recurrent use of alcohol or 
other drugs that causes significant impaired control, social impairment, risky behaviors and 
health related risks (American Psychiatric Association, 2013). In 2013 over 22 million people 
needed treatment for alcohol or drug use problems; however, only 4.1 million people actually 
received treatment (SAMHSA (NSDUH), 2014). Among treatment admissions, 22% of 
individuals received some form of residential care, and a large proportion (34%) of these 
individuals receiving treatment were emerging adults (ages 18-29; SAMHSA, 2013). In 2000 
Jeffry Arnett laid the groundwork for developing the theory of emerging adulthood, which he 
argued is a distinct and separate developmental period from adolescence and adulthood. 
Specifically, emerging adulthood is the developmental period between the ages of 18 and 29 in 
which individuals begin to separate from their parents and experience autonomy. One of the 
most common activities of emerging adults is drug and alcohol use. As a matter of fact, emerging 
adults have the highest rates of drug and alcohol use compared to adolescents and older adults 
(SAMHSA (NSDUH), 2014). Unfortunately, few studies exist, in comparison to the college 
literature, on interventions for non-college attending emerging adults (Davis, Smith, & Briley, 
2017).  
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The Institute of Medicine recently released a report on the health and well-being of 
emerging adults, (IOM & National Research Council, 2014) calling for a more comprehensive 
investigation of the risks, health, safety, and development of marginalized emerging adults, in 
particular. Marginalized emerging adults – those who have been involved in the child welfare 
system, criminal justice system, or have not attended some form of higher education – have high 
risk for mental and physical health problems, as well as substance use problems (McNiel, 
Binder, & Robinson, 2014; Traube, James, Zhang, & Landsverk, 2012; Walters et al., 2014; 
White, Labouvie, & Papadaratsakis, 2005). Epidemiological studies have found that during this 
developmental period alcohol use increases nearly fourfold, with binge drinking increasing 
fivefold (SAMHSA (NSDUH), 2014). Non-college-attending emerging adults also exhibit 
significantly higher levels of drug use than their college-attending counterparts (White et al., 
2005). In a recent meta-analysis investigating the effect of substance use treatment in non-
college settings for emerging adults Davis and colleagues (in press) found larger treatment 
effects for studies that contained a higher proportion of participants currently in college or 
university.  Results from this study indicate a need to understand, more fully, treatment effects 
among emerging adults outside of the college or university system.  
While numerous risk factors for substance use have been identified, stress remains one of 
the most important contributors (Sinha, 2001; Sinha, 2008). Chronic exposure to stress such as 
adverse childhood events (ACEs; e.g. childhood neglect, abuse, emotional abuse) has been 
associated with increased prevalence of alcohol use, depression, drug use (Bierhaus et al., 2003; 
Edwards, Holden, Felitti, & Anda, 2003; Felitti et al., 1998; Shonkoff & Garner, 2012; Sinha, 
2008), a variety of physical health issues such as cardiovascular disease (Cohen, Janicki-Deverts, 
& Miller, 2007; Miller, Cohen, & Ritchey, 2002) and inflammation-related diseases (Cohen et 
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al., 2012). Specifically, emerging adults experiencing chronic stress compounded from multiple 
ACEs are more likely to use substances and have problems related to substance use such as 
dependence diagnoses, associations with deviant peers, and problems with the law (Andersen & 
Teicher, 2009; Dembo et al., 2000; Paternoster, McGloin, Nguyen, & Thomas, 2013; Schilling, 
Aseltine, & Gore, 2007; Shonkoff & Garner, 2012; Sinha, 2008). In a recent review on the effect 
of stress on long term health outcomes, Thoits (2012) suggests that the top two priorities moving 
forward should be focusing on implementing interventions that effectively buffer the effects of 
stress and focusing on populations that are most at “risk for risk.” This anecdote can easily be 
understood in the context of studying populations such as marginalized emerging adults in 
residential substance use treatment.  
Unfortunately, there is a lack of research on emerging adults in substance use treatment 
outside of college settings compared to college samples despite being the larger subgroup of the 
population of substance users. For example, Davis and colleagues (2017) meta-analyzed 50 
studies over the past 30 years, compared to over 100 studies investigating effects of brief alcohol 
interventions for college students (Borsari & Carey, 2003; Carey, Scott-Sheldon, Carey, & 
DeMartini, 2007; Carey, Scott‐Sheldon, Elliott, Bolles, & Carey, 2009). Further, the majority (> 
50%) of studies in the Davis meta-analysis comprised of brief motivational interviewing or 
cognitive behavioral (CBT) interventions. Results indicated strong effects for CBT and MI 
across studies and effect sizes were, in general, similar to other meta-analyses on college 
drinking interventions (e.g., Carey et al., 2014). That is, CBT tends to be effective in reducing 
drug and alcohol use across emerging adult populations.  
While CBT has proven to be efficacious, more nuanced treatments such as mindfulness 
based interventions also have become widely used. Mindfulness is rooted in Buddhist traditions 
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and is commonly defined as the “state of being attentive to and aware of what is taking place in 
the present” (Brown & Ryan, 2003). Specifically, mindfulness treatments have significant 
advantages over traditional treatments (Brewer et al., 2013) given this approach helps patients 
stay in touch with their present experiences (Chiesa, Anselmi, & Serretti, 2014).  In a recent 
meta-analysis on the effect of mindfulness interventions for substance misuse only one (out of 
42) studies in were focused on emerging adults, unfortunately this study was a convenience 
sample of college students.  Of the remaining studies, only three studies assessed the effect of 
Mindfulness Based Relapse Prevention (MBRP; Bowen & Chawla, 2011; Witkiewitz, Bowen, 
Douglas, & Hsu, 2013). Mindfulness based interventions such as Mindfulness Based Relapse 
Prevention (MBRP) have been integrated with variations of CBT and have been shown to reduce 
depressive symptoms (Zgierska et al., 2008), perceived stress (Brewer, Bowen, Smith, Marlatt, 
& Potenza, 2010) and days of substance use (Bowen & Chawla, 2011; Brewer, Elwafi, & Davis, 
2013). Specific to substance use, MBRP has been shown to improve recovery rates (Marcus & 
Zgierska, 2009; Zgierska et al., 2008) and, simultaneously, reduce physiological and perceived 
stress levels (Matousek, Dobkin, & Pruessner, 2010). While several studies have shown 
promising results of MBRP with adults (e.g. Bowen & Chawla, 2011; Li, Howard, Garland, 
McGovern, & Lazar, 2017; Witkiewitz, Marlatt, & Walker, 2005) little is known regarding how 
MRBP may work for a sample of marginalized emerging adults or the mechanisms though which 
MBRP works.  
The purpose of this study was to investigate the effectiveness of MBRP with emerging 
adults entering residential substance use treatment. Specifically, this study used a randomized 
controlled design to test the effects of MBRP versus treatment as usual (TAU) among a sample 
of marginalized emerging adults. Further, this study investigated mechanisms through which 
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MBRP may work. In particular, we investigated change in perceived stress as a mechanism 
through with MBRP may aid in reducing risk of relapse, days of substance use, and craving 
during the treatment phase as well as the follow-up phase. As a subsidiary analysis, we also 
collected physiological data (hair samples) to assess the effect of MBRP on physiological 
markers of stress. Finally, we explored the potential mitigating effect of ACEs on treatment 
outcomes. Research into the efficacy of treatments for emerging adults is in its infancy – this is 
the first study to investigate the effect of MBRP on a high risk sample of emerging adults and 
one of the few studies to investigate mechanisms of change related to stress response.  
Background 
Prevalence of Substance use among Emerging Adults 
 Emerging adulthood is marked as a time of increased risk for psychopathology and 
substance use (SAMHSA, 2014a; SAMHSA (NSDUH), 2014). Specifically, emerging adulthood 
is a period of life when individuals are most prone to develop one or more substance use 
disorders or addictions (Sussman & Arnett, 2014). Overall, emerging adults exhibit the highest 
rates of cannabis use (19%), alcohol use (59.6%), binge drinking (37.9%), and illicit drug use 
(21.5%) compared to adolescents and older adults (SAMHSA (NSDUH), 2014). Trends in 
overall alcohol use (~60%), binge drinking (~40%; consuming more than 5 drinks) and heavy 
episodic drinking (~13%; having multiple binge episodes in one month) have not changed for 
emerging adults over the past decade – remaining both steady and higher than adolescent and 
older adult rates (Park, Scott, Adams, Brindis, & Irwin, 2014). Similar results were found for 
cannabis use (~19%), with past decade trends remaining flat (e.g. no change) among emerging 
adults. The rate of substance dependence and abuse disorders (18.9%) is also highest among 
emerging adults compared to adolescents and older adults (SAMHSA (NSDUH), 2014). 
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Prevalence rates of substance use among emerging adults is alarming- yet there remain vast 
differences in use among subgroups of emerging adults. In particular it is important to 
acknowledge differences in use among emerging adults in college versus their peers who do not 
attend college.   
Prevalence Rates by Specific Demographic variables  
 Education. Of the 59.4 million emerging adults in the United States the majority (60%) 
are not enrolled in college or university and, of those that do attend college or university only 
28% finish by the age of 25 (Fouad & Bynner, 2008; U.S. Department of Education, NCES, 
2013). Several studies have assessed variation in drug and alcohol use across college attending 
and their non-college attending peers. In 2013 the National Survey on Drug use and Health 
reported illicit drug use to be higher among individuals who did not complete high school 
(11.8%) than those who had graduated high school (9.9%), had some college education (10.8%), 
and those who had graduated from college (6.7%). Alcohol use, on the other hand, shows very 
different results. Overall alcohol use is shown to increase as number of years of education 
increases. For example, among individuals who do not have a high school degree only 36.5% 
were current drinkers compared to the 69.2% of college graduates who were current drinkers. 
Further, individuals who are in college were more likely to report current binge drinking 
(Courtney & Polich, 2009; Gmel, Kuntsche, & Rehm, 2011; Wechsler & Nelson, 2001) and 
heavy episodic drinking (Courtney & Polich, 2009; Gmel et al., 2011) compared to their non-
college peers. However, when one considers high risk behavior such as daily drinking, college 
and non-college attending emerging adults have the same prevalence rates (4%). Drug use 
disorder prevalence is also higher among non-college attending emerging adults compared to 
their college attending peers (Blanco et al., 2008). Finally, non-college attending emerging adults 
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had a higher risk of ongoing drug and alcohol use and problems related to drug and alcohol 
consumption compared to their college bound peers (Thompson, Stockwell, Leadbeater, & 
Homel, 2014; White et al., 2005). When we look at who is entering treatment at publically 
funded facilities – only .06% are referred from school/universities (SAMHSA, 2014) indicating 
emerging adults in public treatment facilities are more likely to present with more severe 
problems. Sahker, Acion, and Arndt, (2014) found college students were more likely to list 
alcohol as their primary problem substance, less likely to have early onset substance use (e.g. 
before age 14), less likely to list illicit drugs as their primary problem, and, most importantly, 
more likely to successfully complete treatment than non-students (56% versus 42%, 
respectively).  
 While we have a vast knowledge on how treatments work on college campus settings and 
with college students – however we do not know how well treatments may work outside of the 
college setting. Using data from above, we can see that treatment completion rates are lower for 
non-college attending emerging adults and many of the referrals to treatment centers in non-
college settings are from criminal justice settings. There is clearly a gap between college and 
non-college attending emerging adults, and this gap is paramount for emerging adults entering 
residential substance use treatment. Finally, if we look back at the Institute of Medicines 
definition of marginalized it is clear that emerging adults entering treatment would fit this 
definition. More research is needed to explore this gap in the literature, especially given the large 
number of emerging adults who are not in college or university.  
Theoretical Orientation: Understanding Emerging Adult and Stress Related Theories 
Theory of emerging Adulthood. Early developmental theory postulated that individuals 
moved from adolescence, the period lasting from puberty through the mid-teens, to young 
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adulthood, which lasted from late teens to about age 40 (Erikson, 1950). While this theory set the 
stage for understanding the life course, as individuals started developing changing attitudes 
toward what was expected of them such as pursuing higher education, and viewing the late teen 
and early 20’s as a time of transition – developmental theory was beckoned to change. In 2000, 
Jeffrey Arnett proposed the theory of emerging adulthood to describe the developmental 
transition between adolescence and young adulthood. Specifically, this period was demarked to 
include individuals between the ages of 18 and 25 (although more recently this has been 
proposed to extend to age 29; Arnett, 2000; Arnett, 2005; Arnett & Tanner, 2006; Côté, 2006) in 
which individuals are delaying traditional adult roles (e.g. marriage, buying a home, settling 
down”, having children) and are now engaging in more identity exploration (Arnett, 2001; Côté, 
2006; Goldscheider & Goldscheider, 1999; Mulder, 2009). Emerging adulthood is also a period 
of instability and individuals are posited to engage in more experimentation (e.g. relationships, 
drugs, alcohol; Sussman & Arnett, 2014). With these developmental transitions in mind, it has 
also been noted that individuals who are characterized as having more identity exploration, 
increased instability and experimentation, and are free from parental monitoring (typically 
characterized in adolescence), and are not burdened with the responsibilities of full-fledged 
adulthood (Sussman & Arnett, 2014) are at increased risk for substance use and psychopathology 
(Schulenberg & Zarrett, 2006; Schulenberg & Maggs, 2002). Taken together, Arnett proposed 
emerging adulthood is a completely separate and distinct developmental period and included five 
dimensions: the age of identity exploration, the age of instability, the self-focused age, the age of 
feeling in-between, and the age of possibilities (Arnett, 2014). The dimensions may help explain 
why substance use and psychopathology rise during emerging adulthood.  
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Theories of self-regulation and stress. Briefly, there are two theories that aid our 
understanding of how early exposure to stress may alter self-regulatory processes (thus 
influencing substance use) and long-term dysfunction. The first is the self-control strength 
model, which posits that self-control is a finite resource and, once depleted, leads to impaired 
self-control (Baumeister & Vohs, 2003; Muraven & Baumeister, 2000). It may be that excessive 
stress stemming from early childhood adversity may lead to a depletion of self-regulation, which 
may in turn affect an individual’s behavior (e.g., increased substance use).  The second is the 
toxic stress or allostatic load model (McEwen, 2012; Shonkoff et al., 2009), which posits that 
the amount of stress an individual experiences over time contributes to pathogenic outcomes 
(Juster et al., 2011).  
Briefly, self-control is the ability to override competing urges or desires and is otherwise 
used to maximize the long-term best interests of an individual (Agnew et al., 2011). The self-
control strength model balances on the tenet that each time an individual self-regulates, they are 
drawing on a resource that, once depleted, results in reduced capacity to regulate emotions or 
impulses (Hagger, Wood, Stiff, & Chatzisarantis, 2010). Thus, when an individual exerts 
repetitive energy to self-regulate behavior, attempts thereafter should, in theory, fail indicating a 
lapse in time when decision making and impulsivity may play a larger role in problematic 
behaviors. Others have tested this model on alcohol consumption finding that exerting self-
control (prior to alcohol consumption) resulted in higher levels of alcohol use (Muraven, Collins, 
& Neinhaus, 2002). Thus, it follows that emerging adults who are exposed to heightened stress 
may be exerting more self-control than those not experiencing stress and, subsequently, may 
have dysregulated self-regulation processes which may be linked to neurological dysfunction 
(e.g., prefrontal cortex, impulsivity) and increased substance use.   
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The toxic stress or allostatic load model underscores the importance of long-term, 
frequent, and prolonged exposure to stressful life experiences and the body’s repeated 
neuroendocrine response (e.g., the way our body responds to stressors). The allostatic load model 
represents this ‘wear and tear’ (Juster et al., 2011; McEwen & Stellar, 1993) on the body and 
highlights the over-activation of the autonomic nervous  system (e.g., sympathetic-adrenal-
medullary (SAM) and the hypothalamic pituitary adrenal (HPA) axis) (Korte, Koolhaas, 
Wingfield, & McEwen, 2005; Sapolsky, Alberts, & Altmann, 1997). Prior studies have found 
that among low income youth, chronic exposure to stress mediates the association between 
poverty and allostatic load in young adulthood (Evans & Kim, 2012). This chronic exposure can 
result in dysregulation of multiple physiological systems which predict deleterious outcomes 
including cognitive functioning, cardiovascular disease, mortality, self-regulation problems, and 
substance use (Romeo & McEwen, 2006). Recently, Evans and Kim (2012) explained that 
chronic exposure to stressors during childhood and adolescence (specifically among low income 
youth) can lead to disruption in self-regulatory processes that aid in coping with external and 
acute stressors later in life. Several studies have echoed these findings such that youth tend to 
have higher concentrations of cortisol (HPA axis) when exposed to stressors (Gunnar et al., 
2009).  
In addition to the stress response system (e.g., HPA axis), exposure to chronic stress, 
absolute levels of stress, and history of stress also  influence the prefrontal cortex, which serves 
as the area of the brain responsible for self-regulation (Pechtel & Pizzagalli, 2011). Prior studies 
have found prefrontal cortex dysfunction to be a phenotype important for the neural basis of 
addiction and is associated with impulsivity which increases risk of alcohol neurotoxicity 
(Reynolds, 2006). For example, studies of adolescents with alcohol use disorder show smaller 
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white and grey matter in the prefrontal cortex compared to adolescents without alcohol use 
disorder (De Bellis et al., 2005). Exposure to trauma, especially during adolescence when the 
brain in maturing and developing (Steinberg & Morris, 2001), can lead to a cascade of negative 
events (McEwen, 2003). As a matter of fact, most theories of addiction posit that acute and 
chronic stress play a large role in motivation to use substances (Koob & Le Moal, 2001; Koob & 
Le Moal, 2005; Koob & Le Moal, 1997; Leventhal & Cleary, 1980; Marlatt & Gordon, 1985;  
Russell & Mehrabian, 1975; Shiffman, 1982; Tomkins, 1966; Wills & Shiffman, 1985). For 
example, Marlatt & Gordon (1985) proposed the relapse prevention model and postulated that, in 
addition to bio-psychosocial risk factors such as deviant peers, parental substance use, and 
positive expectancies of substance use, individuals with poor coping strategies are at increased 
risk of substance use.  
Among one of the more popular theories, the self-medication theory, Khantzian (1985) 
proposed that people use drugs and alcohol to enhance their experiences and mood in an attempt 
to temporally relieve emotional distress. Taking a more biological approach, Koob and Le Moal 
(1997) posited that stress leads to state-related changes in the brain’s neurological circuitry – 
thus resulting in greater sensitivity to the reinforcing properties of substance use and increasing 
motivation and impulsivity to use substances to relieve distress. This may be especially true for 
emerging adults involved in the substance use treatment as they have experienced more trauma 
than community samples (Gordon, 2002), and the biological adaptation that occurs (e.g., 
impairment of HPA axis and prefrontal cortex) may make them more prone to impulsive 
decision making, heightened emotional reactions, and disorganized coping styles (Ford & 
Blaustein, 2013; Ford, Hartman, Hawke, & Chapman, 2008).  
Substance Use Treatment Outcomes among Emerging Adults  
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 In 2013 over 22 million people needed treatment for alcohol or drug use problems; 
however, only 4.1 million people actually received treatment (SAMHSA (NSDUH), 2014). 
Among treatment admissions, 22% of individuals received some form of residential care, and a 
large proportion (34%) of these individuals receiving treatment were emerging adults 
(SAMHSA, 2013). Until recently, many treatments that were developed for adults have been 
implemented with emerging adult populations without modification (Dennis et al., 2003; Muck 
et al., 2001). This is unfortunate, as evidence suggests that emerging adulthood is a period in 
which individuals experience unique aspects development compared to adolescence and in 
young or older adulthood (Arnett, 2000; Arnett, 2005). This is important to consider given how 
little is known regarding how well emerging adults respond to treatment compared to their 
younger (adolescents) and older (older adult) counterparts. Among the studies that have 
investigated these comparisons, all have found that emerging adults have lower treatment 
motivation, report higher substance use and more psychopathology at treatment intake, and have 
worse treatment outcomes. For example,  Dennis, White, & Ives, (2009) used data from over 100 
treatment programs across the United States to compare adolescents (n = 13,625) and emerging 
adults (n = 1,149). At intake emerging adults, compared to adolescents, reported higher risky 
environments (e.g. friends and family members who use substances), more substance use 
treatment episodes, perceived their substance use to be more problematic, had earlier age of 
onset, reported more victimization, and had more involvement in the criminal justice system. In 
another study that compared individuals from adolescence through adulthood – emerging adults 
were most vulnerable to co-occurring psychological and substance use problems compared to 
any other age group (Chan, Dennis, & Funk, 2008). Other studies have found that emerging 
adults have lower motivation for treatment compared to their older adult counter parts 
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(DiClemente, Doyle, & Donovan, 2009; Mason & Luckey, 2003; Satre, Mertens, Areán, & 
Weisner, 2003), indicating that not only are emerging adults worse coming in to treatment but 
they are less motivated which will impact treatment success. In terms of treatment outcomes two 
studies have investigated differences between older adults and emerging adults. Satre et al., 
(2003) showed that emerging adults, compared to their older adult counterparts, had higher rates 
of drug dependence and psychiatric symptoms, were less likely to have abstinence as a goal, and 
had lower post treatment (6 months) abstinence rates. Further, Satre, Mertens, Arean, & Weisner, 
(2004) found that emerging adults, compared to older adults, had less treatment retention, had 
more friends who encouraged drug and alcohol use, and were less likely to report abstinence. 
Smith, Godley, Godley, & Dennis, (2011) compared adolescents and emerging adults who were 
receiving the same treatment, Adolescent Community Reinforcement Approach (ACRA). 
Results indicated emerging adults were less likely to be abstinent at follow up and had more days 
of alcohol use compared to adolescents. Finally, Davis et al., (2016) compared emerging adults 
to older adults in Project Match (Project MATCH Research Group, 1993) across three 
treatments: Cognitive Behavioral Therapy, Motivational Enhancement Therapy, and Twelve-
Step facilitation. Results indicated emerging adults showing significantly worse drinking 
outcomes during the treatment phase (e.g. first 3 months of study). However, these differences 
were no longer present during the year follow up, suggesting that emerging adults may have 
difficulty during the initial treatment phase and ‘catch up’ to older adults after treatment 
completion.   
In general, emerging adults have worse profiles coming in to and out of substance use 
treatment compared to adolescents and older adults. With the low prevalence rate of treatment 
initiation among emerging adults and low treatment motivation it is imperative research continue 
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to develop ways to encourage treatment engagement. Further, results from these studies indicate 
a true need to both view emerging adults as a separate and distinct developmental period and to 
begin to understand what treatments work best for emerging adults. To do this, it is crucial 
practitioners and researchers understand why this developmental period is so unique and what 
aspects of this period are most predictive of substance use. This study will further the literature 
on emerging adulthood and how individuals respond to MBRP. Specifically, this will be the first 
study to investigate the impact of MBRP on an emerging adulthood population – thus furthering 
our knowledge base on the effect of mindfulness based interventions and on the developmental 
period of emerging adulthood.  
Mindfulness Based Treatments for Substance Use Disorders  
Studies of clinical populations have shown that clients entering substance use treatment 
report heightened levels of stress and an inability to adaptively cope with acute stressors (See 
Sinha, 2007 for review). This correlation between stress and increased substance use has led to 
the wide spread use of behavioral interventions (e.g. cognitive behavioral therapy (CBT)) in the 
treatment of addictions (Marlatt & Donovan, 2005; Monti et al., 1999). Though CBT has proven 
to be efficacious, more nuanced treatments such as Mindfulness Based Relapse Prevention 
(MBRP; Bowen et al., 2009; Witkiewitz et al., 2005) have been integrated with cognitive based 
therapies and shown to reduce depressive symptoms (Zgierska et al., 2008), perceived stress 
(Brewer et al., 2010), and days of substance use (Bowen & Chawla, 2011; Brewer et al., 2013). 
Mindfulness is rooted in Buddhist traditions and is commonly defined as the “state of 
being attentive to and aware of what is taking place in the present” (Brown & Ryan, 2003). Some 
researchers have suggested that mindfulness based treatments may have significant advantages 
over traditional treatments (Brewer, Elwafi, & Davis, 2012) given this approach fosters the 
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patients’ ability to stay in touch with their experiences rather than avoid or remove negative 
stimuli (Chiesa et al., 2014). In a recent review of the literature, mindfulness based interventions 
reduced consumption of alcohol, marijuana and opiates as well as reduced cravings compared to 
waitlist controls and support groups (Chiesa & Serretti, 2014). Mindfulness based treatments 
have been associated with structural changes in the brain (Hölzel, Lazar et al., 2011), changes in 
self-perception of stress (Holzel et al., 2010), and reduce cortisol levels thus establishing a direct 
link from mindfulness based treatments and indicators of stress physiology (Brand, Holsboer-
Trachsler, Naranjo, & Schmidtl, 2012; Esch , Duckstein, Welke, & Braum, 2007).  
Efficacy of Mindfulness Based Relapse Prevention  
Recent studies have shown mindfulness based treatments to have medium effect sizes on 
relevant outcomes (d = 0.5; Grossman, Niemann, Schmidt, & Walach, 2004).  These studies also  
show promising results in reducing both perceived and physiological stress, improving substance 
use treatment outcomes, reducing craving, and increasing trait (or state) mindfulness (Bowen & 
Chawla, 2011; Zoogman, Goldberg, Hoyt, & Miller, 2015). In a recent meta-analysis Li and 
colleagues (2017) found an overall effect of mindfulness based treatments of d = -.33 for any 
substance use. Specific to illicit drug use, results were replicated with a Cohen’s d of -.51 for 
opiate use. One of the strongest effects of mindfulness based interventions was on stress with an 
overall effect size of d = -1.21. Thus, the efficacy for mindfulness based interventions is strong, 
yet little is known in regards to how well mindfulness based treatments, specifically MBRP, 
work for emerging adults.  
Specifically, MBRP was developed to target negative thought processes such as 
rumination and craving which both play significant roles in substance use relapse (Witkiewitz et 
al., 2013). Staying true to the principals of mindfulness based practices, MBRP aims to increase 
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a patient’s ability to tolerate problematic cognitive, as well as physiological experiences by 
helping patients to remain present focused which is typically achieved through meditative 
practice (Bowen et al., 2009). This means during treatment participants are taught to “respond” 
to situations that may trigger use or rumination through present-moment focus rather than acting 
or reacting in a habitual manner (Witkiewitz & Bowen, 2010). MBRP adds an interesting aspect 
to mindfulness-based treatments in that the intention is to enhance awareness of their internal and 
external triggers (Bowen, Witkiewitz, Chawla, & Grow, 2011). That is, MBRP adds an element 
of traditional cognitive behavioral exercises that aid in identifying high risk situations while 
creating alternative responses and coping strategies to respond to those triggers (Witkiewitz & 
Bowen, 2010). These skills are vitally important to master as both impulsivity and rumination are 
significant hindrances to post-treatment success. However, to date no study has investigated the 
relationship between receipt of MBRP, changes in perceived (or physiological) stress levels, and 
substance use outcomes (days of use and craving).  
In an early MBRP trial Zgierska et al., (2008) examined the feasibility of implementing 
MBRP with 15 adult outpatients in treatment for alcohol dependence. A large percentage of 
individuals (53%) reported meditating 4 or more days per week in the 2 months following 
treatment. Alcohol outcomes indicated individuals reported fewer heavy drinking days 1 month 
after treatment and significant reductions in stress, depression and anxiety 2 months following 
treatment. These findings spurred two other smaller trials that pulled from various aspects of 
mindfulness based treatments. First, Vieten, Astin, Buscemi, & Galloway (2010) tested an 8-
week manualized coping and relapse prevention program (using aspects of MBRP and other 
mindfulness based interventions) for 23 adults with alcohol use disorders. Individuals reported 
significant decreases in craving, negative affect, emotional reactivity, and perceived stress 
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immediately following completion of the 8-week intervention. However, this study did not find 
significant reductions in drinking. Second, Garland, Gaylord, Boettiger, & Howard (2010) 
randomly assigned individuals (n = 53) with alcohol dependence to a 10-session mindfulness 
based treatment or support group. The researchers were interested in investigating reductions in 
perceived stress, craving, psychiatric symptoms and thought suppression as well as increases in 
heart rate variability. Those assigned to the mindfulness based treatment significantly reduced 
their stress and thought suppression, and increased their physiological recovery from alcohol 
cues (heart rate variability). However, this study did not investigate the impact of reduced 
perceived stress and heart rate variability and subsequent alcohol use outcomes. The proposed 
study will address this gap in the literature by measuring perceived stress as a potential 
mechanism through which individuals remain abstinent (or have less days of use) post treatment 
and craving after receipt of MBRP.  
Later, Bowen et al. (2009) randomly assigned participants (n = 168) to MBRP versus 
standard care. Individuals assigned to MBRP had significantly fewer days of alcohol and drug 
use two months following the intervention. However, these group differences were no longer 
significant at four months. Further, individuals assigned to MBRP showed significant reductions 
in craving and acceptance and a large majority (58%) reported continued practice 4 months after 
completion of treatment.  
In the first evaluation of MBRP as a stand-alone treatment Brewer et al. (2009) randomly 
assigned participants (n = 36) who had alcohol or cocaine use disorders to MBRP or group 
cognitive behavioral therapy. At follow-up, no significant group differences were found for 
substance use outcomes, but those assigned to mindfulness training had significantly better 
reductions in physiological and psychological stress reactivity following a stress provocation lab 
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task. Again, while Brewer and colleagues have shown reductions in stress, this was done by 
assessing stress reactivity within a lab setting. The proposed study will investigate perceived 
stress levels while individuals are both in residential treatment as well as living in the 
community. This level of analysis will add a more comprehensive and “true to life” aspect given 
individuals are likely to experience stressful life experiences once discharged from treatment.  
Most recently, Witkiewitz et al. (2014) investigated the effect of MBRP versus relapse 
prevention among women offenders in residential substance use treatment. Participants (N = 
105) were randomly assigned to receive 8-sessions of MBRP (n = 55) or RP (n = 50). Results 
indicated at 15-week follow up individuals assigned to MBRP showed significantly fewer days 
of drug and alcohol use (d = .36 - .45), and significantly fewer legal problems (d = 1.18) 
compared to individuals assigned to relapse prevention. Bowen et al. (2014) randomly assigned 
adults assigned to MBRP (n = 103), relapse prevention (n = 88), and treatment as usual (TAU; n 
= 95). Compared to TAU, individuals assigned to MBRP and relapse prevention showed a 54% 
decreased risk of relapse for drug use and a 59% decrease risk of relapse to heavy drinking. 
Compared to the relapse prevention group, individuals assigned to MBRP showed a 21% 
increase in risk in relapse for drug use. No significant differences were found between MBRP 
and relapse prevention on any alcohol outcomes. At 6 month follow up individuals in MBRP or 
relapse prevention reported 31% fewer days of heavy drinking and a lower probability of relapse 
compared to TAU participants. No significant differences were found between relapse 
prevention and MBRP at 6-month follow up. Finally, at 12 months individuals assigned to 
MBRP reported 31% fewer drug use days and a significantly higher probability of no heavy 
drinking days compared to relapse prevention participants.  
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Overall, MBRP appears to be effective in reducing substance use, physiological stress, 
perceived stress, negative affect, and cravings. While understanding the main effects of MBRP is 
important for implementation and validation – previous large scale studies (e.g. Project MATCH, 
UKATT) that have sought to find the “best treatment” have found, on average, treatments work 
about the same (Heather et al., 2008; Project MATCH Research Group, 1998). One way to 
understand why treatments work is to investigate mechanisms of change. That is, investigating 
what factors, if any, mediate and moderate the association between group assignment and 
outcomes.  
Among the studies that have used MBRP none have investigated its effects among an 
emerging adult population. This is important for two reasons. First, we know that emerging 
adults have worse treatment outcomes compared to older adults and adolescents. Therefore, it 
may be that, among the trials investigating the impact of MBRP, results will not translate to an 
emerging adult sample. For example, in the most recent study by Bowen and colleagues (2014) 
and Witkeiwitz and Bowen (2014) the average age was 38 and 40 years old, respectively. As 
discussed earlier emerging adults have much lower treatment motivation and a lower percent of 
treatment completion. It may be that MBRP is an appropriate treatment for older adults, but may 
have different effects for emerging adults. That is, treatment may work through “mechanisms” in 
different ways for emerging adults versus older adults given this period of life is a time of 
transition and identity development. Table 1 is an excerpt from Davis and colleagues (2016) 
investigating the differences between emerging adults and older adults assigned to CBT, 
Motivational Enhancement Therapy, and Twelve Step Facilitation from Project MATCH (Allen 
et al., 1997). As emerging adults enter treatment they are coming in with more risky social 
environments (e.g. more support for consumption), less support for abstinence, higher days of 
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substance use, and report more days of traumatic stress/victimization (Davis, Bergman, Smith, & 
Kelly, 2016; Dennis et al., 2009; Smith et al., 2011). With these higher risk profiles it is 
imperative that researchers develop, test, and fully understand which treatments 1) work for 
emerging adults and 2) are developmentally appropriate. Finally, while MBRP has been 
validated as an effective treatment for older adults it is important to determine its effectiveness 
for emerging adults given the large differences that exists between older adults and emerging 
adults. For example, among the studies that have found MBRP reduces both physiological and 
psychological stress, these have been with older adult populations who potentially have more 
salient coping mechanisms. With the amount of transitions and instability that exist during 
emerging adulthood, especially in a population of emerging adults entering residential substance 
use treatment (large percentage are criminal justice referred), reductions in perceived and 
physiological stress may have differential effects – especially for individuals who have 
experienced a large proportion of ACEs.  
 
Table 1. Baseline differences between Emerging Adults and Older Adults M(SD) or n(%) 
 EA 
N = 267 
OA 
N = 1459 
t/χ2 p 
DDD* 14.7 (8.05) 17.0 (11.0) 4.00 <.001 
PDA* 0.40 (0.31) 0.29 (0.30) -5.49 <.001 
Psych Severity 0.23 (0.21) 0.20 (0.19) -1.56 .119 
BDI 10.1 (8.37) 10.2 (8.22) 0.16 .875 
URICA 10.7 (1.73) 10.8 (1.66) 1.03 .302 
DrlnC Total  52.2 (23.0) 51.7 (23.4) -0.30 .762 
DrlnC Interpersonal 11.8 (6.92) 12.3 (6.99) 0.94 .349 
DrlnC physical* 8.37 (4.80) 9.68 (4.94) 3.97 <.001 
DrlnC social* 8.46 (4.56) 7.31 (4.72) -3.65 <.001 
Social functioning  0.47 (0.18) 0.48 (.017) 1.10 .270 
Self-efficacy – confidence 3.12 (.798) 3.04 (0.93) -1.11 .269 
Self-efficacy – temptation  -.120 (1.34) -.134 (1.56) 0.63 .527 
SOCRATES * 11.4 (4.53) 12.0 (4.01) 2.00 .045 
Social support family  4.05 (2.47) 4.20 (2.44) 0.91 .365 
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Table 1 (cont.)     
Social support friends  3.99 (2.24) 3.95 (2.20) 0.01 .989 
Support for abstinence  21.3 (3.72) 21.7 (3.85) 1.61 .108 
Support for consumption * 22.3 (7.98) 19.5 (7.63) -4.63 <.001 
Illicit drug use n (%)* 167 (62.5) 495 (33.9) 78.2 <.001 
EA = emerging adult; OA = older adult; DDD = drinks per dinking day;  
PDA = percent days abstinent; BDI = Becks depression inventory;  
DrlnC = Drinker Inventory of Consequences; SOCRATES = Stages  
Of change Readiness and Treatment Eagerness Scale. 
* p< .05,  
Empirical Evidence of the Stress and Substance Use Relationship 
Early researchers believed that when an organism is stressed the body uses physiological 
signals (e.g. cortisol) to respond to the stressor and eventually return to a homeostatic state 
(Selye, 1982). However, Selye posited that when an organism is exposed to prolonged stressors 
an adaptation takes place and the organism will eventually ‘submit’ to the disease. Though this 
theory was developed nearly 70 years ago, researchers have uncovered a vast array of 
information regarding the neurobiological and psychological aspects of stress.  
For the past 50 years, stress has been associated with negative health outcomes including 
psychological distress, lower reports of well-being, lower life-satisfaction, and physical health 
problems (Thoits, 2010). Researchers interested in the stress response system have primarily 
focused on four major aspects of stress: 1) the events that cause stress (e.g. stressful life events); 
2) the cognitive processes that evaluate the stressor (e.g. appraisal); 3) physiological responses to 
stress; and 4) behavioral responses to the stressor (e.g. coping; Sinha, 2001). In general when an 
individual experiences a stressful event the response is usually one or more conditioned (or 
unconditioned) emotional reactions such as anger, fear, sadness, excitement, or pleasure. 
Regardless of what emotion arises, the reaction is reliant on the appraisal of the event, 
availability of appropriate coping mechanisms, and the prior emotional state of the individual 
(Sinha, 2001). Taken together, all of these “steps” in the stress response system vary within each 
individual based on their prior experiences (e.g. early life stress) and their ability to appropriately 
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appraise the stressor. The variation in these responses is what allows researchers to develop a 
better understanding of how certain individuals respond to treatments and what factors may 
mitigate those responses.  
Early life stress and substance use in non-human studies. In both clinical, population, 
and animal studies chronic stressors such as childhood physical, sexual, and emotional abuse 
have been shown to lead to alcohol or drug use (Andersen & Teicher, 2009; Dembo et al., 2000; 
Gordon, 2002; Sinha, 2008; Weiss et al., 1997). For example, early animal research has shown 
that rhesus monkeys raised by their peers, compared to rhesus monkeys raised by their mothers, 
consumed significantly more alcohol as adults (Higley, Hasert, Suomi, & Linnoila, 1991). 
Interestingly, when stress was induced through social separation, mother-reared monkeys’ 
alcohol intake increased and peer-reared monkeys remained the same, indicating that early life 
stress (e.g. isolation, separation, parental bonding) increases self-administration of alcohol. Other 
results indicate when monkeys are exposed to early life stress they show increased levels of 
corticotrophin releasing factors (CRF) which is linked to chronic distress (Arborelius, Owens, 
Plotsky, & Nemeroff, 1999; Coplan et al., 1996), hypercortisolism (typically found in individuals 
with chronic depression; (Sapolsky, Alberts, & Altmann, 1997), and long-lasting changes in the 
HPA response system, indicating increased sensitivity to behavioral stress response leading to 
increased alcohol intake later in life (Fahlke et al., 2000; Higley et al., 1991; Schneider, Moore, 
Kraemer, Roberts, & DeJesus, 2002).  
Early life stress and substance use in human studies. Studies investigating the impact 
of early life stress in humans have found, in general, individuals who experience ACEs are at 
risk of increased drug and alcohol use (Andersen & Teicher, 2009; Dembo et al., 1988; Dembo 
et al., 2000; Gordon, 2002; Harrison, Fulkerson, & Beebe, 1997; Teicher et al., 2003). Early 
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stress also enhances our stress response system (e.g. reward pathways), such as HPA axis, to 
increase risk of drug use and dependence (see Andersen & Teicher, 2009). In particular, chronic 
exposure to stress has been associated with increased prevalence of alcohol use, depression, and 
drug use (Cohen et al., 2007; Miller et al., 2002). Further, ACEs have also been linked to: 1) 
permanent changes in the HPA axis (Enoch, 2011),  2) altered brain development that negatively 
impacts executive decision-making regarding substance use and other deficits in impulse 
control/disinhibition (Shonkoff & Garner, 2012) , and 3) increased risk of early (< 14 years old) 
alcohol or drug use (Andersen & Teicher, 2009; Dembo et al., 2000; Gordon, 2002; Sinha, 2008; 
Weiss et al., 1997). Individuals who have experienced ACEs may also possess altered stress 
response systems (i.e. altered cortisol secretion, elevated or blunted cortisol) and be at 
heightened risk of substance use relative to those who have not experienced ACEs (Coplan et al., 
1996; Raposa et al., 2014; Shonkoff & Garner, 2012; Sinha, 2008). For example, Tykra et al. 
(2012) found, individuals under a lab stress test, who had experienced more ACEs showed 
increased methylation of genes associated with increased cortisol patterns (Tyrka, Price, Marsit, 
Walters, & Carpenter, 2012). These results suggest that ACEs may lead to modifications in the 
glucocorticoid receptor gene (associated with the HPA axis) which has implications for 
alterations to the stress response system and, more importantly, risk for psychopathology and 
substance use.  
 It is clear that ACEs are an important factor to consider when investigating both stress 
and substance use. As a matter of fact, in a recent review on the impact of stress on long term 
health outcomes, Thoits (2012) suggests that the top two priorities moving forward should be 
focusing on implementing interventions that effectively buffer the effects of stress and focusing 
on populations that are at the highest risk of developing long term dysfunction. The proposed 
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study will utilize a measure of childhood trauma and parental bonding to create a latent construct 
for assessing adverse childhood events. To assess stress, we will use both a perceived stress 
measure as well as a proxy for chronic physiological stress (see next section below). Given 
mindfulness based interventions have been shown to have a profound impact on stress (d = -1.3) 
we will assess the acute (treatment phase) and long term (duration of study) effects of MRBP on 
perceives stress and self-regulation (e.g., impulsivity).  
Overall, the literature on the associations between both current and chronic stress (e.g. 
ACEs) and substance use is vast. As a matter of fact, these associations go back nearly 50 years. 
Our understanding of this association has led to advances in research such as understanding 
various ways to measure stress subjectively (e.g. perceived stress) and objectively (e.g. cortisol, 
HPA axis dysfunction). Interestingly, these two distinct ways of measuring stress have been 
shown to have high correlations such that those who report increased stress also report 
dysfunctional stress response systems. However, one aspect of the literature that has been 
ignored is the role stress (or change in stress) plays as a mechanism of change during 
intervention. Specifically, investigating how interventions that are designed to reduce stress 
impact both perceived and physiological stress patterns can aid our understanding of the process 
through which desired outcomes are achieved. One type of intervention that has received a lot of 
attention in the past several years is mindfulness based treatments.  
Mindfulness, mechanisms of change, and stress 
 Mindfulness based treatments are cited as one of the only treatments to significantly 
lower cortisol levels (acute stress) at post-test compared to control groups, (Brand, Holsboer-
Trachsler, Naranjo, & Schmidt, 2012; Matousek et al., 2010) and completing mindfulness based 
treatments results in reduced perceived and physiological stress patterns (Creswell, Pacilio, 
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Lindsay, & Brown, 2014; Davidson et al., 2003; Matousek et al., 2010). At the epicenter of 
mindfulness based practices is the potential for physiological, psychological and neurobiological 
stress reduction (Jung et al., 2010; Marchand, 2012; Mohan, Sharma, & Bijlani, 2011; Stefano, 
Benson, Fricchione, & Esch, 2005; Stefano, Fricchione, & Esch, 2006). For example, researchers 
have shown that when someone enters a meditative state there is a potential to elicit a “relaxation 
response” (Some researchers have posited that measuring salivary alpha amylase is a proxy for 
the relaxation response; Benson, 2000) which is thought to be an antagonist of the ‘stress 
response’ (Esch, 2014). In general, when under stress our body activates an automatic or “auto 
pilot” response typically in the form of rumination, negative thoughts, assumptions about what 
will happen, and impulsivity (Esch, 2014). In a recent review, researchers found that mindfulness 
may enhance positive emotional regulation strategies, self-compassion, increase trait (or state) 
mindfulness, and decrease rumination and experiential avoidance (Chiesa et al., 2014). Most 
importantly, these mechanisms were found to improve several clinical outcomes including 
depression levels, positive emotions and stress levels.  
From a neurocognitivepoint of view, there have been two proposed pathways to aid in 
explaining the association between mindfulness, drug craving, and stress. The first pathway is 
through a “top down” approach in which individuals exhibit executive control over craving and 
the second, a “bottom up” approach, in which individuals change their subjective experience of 
craving (Westbrook et al., 2013; Witkiewitz et al., 2013). In a secondary analysis Witkiewitz & 
Bowen (2010) sought to test moderated mediation pathways between negative affect, craving, 
and post-treatment substance use outcomes. Results indicated that MBRP attenuated the 
associations between self-reported negative affect scores and craving, with craving significantly 
mediating the relation between treatment assignment and days of drug and alcohol use at follow 
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up. Interestingly, the relationship between negative affect and post-treatment substance use was 
mediated by craving among the TAU group and not MBRP participants. Further analyses 
revealed that the differences in craving between MBRP and TAU groups were partially 
explained by greater mindful acceptance, awareness and nonjudgement among individuals 
assigned to MBRP (Witkiewitz et al., 2013). These results support the purpose and use of 
mindfulness based treatments such that MBRP is designed to help clients experience a challenge 
or difficult situation and not react in an “automatic” way. That is, by actively controlling (“Top 
down”) reactivity individuals are able to effectively alter their conditioned response to craving in 
the presence of negative affective states. Further, results from this study could indicate that 
MBRP (i.e. treatment condition) moderated the mediated pathway from negative affect to 
substance use through craving response, thus it may be that MBRP had a positive impact on 
managing craving.  
Similar pathways have been proposed for stress experience and exposure. For example, 
Sinha (2001) proposed a model in which maladaptive stress response (e.g. higher or lower 
reactivity/sensitivity to stress followed by slow recovery to baseline stress levels) mediate the 
increased frequency and chronic drug use among vulnerable individuals after exposure to a 
stressful situation. That is, when an individual experiences an acute stressor and they have a 
dysfunctional stress response system – that maladaptation may mediate the relationship between 
treatment and subsequent substance use outcomes. Further, Sinha also proposed neuroadaptions 
in the brain’s stress and reward circuits as a moderator that promotes the maladaptive stress 
responses leading to chronic and continued substance use. 
Both of these proposed models indicate various ways in which the stress response system 
can be activated and regulated. These findings indicate that mindfulness, and specifically MBRP, 
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may impact outcomes through reducing subjective experiences of craving, teaching individuals 
to practice acceptance (accepting their current craving as just craving), being nonjudgmental 
(noncritical of themselves and craving), changing the way they react to negative stimuli, changes 
in key areas of the brain (Cingulate cortex, changes in white – and – gray matter), and through 
stress response systems (both perceived and, potentially, physiological). One of the clear 
connections between these models and other theoretical models of stress response is the idea that 
stress regulation (e.g. changes in stress response patterns) can alter long term substance use 
outcomes. Despite efforts at reducing drug and alcohol use, high rates of relapse among 
emerging adults (60% with prior treatment episodes) have not declined. One potential way to 
address this is investigating how treatment may impact changes in our stress response system, 
thus impacting treatment outcomes. That is, investigating how MBRP may impact both 
perceived and physiological stress could impact how individuals respond to treatment. 
Witkiewitz et al., (2013)  hypothesized that long-term effects of MBRP may be observable 
through physiological processes (e.g. alterations in stress response systems such as HPA axis) 
and perceived stress levels and it is important we understand the mechanisms through which 
MBRP improves treatment outcomes. To date only one study has attempted to assess this model 
through changes in hair cortisol concentrations (measure of chronic stress) for cigarette smoking 
(Goldberg et al., 2014).  Results showed HCC was associated with decreases in cigarette 
smoking behavior and negative affect after mindfulness training, indicating that HCC may be a 
key player in understanding changes in other substance use behaviors. 
 In this sense, MBRP may work through reduction in both perceived and chronic stress 
patterns to improve substance use outcomes. Based on previous research we have seen that 
MBRP lends a direct link to reductions in both substance use and craving as well as changes in 
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perceived stress (and on occasion lab tested physiological stress patterns). However, no study has 
tested these potential mechanisms through which MBRP may work. Understanding mechanisms 
of behavior change takes research one step further by asking the question “how does this work” 
versus simply “does this work.” It may be that MBRP is a successful treatment in aiding 
reductions in craving and days of substance use, however this may work primarily through how 
we appraise stress or how our body reacts to stress.  
Summary and Hypotheses 
The primary goal of the proposed study was to examine the effect of MBRP on perceived 
stress, craving and substance use. Further, this study sought to understand how changes in both 
perceived and chronic stress influence days of substance use and craving over six months 
following treatment discharge. The main analysis will investigate perceived stress as the 
mechanism of change. Emerging adults entering residential substance use treatment were 
randomized to treatment as usual plus MBRP (MBRP) or Treatment as Usual (TAU) plus 
additional self-help recovery meetings. The experimental group received treatment as usual 
along with eight sessions of MBRP, while individuals assigned to TAU received treatment as 
usual and attend additional Alcoholics or Narcotics Anonymous meetings. As a secondary goal 
we investigated how changes in stress patterns and subsequent days of substance use were 
moderated by ACEs. This study has 4 hypotheses outlined below.  
Aim 1: Test the effect of MBRP on days of use and craving. This study investigated the effect 
of MBRP vs TAU among high risk 
emerging adults – a developmental 
span known to have the highest 
rate of substance use and relapse 
MBRP vs. 
TAU 
Craving/ 
Substance 
Use H1     H2           
Figure 1. Hypothesized model for H1 through H2.  
-           
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(SAMHSA, 2014b). Specifically, we hypothesize (H1) that (random) assignment to MBRP (vs. 
TAU) will be associated with fewer days of use during the post-treatment phase, and (H2) lower 
craving during the treatment and post-treatment phase (Figure 1).  
Aim 2: Test the effect of MBRP on measures of stress. The third hypothesis (H3) is that 
assignment to MBRP (vs. TAU) 
will result in greater decreases in 
stress during the treatment phase 
and post-treatment phase (Figure 
2). 
Aim 3: Evaluate the extent to which chronic stress mediates the effect of MBRP on 
substance use outcomes and the attenuating effect of ACEs. A full model will be employed to 
test the potential mediating effects of reductions in stress during the treatment phase on 
substance use during the post-treatment phase. Thus, the fourth hypothesis (H4) is that changes 
in stress during the treatment 
phase will mediate the effects of 
treatment assignment (MBRP vs 
TAU) on substance use during 
the follow up phase. 
Specifically, those assigned to 
MBRP will have greater 
reductions in stress during the treatment phase (compared to TAU) and these reductions will act 
as a mechanism in reduced substance use during the post-treatment phase.  Finally, the 
attenuating effect of ACEs (H5) will be assessed as a potential moderator for main effects (e.g., 
 STRESS 
MBRP vs. 
TAU 
Use/craving 
ACEs 
H1    H2     
H3  
H4 
Figure 3. Hypothesized model for H3-H5 
H5 
MBRP vs. 
TAU 
Stress 
 
H3            
Figure 2. Hypothesized model for H1 through H2.  
-           
30 
 
main effects on stress, craving, and substance use) as well as a moderator in our moderated 
mediation model (Figure 3).  Specifically, ACEs will influence stress, craving, and substance use 
for the TAU group only – indicating that those assigned to MBRP will see reductions in all three 
constructs regardless of ACEs experience.  
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Chapter 2: Methods  
Participants 
 This study has been approved, and held up, by the University of Illinois Internal Review 
Board (IRB # 15434) and was supported by a Campus Research Board grant (RB15247 – PI: Dr. 
Brent Roberts), a National Institute on Drug Abuse R36 grant (1R36DA041538 – 01- PI: Jordan 
Davis), and the Fahs-Beck Fund for Research and Experimentation (PI: Jordan Davis). All 
participants provided informed consent prior to participating. The study was conducted at one 
site, the Prairie Center Residential Substance Use Treatment Center in Champaign Illinois, a 
nonprofit public treatment facility. All participants (N = 79) had at least one diagnosed substance 
use disorder. All participants had a wide range of involvement in illegal activities such as drug 
use, drug possession, drug manufacturing, burglary, prostitution, and vandalism. The most 
common substances were heroin (n = 26, 32.5%), methamphetamine (n = 21, 26.3%), cannabis 
(n = 12, 15%), alcohol (n = 8, 10%), crack/cocaine (n = 6, 7.5%), and other drugs (e.g., bath 
salts, synthetic cannabis; n = 7, 7.5%). For participants to be admitted to the treatment facility 
each participant took and passed a drug screening through urine analysis. Participants were 
allowed to be positive for cannabis and barbiturates as these substances have a long half-life. 
Given this aspect of admittance into the facility participants had very few substance using days 
in the two weeks prior to entering treatment.  
Design and Procedure 
 Recruitment for the study began on September 1st, 2015 and ended on November 15th 
2016. Inclusion criteria for the study were residency at the treatment center, between the ages of 
18 and 29, proficiency in the English language, and clear cognitive ability to understand and 
provide consent.   
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Recruitment and consenting. During the standardized intake procedure that each 
participant underwent as a new patient at Prairie Center, individuals who were within the 18-29 
year old age range were given a study flyer and a demographics and interest sheet (See Appendix 
A). Research team members were notified of incoming emerging adults a week prior to their 
arrival. The project manager and Co-PI (Jordan Davis) retrieved demographic and interest sheets 
each day at the Prairie Center and set up a time for the following day to meet with interested 
participants. Prior to entering the study, each participant met with a member of the research staff 
to discuss the purpose of the study, what role they would play, the difference between 
experimental and control groups, intake and follow up procedures, and expectations during the 6-
month study period. If participants agreed to enter the study, they completed an informed written 
consent (See Appendix B) prior to commencing the study. Each participant was read the 
informed consent documents and was given a copy of the signed consent. All participants who 
consented to participate in the study did not accrue any costs.  
Following consenting procedures all participants underwent an initial baseline 
assessment. The baseline assessment took, on average, between 40 and 60 minutes to complete. 
Assessment procedures included gathering Locator Information from each participant. Locator 
information was used to track participants once they were discharged (or in the case that 
participants were excused from the Prairie Center for disciplinary reasons). We asked 
participants to provide us with the contact information for close family members, friends, 
relatives, or spouses/partners. We asked, specifically, for participants to provide both phone 
numbers, addresses, and e-mail addresses for their locators. When communicating with 
participants (by e-mail or telephone) we referred to the trial as a “the stress study” and did not 
reveal that the trial involved interventions to treat substance use disorders. Similar procedures 
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were used when contacting a close friend or family member from the “Locator Form.” When 
communicating with individuals listed by a participant we began by stating “We are attempting 
to get in contact with (NAME). He/she is involved in a study with the University of Illinois on 
stress, and they are due for a follow up assessment.”  At no time was any information be relayed 
to individuals listed by participants as their locator contact regarding substance use treatment or 
services they had received from the University of Illinois or Prairie Center. Immediately 
following data collection on locators, research assistants began the baseline assessment using the 
online platform Qualtrics. All measures (see “measures” section below) were uploaded to 
Qualtrics for online assessments. Qualtrics LLC., our main outcome instrument, is an online 
survey instrument that may be accessed via e-mail or mobile technology. While there exists the 
potential for a breach of confidentiality, Qualtrics LLC has put security measures in place to 
safeguard against these. First, the Qualtrics system complies with HIPAA security requirements 
for secure web transmission of data. All data stored on their servers are firewall protected, with 
vulnerability scans and backups performed nightly. Second, Qualtrics uses Transport Layer 
Security encryption when data is being transferred via the web. All complete survey data are 
encrypted and hosted by a third-party data center which is SSAE-16 SOC II certified. More 
information on Qualtrics security and system can be found at www.qualtrics.com.   
After consenting participants were randomized to receive MBRP or TAU. Treatment 
allocation was performed randomly by an online “Clinical trial randomizer” 
(www.randomization.com; Suresh, 2011) to assign individuals into their respective groups.  
Therapists were not blind to treatment allocation, however research assistants aiding in the 
follow-up assessments were blind to treatment allocation.  
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Assessments. During the treatment phase (approximately 4-6 weeks post baseline 
assessment) participants, regardless of treatment allocation, completed follow-up assessments 
(see “Instruments and Measures” section below for list of measures used in follow up and Table 
2 for trial procedures) every two weeks. 
Table 2. Time Line for Trial Procedures  
 1st Year 2nd 
Year 
   
 Intake Residential 
Stay 
Discharge Bi-Monthly 
follow-up 
Quarterly 
follow -up 
 
Randomization  X      
Tx   X     
Assessments X X X X   
Cortisol (Hair)  X  X  X  
Data Analysis       X 
  
That is, if an individual remained in treatment at the Prairie Center for 30 days, they 
completed the baseline assessment and two follow up assessments. Follow-up assessments were 
shorter, taking approximately 20 - 30 minutes to complete. All follow-up assessments collected 
data on substance use, perceived stress, craving, coping, mindfulness, and emerging adult 
development. Once participants were discharged from the Prairie Center, we continued to contact 
individuals for follow-up assessments every two weeks for the remaining time in the 6-month 
study period. One of the major differences between this study and other studies was our approach 
to assessment. Our approach used assessments on a bi-monthly basis, as opposed to traditional 
methods that assess on a quarterly basis (e.g. 3, 6, 9 month follow-up). The major advantage of 
this approach is that we could assess nuanced changes in behavioral measures, thus allowing us 
to determine more precisely when individuals were at most risk for relapse, which in turn will 
contribute to the field’s understanding of how to time and structure post-discharge treatments.  In 
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total, if a participant were to complete each assessment (including baseline) we had 15 data 
points over a 6-month period.  
Remuneration. Each participant received $10.00 for each assessment they completed. If 
an individual completed all of the assessments over the 6-month period they earned a total of 
$150.00. Further, we also provided a bonus drawing twice during the follow-up period. For each 
completed assessment the individual was entered into a drawing for a $150.00 dollar gift card. If 
an individual completed 5 assessments over the 6 months they had 5 chances (versus 1) to win 
the gift card drawing.  
Treatment Protocols  
 MBRP. Individuals assigned to the experimental group received the treatment normally 
provided by the Prairie Center as well as eight 1.5-hour group sessions of MBRP. Sessions 
occurred twice weekly given the average residential stay is one month. This allowed us to deliver 
all 8 sessions, which are typically delivered over an 8-week period. MBRP treatment was 
delivered at the Prairie Center Inpatient Unit by the PI, Jordan Davis, and by an advanced 
mindfulness instructor, Ellen Ritter, MA.  Jordan Davis’ mindfulness instructor training included 
completion of the required participation in an 8-week MBCT class in April 2015, personal daily 
practice, and successful completion of the UIUC Psychology Department’s Mindfulness 
Instructor Training Practicum (Psychology 546). The Instructor Training Practicum began in the 
summer of 2015 with completion of “teachbacks” of the MBCT/MBRP guided mindfulness 
practices.  The weekly practicum continued through the 2015/2016 academic year and included 
discussions of mindfulness research articles and dharma articles/talks; engagement with solo and 
interpersonal mindfulness practices; and clinical supervision provided by Dr. Chris Menard. 
Jordan met with Dr. Menard for weekly supervision during the mindfulness practicum and then 
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as needed in the summer and fall of 2016. Therapists abided by the principles and methodology 
established in Mindfulness-Based Relapse Prevention for Addictive Behavior: A Clinician’s 
Guide (Bowen & Chawla, 2011). One important difference in our delivery of MBRP compared 
to the standard version is the use of rolling groups. We developed a protocol which allowed us to 
enroll individuals as they enter treatment at the Prairie Center, rather than employ the standard 8-
week cohort based protocol. To do this we implemented a “common” start to each session which 
included a short discussion (5 – minutes) on the triangle of awareness (see Figure 4), and a short 
(5-10 minutes) meditation incorporating the triangle of awareness streaming into the SOBER 
breathing space meditation. This common beginning also included distributing handouts to any 
new participants which included a “what is mindfulness” handout, a “understanding the triangle 
of awareness” handout, and instructions on how to do the SOBER breathing space (See appendix 
C).   
 
Session Content. Each session targeted a specific theme such as awareness of personal 
triggers, present focus, allowing/letting be, responding to emotional and physical experiences in 
skillful ways, intrusive thought recognition, or kindness in action. Table 3 displays each of the 8 
Body 
Sensations 
Emotions 
Thoughts 
Figure 4. Triangle of Awareness 
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sessions, theme, goals, and what meditations are taught.  For example, two of the more 
prominent techniques are the SOBER breathing space and “Urge Surfing” in which participants 
were taken through steps to remove themselves from what is known as “automatic pilot” mode 
and bring their awareness to the present moment. Individuals were encouraged to make each of 
the exercises their own such that each person used their present experience as the catalyst for 
mindful practice. Participants were be trained on how to utilize mindfulness practices and given 
homework of 20-30 minutes per day. Homework assignments included guided mindfulness 
meditations that corresponded to the prior session as well as some light paper-based homework. 
Participants were also provided materials (e.g. recordings) with which to practice meditation 
during their stay in treatment as well as after discharge. Participants were asked to report how 
many times they practiced mindfulness meditation, how long, and which guided practices they 
used during the treatment phase and at all follow-ups. Individuals in the MBRP group were also 
asked about Alcoholics and Narcotics Anonymous attendance.  
 TAU. Those assigned to the control group (TAU) received treatment normally provided 
by the Prairie Center and were asked to attend up to eight extra social support groups (Alcoholics 
and Narcotics Anonymous) during the residential stay. This approach was taken to mitigate the 
possibility that treatment effects were solely due to the experimental group receiving “extra” 
attention. Attendance at extra support group meetings were equated to the number of hours the 
experimental group received additional MBRP sessions. The basic treatment practice employed 
at the Prairie Center was a mix of cognitive behavioral treatment and 12-step approach to 
recovery. Individuals were asked to report how many Alcoholics and Narcotics Anonymous 
meetings they attended during the treatment phase and at all follow-ups. Like the experimental 
group, individuals in the TAU group were also asked about mindfulness practices.  
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Table 3. Mindfulness Based Relapse Prevention Session Content 
Session Theme Skills acquired Meditations 
Session 1  
 
“Stepping out of 
Autopilot and Anchoring 
in the Present Moment” 
When we experience 
cravings and urges to use 
alcohol or drugs, we often 
engage in reactive 
behaviors, acting on them 
without full awareness of 
what is occurring and 
what the consequences 
will be. On automatic 
pilot, it is easy to drift 
unaware into “doing” 
mode and the ruminative 
thought patterns that can 
tip us back into relapse. 
Habitual doing mode also 
robs us of our potential 
for living life more fully. 
We can transform our 
experience by 
intentionally paying 
attention to it in particular 
ways. 
 
• Mindful of daily 
activity  
• Understanding of 
Auto-pilot  
• SOBER breathing 
space  
• Mindful eating  
• Anchoring in the 
breath 
Session 2 
 
“Using Mindfulness to 
Cope with Triggers and 
Craving” 
 
This session focused on 
recognizing triggers and 
introduces the practice of 
experiencing them 
without automatically 
reacting. We begin by 
learning to identify 
triggers and observe how 
they often lead to a chain 
of sensations, thoughts, 
emotions, and behaviors. 
Mindfulness can bring 
this process into 
awareness, disrupting 
automatic reactive 
behaviors and allowing 
greater flexibility and 
choice. 
• Noticing triggers and 
how to deal 
successfully with 
them  
• Disruption of the 
automatic process 
 
• Urge Surfing  
• Mountain Meditation  
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Table 3. (cont.) 
 
Session 3 
 
“Mindfulness in Daily 
Life”  
 
Mindfulness meditation 
can increase our 
awareness and 
subsequently help us 
make better choices in our 
daily lives. Because 
breathing is always a 
present-moment 
experience, pausing and 
paying attention to the 
breath is a way to return 
to the present moment and 
bring awareness back to 
the body. With this 
presence and awareness, 
we are often less reactive 
and can make decisions 
from a strong, clearer 
place. The SOBER 
breathing space is a 
practice that can extend 
this quality of 
mindfulness from formal 
sitting or lying-down 
meditations into the daily 
situations and challenges 
we encounter.  
 
 
• Integrating SOBER 
breathing space into 
daily life 
• Bring awareness to 
daily activities  
 
• Awareness of 
Hearing  
• Breath meditation  
Session 4 
 
“Mindfulness in High 
Risk Situations”  
In this session, we focus 
on staying present in 
challenging situations that 
have previously been 
associate with substance 
use or other reactive 
behavior. We learn how 
to relate differently to 
pressures or urges to use 
substances and practice 
responding to highly 
evocative stimuli with 
awareness rather than 
reacting automatically or 
out of habit.  
 
• Remaining present 
focused in 
challenging situations  
• Working with 
craving and high risk 
situations 
• Sitting meditation: 
Sound, breath, 
sensation, thought 
• SOBER breathing 
space in a 
challenging situation  
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Table 3. (cont.) 
Session 5 
 
“Acceptance and Skillful 
Action” 
 
It is important to find the 
balance between 
accepting whatever arises 
while also encouraging 
healthy or positive action 
in our lives. When we 
fight against these things, 
however, we tend to feel 
frustrated, angry, or 
defeated, which can be 
triggers for substance use. 
When we accept the 
present as it is, we are not 
being passive. We are 
allowing what already is 
without struggle or 
resistance. This is often a 
necessary first step 
toward change. The same 
is true of self-acceptance; 
it often requires a 
complete acceptance of 
ourselves just as we are 
before real change can 
occur 
• Acceptance practice  
  
• Sitting meditation: 
sound, breath, 
sensation, thought, 
emotion 
• Sober breathing 
space in a difficult 
situation  
 
Session 6 
 
“Seeing Thoughts as 
Thoughts” 
 
We have practiced 
noticing our minds 
wandering and labeling 
what is going on in our 
minds as “thinking.” We 
have practiced gently 
returning the focus of 
attention to the breath or 
body. Now we want to 
turn our focus to thoughts, 
and begin to experience 
thoughts as just words or 
images in the mind that 
we may or may not 
choose to believe. We 
will discuss the role of 
thoughts and belief in 
thoughts in the relapse 
cycle 
 
• Understanding 
thoughts as thoughts 
• Working through 
relapse cycle and 
how/when we can use 
SOBER breathing 
space to break that 
cycle 
 
• Sitting meditation: 
thoughts  
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Table 3. (Cont.) 
 
Session 7 
 
“Self-Care and Lifestyle 
Balance”  
 
We have spent some time 
paying close attention to 
the specific situations, 
thoughts, and emotions 
that put us at risk for 
relapse. In this session, 
we take a look at the 
broader picture of our 
lives, and identify those 
aspects that support a 
healthier, more vital life 
and those that put us at 
greater risk. Taking care 
of oneself and engaging in 
nourishing activities are 
an essential part of 
recovery.  
 
 
• Nourishing and 
depleting activities  
• Where does relapse 
begin and how can 
meditation aid in 
reducing risk 
 
• LovingKindness  
Session 8 
 
“Social Support and 
Continuing Practice”  
Recovery and 
mindfulness practice are 
both lifelong journeys that 
require commitment and 
diligence. This is not an 
easy voyage. In fact, it 
can feel at times like 
swimming upstream. 
Hopefully, this group has 
provided you (or will 
provide you) with a sense 
of community and 
support. Having a support 
network is crucial to 
continuing along the path 
of practice and recovery. 
Having a recovery 
support network can help 
us recognize signs of 
relapse and provide 
support when we feel we 
are at risk. Having 
support around our 
meditation practice can 
help us sustain our 
practice and choose to 
show up for our lives in a 
mindful, intentional, and 
compassionate way.  
 
• Understanding the 
importance of a 
social support 
network 
• Practice outside of 
group and its benefits 
 
• Body scan 
• Walking meditation  
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Treatment fidelity. To prevent bias, therapists were not involved in follow-up 
assessments with the experimental group and were blind to participant responses on all outcomes 
during the treatment and follow up phase. To assess treatment fidelity, the clinical advisor, Dr. 
Chris Menard, attended 16 random sessions throughout the study period. Dr. Menard observed 
each of the 16 sessions in their entirety and rated both therapists using the MBRP Adherence and 
Competence Scale (MBRP-AC) to rate each therapist on style/approach, delivery, attitude, 
inquiry, and adherence to the manual (See Appendix D; Chawla et al., 2010). Dr. Menard acted 
as the clinical supervisor for the entirety of the project. Both therapists met with Dr. Menard 
weekly for supervision.  
 In general treatment adherence refers to the extent to which an intervention is prescribed 
through a treatment manual, is actually delivered to the participants (Waltz, Addis, Koerner, & 
Jacobson, 1993). Competence, however, refers to the actual ability (or skill) of the therapist to 
deliver the treatment (Waltz et al., 1993). The ability to track and assess these treatment integrity 
constructs is essential to the external and internal validity of a study protocol and its findings 
(Bellg et al., 2004). Accounting for the differential adherence, or skill, of therapists aids in 
reducing unaccounted variability and helps determine, to a certain extent, how the treatment 
itself is explains study outcomes (Bellg et al., 2004).  
The MBRP-AC contains two main sections, Adherence and Competence, of which both 
have two subscales. The adherence subscales are: MBRP Treatment Components and Discussion 
of Key Concepts. The Adherence to MBRP Treatment Components is assessed using a “check 
list” of the major topics that are covered in each section to ensure both therapists delivered these 
components. The Adherence to MBRP Treatment Components contains 10-items. The original 
MBRP-AC guide has 10 items for the first session and 7 thereafter. Because we utilized a rolling 
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admissions framework, we incorporated all 10 items for each session as the three additional 
items relate to newcomer or ‘new participant’ material. Example of these check list items are 
“discussion of group format and structure,” “what is mindfulness discussion,” and “discussion 
group structure and format.” The Discussion of Key Concepts subscale assesses the ability of the 
therapists to incorporate the main, or key, concepts from MBRP into the in-session exercises and 
when responding to clients. This subscale, unlike the Adherence to MBRP Treatment 
Components, contains 4 items which are rated using behavioral counts (e.g. tally) of instances of 
each behavior. Example items for the Adherence to MBRP Key Concepts include 
“Noticing/Awareness of Current Experience,” “Acceptance of Current Experience,” and 
“Acceptance versus Aversion.”  
The Competence section also retains two subscales including Therapist Style and 
Approach and Overall Therapist Performance. The Therapist Style and Approach subscale 
consists of 4-items that are rated on a 5 point Likert scale where 1 = low ability and 5 = high 
ability. Therapists are rated on their general competence (e.g. therapists to respond to inquiry 
with open questions, without judgment, and with an open curiosity) as well as mindfulness 
therapist competence (e.g. ability to describe and explain misconceptions of mindfulness based 
practices). Example items include “Inquiry: therapists ability to elicit and respond to both verbal 
and non-verbal feedback)” and “Attitude: therapists ability to model and embody the spirit of 
mindfulness (respond to participants in a way that is curious, focused in the present moment, and 
non-judgmental/accepting of whatever participants bring up.”  The Overall Therapist 
Competence subscale intends to capture therapist’s global competence of treatment delivery such 
as maintaining on topic, not striving, working as a team during group sessions. This subscale 
consists of 4-items that are rated on a 5 point Likert scale in which 1 = not satisfactory and 5 = 
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excellent. Example items include “How would you rate the overall quality of therapy in this 
session?”, “How would you rate the ability of the therapists to work as a team?” and “Please rate 
the overall quality of delivery of the meditation exercise.”  The MBRP-AC has high internal 
consistency with Chronbach α’s ranging from 0.82 to 0.86 (Chawla et al., 2010). Further, 
adherence to the MBRP manual, as rated by the MBRP-AC has been shown to be positively 
associated with post-treatment mindfulness development among participants during the 
intervention (Chawla et al., 2010).  
Measures 
We used the web-based assessment tool Qualtrics LLC for all assessments. Time Line 
Follow Back (Sobell & Sobell, 1992) was used to assesses participants’ recent (past 2 weeks) 
which has been shown to have excellent reliability and validity (Carey, 1997). Copies of 
instruments are in Appendix D.  
Measures of substance use. The Substance Frequency Scale (M. L. Dennis, Funk, 
Godley, Godley, & Waldron, 2004) was used to assess a count of the number of days each 
participant has used a variety of drugs and alcohol. The SFS is the average percent of alcohol, heavy 
alcohol, cannabis, illicit drug, and problems associated with substance use. Higher scores on this scale 
represent increasing frequency of substance use days. Example items include “in the past 2 weeks… how 
many days have you used any kind of alcohol?”, “…used any marijuana?” The SFS also asks about binge 
drinking, which refers to the number of days each individual has drank 5 or more drinks (4 or more for 
females) in one sitting. The SFS has shown good reliability with both adolescent and emerging adult 
samples (Buchan, Dennis, Tims, & Diamond, 2002; Dennis et al., 2002; Lennox, Dennis, Scott, & Funk, 
2006) (α =.85; test-retest rho=.94; self-reported days of use across a variety of substances).   
Craving scale. The items on the craving scale correspond to new DSM V criteria for 
craving. Composite scores were used as one of our primary outcome variables. The Craving 
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Scale includes 14 items has been retained from the GAIN assessment tool (M. L. Dennis, Titus, 
White, Unsicker, & Hodgkins, 2003). Example items include “If I were using alcohol or other 
drugs, I would feel less nervous”, “Using alcohol or other drugs would make things seem just 
perfect”, and “All I want to do is use alcohol or other drugs.” Each item is answered using “yes” 
(coded 1) or “no” and scores will be summed across the 12 items. Reliability for this scale was  α 
=.80 for this sample. This measure was administered at baseline and all follow-ups. 
Childhood trauma questionnaire short form (CTQ-S). The CTQ-S (Bernstein et al., 
2003) is a 25-item measure developed from the original 70 item measure. The CTQ-S was used 
to assess trauma experienced before the age of 16. Participants are primed to answer each item 
with the anchor “Prior to the age of 16…” Example items include “I didn’t have enough to eat”, 
“people in my family called me “stupid”, “lazy”, or “ugly””, “people in my family looked out for 
each other”, and “I believe I was physically abuse.” Each item is rated on a 5-point Likert scale 
ranging from 1 = Never True to 5 = Very Often True.  This measure, administered at baseline 
only, has been validated in emerging adulthood samples. Initial studies with the original CTQ 
with adult substance users has shown excellent test-retest reliability as well as convergent and 
discriminant validity (Bernstein et al., 1994; Foote & Lovejoy, 1995). The CTQ-S has 5 distinct 
subscales including “emotional abuse” (α = .90), “Physical abuse” (α = .92), “Sexual abuse” (α = 
.95), “emotional neglect” (α = .92), and “physical neglect” (α = .79) (Bernstein et al., 2003).  The 
overall reliability of the CTQ-S was high (α = .92). The CTQ-S has high convergent and 
discriminate validity when tested against therapist ratings of abuse and neglect among 4 
psychiatrically referred groups (r = .28 - .51; e.g. mental health patients and substance use 
patients).  
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Stress. To measure stress the Perceived Stress Scale (PSS; Cohen, Kamarck, & 
Mermelstein, 1983) was used. Assessing objective measures of stress implies that the events are 
the precipitating cause of behavior, whereas utilizing a measures of perceived stress allows for 
the appraisal of stressful life events from the perspective of the participant (Cohen et al., 1983). 
An important theoretical aspect of understanding perceived stress is the causal event is the 
cognitive emotional response to an event, and not necessarily the event itself (Lazarus, 1974). 
This, then, inherently suggests that the response is not based only on the event occurring but also 
the contextual and personal factors associated with the event. The perceived stress scale is 14 
items and had good reliability in this sample (α =.83). The PSS has also been validated in studies 
with adolescents, emerging adults, and older adults. Items from the PSS are answered on a 5-
point Likert scale ranging from 0 = Never to 4 = Very Often. Participants are primed with the 
anchor “in the past two weeks…” Example items include “How often have you been upset 
because of something that has happened unexpectedly?”, “How often have you felt that things 
were going your way?”, and “How often have you been angered because of things that happened 
that were outside of your control?”  
Mindful Attention Awareness Scale (MAAS). The MAAS (Brown & Ryan, 2003; 
MacKillop & Anderson, 2007) was used to assess trait (and state) mindfulness. Specifically, the 
MAAS measures a conceptualization of mindfulness as “attention to, and awareness of, what is 
occurring in the present moment” (Brown & Ryan, 2003), p. 824). The MAAS has been shown 
to have discriminate validity by differentiating between general public and Zen Buddhist 
practitioners (Brown & Ryan, 2003). The MAAS has shown high reliability (α = .82-.87) and has 
been used to assess changes in well-being, depression and anxiety symptoms (Zvolensky et al., 
2006), and substance use disorders (Leigh, Bowen, & Marlatt, 2005). In this sample the MAAS 
47 
 
had good reliability α = .85. Participants were asked a series of questions relating to daily 
experiences and how frequently they have each experience. All questions were rated on a 6-point 
Likert scale ranging from 1 = Almost Always to 6 = Almost Never. Example items include “I 
could be experiencing some emotion and not be conscious of it until sometime later”, “I forget a 
person’s name almost as soon as I’ve been told it for the first time”, “I do jobs or tasks 
automatically, without being aware of what I’m doing”, and “I find myself listening to someone 
with one ear, doing something else at the same time.” The MAAS was administered at baseline 
and all follow-up assessments.  
Data Analytic Plan 
 Baseline differences. The first step in the data analysis plan is to assess group 
differences on a variety of baseline measures. To do this a series of t-test and chi-square tests 
were conducted using treatment assignment (MBRP = 1, TAU = 0) as the classification variable.  
Change in stress, craving and substance use. To assess change across the three 
variables of interest (stress, craving, and substance use) a series of multi-level growth models 
(MLM), structural equation models (SEM) and Cox proportional hazard regression models (a 
form of multilevel modeling) were run. In general, growth models (regardless of framework) 
allow for a specific within-person trajectory such that rates of change are constant within-people 
but are allowed to vary between people. Typically in latent growth modeling two latent variables 
are created: latent intercept and latent slope. The latent intercept represents the level (or mean) 
differences between people at the baseline assessment. The latent slope represents the rate of 
change over the observation period. The advantage of using growth modeling is both the latent 
intercept and latent slope are allowed to vary across people and co-vary with each other.  
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To assess change across the three variables of interest (stress, craving, and substance use) 
a series of models were run. Specifically, for each variable of interest, both an SEM and MLM 
model were tested to ensure effects were robust across methods. Across all three variables 
several models were tested: 1) general linear growth independent of treatment assignment, 2) 
general bilinear spline growth model, independent of treatment assignment, 3) effect of treatment 
assignment on both linear and bilinear spline growth models, and 4) multi-group latent growth 
and bilinear spline modeling. In addition to running an SEM and MLM model for substance use 
a survival model was used to assess time to relapse across groups. For example, when assessing 
stress, a taxonomy of models was run for the general trend of stress across the study period (e.g., 
growth of stress regardless of treatment assignment), general trend of stress during the study 
period and follow up period (e.g., bilinear spline growth model regardless of treatment 
assignment), a time-invariant predictor model of both linear and bilinear spline functions (e.g., 
the effects of treatment assignment on stress), and finally testing invariance across groups (e.g., 
treatment assignment) on trajectories of stress. Below, a general description of multi-level 
modeling, structural equation modeling, multi-group analysis, and survival analysis is discussed 
and how each method was used to address specific research questions.  
Multilevel modeling framework  
To assess treatment assignment on main effects of stress, craving, and substance use we 
first explored these associations in a multi-level modeling framework. Multilevel models allow 
us to address within and between person questions about change, simultaneously. The way this is 
done is by specifying a level-1 model (or how each person changes over time) and a level-2 
model (how changes differ across people). The level-1 model represents how each individual is 
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expected to change during the study period (also known as the individual growth model). A 
representative level-1 model (EQ 1) in which change is a linear function of time is:  
𝑌𝑖𝑗 = [𝜋0𝑖 + 𝜋1𝑖(𝑇𝐼𝑀𝐸𝑖𝑗)] + [𝜀𝑖𝑗]   (EQ 1) 
Here, 𝑌𝑖𝑗 represents the repeated measured variable (e.g., stress, craving, substance use) at for 
individual i at time j, 𝜋0𝑖 represents the random intercept or the predicted score for individual i 
when time equals zero. This represents the ‘true’ score at baseline.  𝜋1𝑖 is the random slope or 
linear rate of change for individual i for a one unit change in time. This is the most important 
aspect of the individual level model because it represents change over time. Because our time 
variable is in two week intervals, 𝜋1𝑖 represents individual i’s true rate of change over a two-
week span. Finally, the stochastic part of the level-1 model 𝜀𝑖𝑗 represents random error. This is 
also sometimes referred to as level-1 residuals, as each residual can represent the part of 
individual i’s value of, say stress, that is not predicted by time. Assumptions of level-1 residuals 
is normally distributed 𝜀𝑖𝑗  ~ 𝑁(0, 𝜎𝜀
2). The level-2 model allows the exploration of 
interindividual differences across change trajectories (level -1) and associations with time-
invariant predictors. The level-2 model accounts for basic patterns for the repeated measured 
variable (e.g., this is the between-group difference across intercepts and slopes) as well as 
heterogeneity of between-person patterns within groups. Each level-2 sub model must: 1) 
accommodate each part of the level-1 growth parameters (intercept, slope, random effects), 2) 
each part of the level -2 model must specific a relationship between time invariant predictors 
(e.g., treatment assignment) and individual growth parameters, and 3) allow for stochastic 
variation across individual growth trajectories. Thus, the level-2 sub model (EQ 2) would be:  
 
𝜋0𝑖 = 𝛾00 + 𝛾01𝑀𝐵𝑅𝑃𝑖 + 𝜉0𝑖  (EQ 2) 
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𝜋1𝑖 = 𝛾10 + 𝛾11𝑀𝐵𝑅𝑃𝑖 + 𝜉1𝑖    
Here, 𝛾00, 𝛾01, 𝛾10, and 𝛾11 are all the fixed effects in the multilevel model. These parameters are 
able to capture systematic between-person differences in change trajectories based on values of 
the level-2 time invariant predictors (treatment assignment). The stochastic part of the level-2 
sub model represent the portion of the level-2 outcomes (i.e. ,random between-person variation 
in the lavel-1 parameters) that remain unexplained by any predictor in the level-2 model (in this 
case, treatment assignment). However, given we have a level-2 predictor and because these 
parameters describe the ‘unexplained’ variance around the intercepts and slopes, these are 
typically referred to as conditional residual variances. These variance parameters allow us to 
explore how much heterogeneity in change remains after accounting for the effect of treatment 
assignment on the outcome of interest. Just like with the level-1 residuals, there are assumptions 
that underlie the distribution of the level-2 conditional residual variances. Specifically, level-2 
residual variances (EQ 3) are assumed to be bivariate normal with a mean of 0 and unknown 
variance:  
[
𝜉0𝑖
𝜉1𝑖
] ~𝑁 ([
0
0
] , [
𝜎0
2 𝜎01
𝜎10 𝜎1
2 ])   (EQ 3) 
 
Thus, using the framework a taxonomy of models was run across the three variables of interest. 
Specifically a random intercept model (Model 1), an unconditional growth model (Model 2), an 
uncontrolled effects of MRBP on outcome (Model 3), and a controlled effects of MRBP on 
outcomes (Model 4; controlling for time spent in facility). In addition to testing main effects and 
variation in rates of change across MBRP and TAU participants multilevel modeling was also 
used to assess the mitigating effects of childhood trauma on initial levels and rates of change 
across stress, craving, and substance use.  
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Latent growth modeling  
 Linear growth model. In addition to assessing our research questions in a multilevel 
modeling framework each question will also be assessed using structural equation modeling 
(SEM) as a latent growth model. Latent growth models differ from multilevel models such that 
each are fit using restricted common factor models with the intercept and slope being represented 
by latent variables. The most basic growth model (EQ 4) with restricted factors is written as 
follows:  
𝑌𝑖 =  𝛬𝜂𝑖 + µ𝑖   (EQ 4) 
Where 𝑌𝑖 represents a vector of repeated measures of an observed score for individual i, 𝛬 is a 
vector matrix of factor loadings that define the growth function (e.g., latent factors for intercept 
and slope), 𝜂𝑖 represents a vector of factor scores for each individual i, and µ𝑖 is a vector of 
residual variances. Factor scores for 𝜂𝑖 are expressed as a vector of factor means and residual 
variance 𝜂𝑖 = 𝛼 + 𝜉𝑖. Similar to the multilevel modeling framework, residuals in a latent growth 
of SEM framework follow certain assumptions. Specifically, the means (µ) and covariance’s 
(𝛴)for a simple latent growth model are assumed to be homogeneous (although this can be 
relaxed and tested) such that:  
µ =  𝛬𝛼    (EQ 5) 
𝛴 =  𝛬𝛹𝛬′ + 𝛩   (EQ 6) 
An illustration of a basic latent growth model with a latent intercept and slope is represented in 
Figure 5. 
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Figure 5. Squares represent manifest or observed variables, circles represent latent factors, one headed arrows represent a 
directional relationship, and two headed arrows represent non directional relationships such as variance and covariance. This latent 
growth model represents all time points for the current study (15 total per participant). 𝜂1 = latent intercept, 𝜂2 = latent slope,   𝛹 = 
variance and covariance of the latent intercept and slope, 𝛼 = mean intercept and slope, 𝜃 = residual variance. 
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Using this basic linear growth model framework a series of models were fit for each of the three 
variables of interest. Specifically, a general trend across the entire sample (e.g., in the absence of 
treatment assignment) was estimated where model testing was used to assess the variance 
associated with random linear and quadratic slopes as well as constrained versus free residual 
variances. Negative two log likelihood (-2LL) ratio tests (LRT) were conducted to assess the 
addition of random latent slopes into the general growth modeling framework. For example, a 
model with constrained linear growth to zero is tested using LRT to a model where linear growth 
is allowed to vary freely. Significant reductions in -2LL using a LRT test (𝜒2 distribution) using 
𝛥 − 2𝐿𝐿 𝑎𝑛𝑑 𝛥 𝑑𝑒𝑔𝑟𝑒𝑒𝑠 𝑜𝑓 𝑓𝑟𝑒𝑒𝑑𝑜𝑚 indicate significant increased model fit with the addition 
of a random linear slope.  
Bilinear spline (or piecewise) growth models. In addition to fitting linear growth 
models, piece wise growth models were estimated. Bilinear spline models were used to assess 
the effects of treatment assignment (MBRP vs TAU) during the treatment phase and post-
treatment phase. Bilinear spline models are useful when there are reasons to separate time into 
discrete phases. The usefulness of bilinear spline models is it allows growth (time) to be split 
into discrete phases which can be used to aid in explaining observed rates of change within each 
phase. Each discrete phase is usually a simple growth model and the segments that connect the 
growth models are called knot points or sometimes referred to as transition points. In the current 
study we expect different growth trajectories to emerge during the treatment phase and post-
treatment phase for both stress and craving (substance use is only measured during the post-
treatment phase due to no variability during treatment since each participant was in a residential 
facility).  While a quadratic function can be estimated after a knot point, for simplicity we 
estimated a bilinear spline model with the distinct phases being treatment phase (slope 1) and 
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post-treatment (slope 2). An example of a bilinear spline model with 6 equally spaced time 
intervals is displayed in Figure 6. Only 6 time points are shown as an example of this type of 
model as placing all 15 time points into each theoretical model is difficult to discern.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Diagram of a bilinear spline model with six equally spaced time interval. 𝜂1 = latent 
intercept, 𝜂2 = latent slope for treatment phase, 𝜂3 = latent slope for post-treatment phase,   𝛹 = 
variance and covariance of the latent intercept and slope, 𝛼 = mean intercept and slope, 𝜃 = residual 
variance.  
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A bilinear spline model can easily be fit by adjusting the elements of the 𝜦 matrix that 
follow the function of time that is needed (e.g., linear, quadratic, centering the intercept at a 
certain time point). For example, if we use Figure 6 as our model the new 𝜦 matrix (EQ 6) for a 
bilinear spline model would be:  
 𝜦 =  
[
 
 
 
 
 
 
 
 
 
 1 𝑚𝑖𝑛 (
1−𝑘1
𝑘2
, 0) 𝑚𝑎𝑥 (
1−𝑘1
𝑘2
, 0)
1 𝑚𝑖𝑛 (
2−𝑘1
𝑘2
, 0) 𝑚𝑎𝑥 (
2−𝑘1
𝑘2
, 0)
1 𝑚𝑖𝑛 (
3−𝑘1
𝑘2
, 0) 𝑚𝑎𝑥 (
3−𝑘1
𝑘2
, 0)
1 𝑚𝑖𝑛 (
4−𝑘1
𝑘2
, 0) 𝑚𝑎𝑥 (
4−𝑘1
𝑘2
, 0)
1 𝑚𝑖𝑛 (
5−𝑘1
𝑘2
, 0) 𝑚𝑎𝑥 (
5−𝑘1
𝑘2
, 0)
1 𝑚𝑖𝑛 (
6−𝑘1
𝑘2
, 0) 𝑚𝑎𝑥 (
6−𝑘1
𝑘2
, 0)]
 
 
 
 
 
 
 
 
 
 
   (EQ 6) 
 
Here the first column of the matrix represents the intercept (loadings of 1 to identify), the second 
column is the slope before the knot point (in the current study this would be the treatment phase) 
and the third column represents the slope after the knot point (in the current study this would be 
the post-treatment phase). Thus, if we look at the 𝜦 matrix in terms of factor loadings (EQ 7) we 
would have:  
𝜦 = 
[
 
 
 
 
 
1 −2 0
1 −1 0
1 0 0
1 0 1
1 0 2
1 0 3]
 
 
 
 
 
   (EQ 7) 
 
 
In the current study a taxonomy of bilinear spline models was estimated. Using this bilinear 
spline growth model framework a series of models was fit for each of the three variables of 
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interest. Specifically, a general trend across the entire sample (e.g., in the absence of treatment 
assignment) was estimated where model testing was used to assess the variance associated with a 
bilinear spline growth factor and the functional form of the data. Negative two log likelihood (-
2LL) ratio tests (LRT) were conducted to assess the addition of random latent slopes into the 
general growth modeling framework. Since bilinear spline models have two slopes a series of 
nested models were tested to see if random slopes were needed during the treatment phase and 
post-treatment phase. Significant reductions in -2LL using a LRT test (𝜒2 distribution) using 𝛥 −
2𝐿𝐿 𝑎𝑛𝑑 𝛥 𝑑𝑒𝑔𝑟𝑒𝑒𝑠 𝑜𝑓 𝑓𝑟𝑒𝑒𝑑𝑜𝑚 indicate significant increased model fit with the addition of a 
random slope.  
 Linear and bilinear spline growth models with a time invariant predictor. To assess 
the effect of treatment assignment on growth of stress, craving and substance use a series of 
linear growth models (see “Linear growth model” above) and bilinear spline models (see 
“Bilinear spline (or piecewise) growth models” above) were estimated. When introducing a 
time-invariant covariate we can answer the question “are between-person differences in the 
trajectories of change for stress, craving, and substance use related to treatment assignment?” 
This is the first step in understanding if treatment assignment is associated with change in our 
variables of interest. This type of model was discussed above from a multi-level modeling 
framework. However, when assessing the effects of a time-invariant covariate within latent 
growth models, we use multiple-indicator multiple-cause (MIMIC) modeling (Jöreskog & 
Goldberger, 1975; McArdle & Epstein, 1987). Thus, the time-invariant covariate could be 
considered a causal predictor of the latent variables (e.g., intercept, slope, bilinear spline). Thus, 
when adding a time-invariant covariate a slight change in the foundation model for latent growth 
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(EQ 4) is made such that the latent factors (e.g., intercept and slope) are regressed on the time-
invariant covariate.  
𝑌𝑖 =  𝜦𝜂𝑖 + µ𝑖   (EQ 4) 
𝜂𝑖 = 𝛼 + 𝑩𝑿𝒊 + 𝝃𝒊  (EQ 8) 
 
Where 𝛼 represents a vector of latent intercepts, 𝑩 is a matrix of regression coefficients, X is the 
matrix of time-invariant covariates (this can include any number of time-invariant covariates, 
however for the current study this would represent treatment assignment), and 𝝃𝒊 represents a 
vector of residuals. Figure 7 is a diagram of a bilinear spline model with a time-invariant 
covariate. A similar model could be produced for a basic linear growth model by simply 
excluding the second slope (𝜂3) and all arrows, variances, and covariances associated with it. In 
this figure the time-invariant covariate has a mean (𝜔) and variance (𝜙) as well as effects on the 
intercept and slopes (𝛽). For the current study both a latent linear growth model and a bilinear 
spline model were estimate with time-invariant covariates. Specifically, the best fitting model 
from the overall trend for the latent linear growth and bilinear spline models were used to 
estimate treatment effects using a time-invariant covariate latent growth model across stress, 
craving, and substance use. For the latent linear growth model the intercept, slope, and quadratic 
slope (if applicable) were regressed on the treatment assignment variable (1 = MBRP, 0 = TAU). 
For the bilinear spline model the treatment the intercept, treatment slope, and post-treatment 
slope were regressed on the treatment assignment variable. In addition to understanding the basic 
between group differences in the treatment effect the amount of variance explained by the 
treatment variable was calculated.  
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Figure 7. Bilinear spline model with a time invariant covariate. 𝜂1 = latent intercept, 𝜂2 = latent 
slope for treatment phase, 𝜂3 = latent slope for post-treatment phase,   𝛹 = variance and covariance of 
the latent intercept and slope, 𝛼 = mean intercept and slope, 𝜃 = residual variance. 
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Multi-group modeling. The multi-group growth modeling framework is an extension of the 
growth modeling with time-invariant covariates discussed in the previous section. Assessing the 
effects of treatment on latent growth (linear or bilinear spline) aid is understanding basic 
differences in average growth trajectories. Unfortunately, latent growth modeling is limited to 
only estimating between group differences thus are unable to examine differences of within-
person change and the between-person differences in this process. Thus, these models are unable 
to examine differences in variance and covariance’s within the growth factors (between-person 
differences) or the residual variability (within-person change). In general, multi-group modeling 
allows for growth models to be specified for each group and parameter labels are used to 
constrain certain parameters (e.g., variance, co-variance, residual variance) to be equal (or 
variant) across groups. This method allows for empirical testing of group differences in specific 
aspects of the growth model. Similar to the basic latent growth model the multi group model can 
be written with the same formula (EQ 9), but includes a group indicator:  
𝑌𝑖
(𝑔) = 𝛬𝜂𝑖
(𝑔) + µ𝑖
(𝑔)   (EQ 9) 
Further, the latent factors (EQ10) are written in the same fashion, however they are written as 
deviations from the group-specific means  
𝜂𝑖
(𝑔) = 𝛼(𝑔) + 𝝃𝒊
(𝒈)
  (EQ 10) 
And the mean (EQ 11) and covariance (EQ 12) matrices are also specified as being group 
specific 
µ(𝑔) = 𝛬𝛼(𝑔)    (EQ 11) 
𝛴(𝑔) =  𝛬𝛹(𝑔)𝛬′ + 𝛩(𝑔)   (EQ 12) 
Figure 8 represents a basic multi-group linear latent growth model for participants assigned to 
MBRP or TAU. Only 6 time points are represented for readability, however all 15 time points 
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were estimated. Further, Figure 9 represents a multi-group bilinear spline model for participants 
assigned to MBRP or TAU.  
61 
 
TAU 
𝛹22
(1) 
𝛼1
(1) 𝛼2
(1) 
𝛹11
(2) 
𝛹22
(2) 𝛹21
(2) 
𝛼1
(2) 
𝛼2
(2) 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 8. Multi-group linear growth model. Here, the latent means for the intercept and slope as well as the variances for the 
intercept and slope are group varying. 𝜂1 = latent intercept, 𝜂2 = latent slope for treatment phase, 𝜂3 = latent slope for post-treatment  
phase,  𝛹 = variance and covariance of the latent intercept and slope, 𝛼 = mean intercept and slope, 𝜃 = residual variance. 
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Figure 9. Multi-group bilinear spline model. Here, as an example, the latent means for the intercept and slope are group varying, represented by group codes (1) 
and (2). All other factors such as intercept and slope variances, covariances, and residual variances are constrained to be equal across groups (lack of group 
code).  𝜂1 = latent intercept, 𝜂2 = latent slope for treatment phase, 𝜂3 = latent slope for post-treatment phase,  𝛹 = variance and covariance of the latent 
intercept and slope, 𝛼 = mean intercept and slope, 𝜃 = residual variance. 
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To assess variation in between-person process as well as within-person differences the multi-
group method typically yield four models.  The first model is the invariance model where all 
parameters are invariant (the same) across the groups. This model should parallel results from 
the linear latent growth model and bilinear spline models without the grouping variable (e.g., not 
using the time-invariant covariate to predict intercepts and slopes). For example, the means of 
the intercept and slopes would be constrained to be the same between participants in the MBRP 
and TAU groups. The second model is called the means model where constraints are relaxed for 
the latent variable means (intercept and slopes) for each group. These are the only parameters 
that are allowed to be group varying and all other parameters (variances, covariance’s, and 
residual variances) are constrained to be equal across groups. This model should be equivalent to 
the latent linear and bilinear spline models with the treatment (time-invariant) covariate model. 
Significantly better model fit based on a LRT test (model 1 vs. model 2) would reveal significant 
differences in average trajectories. Model 3 is the means and covariance’s model which allows 
for the latent variable means, variances, and covariance’s to vary across groups. Here parameter 
constraints remain on the residual variances only (e.g., residual variances are assumed to be 
homogeneous across groups).  Significant difference’s when comparing Model 3 to Model 2 
using the LRT would indicate the magnitude of between-person variability and covariability of 
the growth parameters.  Finally, the fourth model is the means, covariances, and residual 
variances model where all parameter constraints are relaxed across groups. By allowing the 
residual variances to vary across groups (e.g., constrained to be the same within group but vary 
between group) we can identify the magnitude of unexplained within-person variability over 
time. For the current study, all four of these models were run for stress, craving, and substance 
use and LRT tests were run to determine if constraints aided in significantly better model fit. A 
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5th model was estimated where the best fitting model was estimated based on LRT results across 
models 1 – 4.   
 Survival analysis.  In addition to assessing group differences using latent growth 
modeling for substance use during the post-treatment phase a series of Cox Proportional Hazard 
Regression model were estimated. Cox proportional hazard models is used when time to an event 
(in this case relapse) is measured on a continuous scale (e.g., two week follow ups). One of the 
primary advantages of using a proportional hazard model is the strict assumptions that 
accompany traditional survival analyses (e.g., distribution of event occurrence) do not apply. A 
proportional hazard model requires two pieces of data: 1) an indicator if the event occurred by 
the end of the follow up period and 2) an indicator of how much time occurred up to the event 
(or non-event).  The proportional hazard model assesses the hazard as the rate or ‘risk’ that an 
event will occur within an interval (e.g., time interval). Thus, the hazard function asks “given a 
certain interval width, how often does the event time 𝛵 occur between two ends of an interval, t 
and 𝛥𝑡, if the event has not occurred before that interval?” (Newsom, 2015, p. 337) The hazard 
function (EQ 13) can be stated as  
ℎ(𝑡) =  lim
𝛥𝑡→0
𝑃(𝑡≤𝑇>𝑡+ 𝛥𝑡|𝑇≥𝑡)
𝛥𝑡
   (EQ 13) 
Here the hazard rate ℎ(𝑡) represents the risk of an event occurring in a certain time period. The 
𝛥𝑡 represents the time interval on a continuous scale that must decrease over time and this 
probability is conditional on the event having not already occurred in a prior interval (|𝑇 ≥ 𝑡). 
The survival function (EQ 14; or the probability of still being at risk for event occurrence) is a 
simple transformation of the hazard function  
𝑆(𝑡) = 𝑃(𝑇 > 𝑡)    (EQ 14) 
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In the current study, proportional hazard regression was estimated assessing time to first relapse 
from the first follow up time point to the last (14 time points in total). Three separate cox 
regression models were run: 1) time to first use of alcohol or drugs, 2) time to first use of alcohol 
or heavy drinking episode, and 3) time to first use of any illicit drug (i.e., excluding alcohol use). 
Individuals who were lost to follow up or never experienced the event during the study period 
were censored. We used both time varying and time invariant predictors of the hazard function. 
Specifically, time to event occurrence was predicted using the treatment assignment variable (1 = 
MBRP, 0 = TAU). Two control variables were also used. A time varying covariate which 
assessed the maximum number of days each participant was not in the community (e.g., 
treatment facility, jail, hospital) was used to control for ‘nonuse’ due to the inability to access or 
utilize substances. The baseline value for past 14-day substance use was also used as a control 
variable. Three plots will be displayed: survival plot, log survival plot, and a hazard plot (kernel-
smoothed hazard function). Hazard Ratios (HR) are reported as the standardized metric for cox 
proportional hazard regression. 
 Mediation. To assess if changes in stress mediated the association between treatment 
assignment and substance use and craving a series of structural equation models were estimated. 
Specifically, latent growth models were estimated for both stress and the outcome of interest 
(craving or substance use). To assess of changes in stress mediated the association between 
treatment assignment and craving or substance three regressions were estimated:  slopes for 
stress change (treatment assignment predicting slopes in stress; a path), slope for change in 
craving or substance use (treatment assignment predicting craving or substance use, c path), and 
changes in stress predicting changes in craving or substance use (b path). Mediation was tested 
by assessing the indirect effect (e.g., a path * b path). In addition to the model based approach, 
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mediation was also tested using factor scores. That is, factor scores (FSCORES) were saved in 
Mplus when estimating the latent growth model for stress, craving, and substance use. These 
factor scores were then standardized and used in a bootstrapped (iterations = 10,000) indirect 
effect model. This was used as a robustness check and is akin to a Sobel test, however using 
bootstrapped methods are superior to basic Sobel tests (Preacher & Hayes, 2004).  
Mediated Moderation. To assess the effect of early childhood trauma a mediated 
moderation model was estimated. Specifically, the latent growth indirect effect models for both 
substance use and craving were used. A latent variable for childhood trauma was created with the 
five subscales of the Childhood Trauma Questionnaire (sexual abuse, physical abuse, emotional 
abuse, physical neglect, and emotional neglect). The variance of the latent variable is set to 1 so 
it is standardized. To assess moderation a latent variable interaction was created using the 
XWITH command in Mplus between treatment assignment and the latent variable for childhood 
trauma. The main effect of the latent variable for childhood trauma as well as the latent 
interaction were then regressed on the mediating variables, changes in stress. Evidence of 
moderated mediation is assessed by a significant interaction term. If the interaction term is 
significant, the moderation is examined further by probing the interaction at reasonable values 
for the moderator. Typically, values corresponding to the mean, -1, and +1 standard deviations 
are used.  
Missing data. One of the major advantages of using MLMs is how these models handle 
missing data. Specifically, MLMs make use of all the data available in the estimation model due 
to the flexible treatment of the time variable. To address attrition all models will be fit using the 
full information maximum likelihood (FIML) estimator in Mplus (Muthén & Muthén, 1998 -
2012), treating all observed predictors as single-item latent variables. That is, in each model 
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individuals will contribute whatever data they have to the likelihood function (i.e. both X and Y 
variables). For example, if an individual only has data at baseline will remain included in the 
analysis and contribute to the estimation model of parameters for baseline only. However, the 
validity of these methods lies under the assumption that missing data are “missing at random” 
(MAR) that is, the data are conditionally random after adjusting from the other variables 
included in the likelihood function—our estimates should by unbiased by missing data (Enders, 
2011). One way to address the MAR assumption is to include covariates in the model that 
attribute to missingness. For example, if individuals were missing data due to being discharged 
from treatment early, this variable can be entered into the model to “retrieve” the missing 
pattern. Thus, given that prior values on X and Y variables are often reasonable predictors of 
missingness in longitudinal data, this lends support to the plausibility of this assumption.  
Power Analysis.  Although our sample size is small (N = 79), preliminary Monte Carlo 
simulations (Mplus(B. Muthén & Muthén, 1998 -2012) ) suggested that it is quite reasonably 
powered (.81) to detect the small between-person effect sizes (d = 0.3) that are common in the 
relevant literature. Further, given the extensive number of longitudinal observations collected 
(i.e., substantial within-person variability), there is good reason assume that we have ample 
power to detect moderate within-person effects (Bolger & Laurenceau, 2013). Because the 
research questions utilize several complex analyses (e.g., mediation, moderated mediation), 
extant data with respect to plausible effect sizes is limited. However, prior work (Thoemmes, 
MacKinnon, & Reiser, 2010) has shown that 90 is needed to detect a modest mediated effect 
with a power of .80 with dichotomous treatment assignment. To address asymptotic assumptions 
of normality potentially challenged by both sample size and mediation parameters (i.e., product 
of the comprising pathway), all standard errors were bootstrapped (i.e. 5000 iterations). 
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Chapter 3: Results  
Participants 
 Figure 10 displays the recruitment and follow up flow of the study. Due to the large 
number of follow-up assessments (15 per participant) the average retention rate is reported for 
specific time points throughout the study (e.g., 1 month, 3 month, 5 month). In total, 84 
participants were eligible for participation in our study with 95% (N = 80) being successfully 
recruited. Currently, there are 1,050 time points across the 79 participants. Over the course of the 
study average retention rate was 83% (range 71% - 96%). The average number of days 
participants were at the treatment facility was 41.5 (SD = 26.3). No differences were found 
between MBRP and TAU groups in terms of days in residential treatment (t = -.67, df = 78, p = 
.50).  
Table 4 displays means, standard deviations, and frequencies across a multitude of 
baseline variables. To assess if any baseline differences existed between individuals assigned to 
MBRP or TAU independent groups t-tests (continuous variables) and chi-square tests 
(categorical variables) were run for all items and measures in Table 4. On average, participants 
were 25 years old (SD = 2.7), primarily male (n = 52, 65%), and White (n = 73, 91.3%). The 
majority of participants were single (n= 48, 60%), not in college or university (n = 70, 87.5%) 
prior to entering the residential facility, on average participants had a high school degree (or 
equivalent; Mean years of education = 11.9 (SD = 1.6)), and were primarily unemployed (n = 52, 
65%). When looking at salary (a crude measurement of socio-economic status) the median salary 
was 5,500 USD per year. However, because we ask participants about their income from legal 
and illegal (e.g., selling drugs) means the average salary was 16,807 USD per year. No 
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significant differences were found between MBRP or TAU groups across all demographic 
variables.  
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Figure 10. Consort flow diagram for recruitment, randomization, and analysis.  
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 In terms of family characteristics most participants had parents with a high school degree 
or less (Mother: 66%, Father: 83%) and parents who abuse alcohol or other drugs (Mother: 73%, 
Father: 88%). We did find significant differences between MBRP and TAU group in terms of 
mother alcohol or drug use 𝜒2 = 4.87, 𝑑𝑓 = 1, 𝑝 =  .03), however if we use a Bonferroni 
adjustment for the number of tests (t-tests: 50, p = .001; 𝜒2 = 10, 𝑝 =  .005) run in Table 4 
differences between groups were no longer significant. Further, the items asking about parental 
substance use was rather broad and did not assess if their parent had a substance use disorder or 
had ever received treatment. Rather, it asked only if their mother or father used alcohol, thus it is 
difficult to determine if “use” in this case is clinically or substantively relevant.  
 
Table 4. Baseline demographic characteristics between MBRP and TAU   
 Total  
M (SD) or 
n (%) 
MBRP 
M (SD) or 
n (%) 
TAU 
M (SD) or 
n (%) 
t-test 𝜒2  
 
p 
Participant 
Characteristics  
      
   Days in residential  41.6 (26.3) 43.3 (35.1) 39.3 (30.7) -.670  .50 
   Age 25.3 (2.70) 25.3 (2.80) 25.3 (2.64) .040  .97 
   Female n (%) 28 (35.0) 17 (37.8) 11 (31.4)  .350 .55 
   Race/Ethnicity n (%)       
       White   73 (91.3) 42 (93.3) 31 (88.6)  2.13 .35 
       African-American   6 (7.5) 2 (4.44) 4 (11.3)    
       Native American  1 (1.25) 1 (2.22)     
   Children  1.10 (1.26) 1.31 (1.26) .828 (1.22) -1.71  .09 
   Relationship        
      Single  48 (60.0) 25 (55.6) 23 (65.7)  1.61 .66 
      Divorced  8 (10.0) 6 (13.3) 2 (5.71)    
      Serious relationship  16 (20.0) 9 (20.0) 7 (20.0)    
         Married  8 (10.0) 5 (11.1) 3 (8.57)    
Education & Employment       
   School n (%)       
      Not in school 70 (87.5) 41 (91.1) 29 (82.9)  2.46 .29 
      Adult Education a 3 (3.75) 2 (4.44) 1 (2.86)    
      2 year college  7 (8.75) 2 (4.44) 5 (14.29)    
   Last grade completed 11.9 (1.63) 11.9 (1.75) 11.9 (1.48) -.150  .88 
   Employment n (%)       
      Full-time 23 (28.8) 14 (31.1) 9 (25.7)  1.74 .42 
      Part-time 5 (6.25) 4 (8.89) 1 (2.86)    
      Unemployed 52 (65.0) 27 (60.0) 25 (71.43)    
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Table 4. (cont.)       
   Salary (median) 5,500 6,000 5,000    
   Salary (mean) 16,807  
(36, 185) 
18, 617 
(31,337) 
14, 479 
(41, 971) 
-.510  .62 
Table 4 (cont.)        
Delinquency        
   Delinquency  12.8 (4.27) 12.7 (4.53) 13.0 (3.96) .370  .71 
   Days in jail P90 41.3 (34.5) 37.1 (34.9) 46.7 (33.8) 1.23  .22 
Family Characteristics        
   Mother HS Education b  53 (66.3) 32 (71.1) 21 (60.0)  1.09 .30 
   Father HS Education     66 (82.5) 38 (84.4) 28 (80.0)  .269 .60 
   Mother AOD c 58 (72.5) 37 (82.2) 21 (60.0)  4.87 .03 
   Father AOD 70 (87.5) 41 (91.1) 29 (82.9)  1.22 .27 
Substance use d        
   Age first use  12.7 (2.77) 13.1 (2.51) 12.3 (3.04) -1.21  .23 
   Alcohol P90 
   Alcohol P14 
   Alcohol P14ce 
17.5 (21.8) 
2.51 (4.48) 
2.18 (4.29) 
14.6 (21.8) 
2.51 (4.48) 
1.60 (3.60) 
21.2 (24.5) 
4.02 (5.44) 
2.91 (5.01) 
1.27 
1.37 
1.36 
 .21 
.18 
.18 
   Drunk P90 
   Drunk P14 
   Drunk P14ce 
14.3 (21.4) 
2.68 (4.79) 
1.73 (3.98) 
12.0 (20.3) 
2.22 (4.04) 
1.36 (3.42) 
17.3 (22.8) 
3.26 (5.24) 
2.20 (4.60) 
1.09 
.960 
.940 
 .28 
.34 
.35 
   Cannabis P90 
   Cannabis P14 
   Cannabis P14ce 
27.4 (35.8) 
4.36 (6.18) 
2.40 (5.00) 
26.3 (35.9) 
4.00 (6.15) 
2.13 (4.78) 
28.8 (36.2) 
4.83 (6.28) 
2.74 (5.32) 
.300 
.590  
.540 
 .76 
.56 
.59 
   Cocaine P90 e 
   Cocaine P14 
   Cocaine P14ce 
7.19 (25.4) 
1.2 (4.15) 
.156 (1.04) 
2.31 (11.9) 
.156 (1.04) 
.156 (1.04) 
13.5 (35.2) 
2.54 (5.95) 
1.00 (2.95) 
1.79 
2.34 
1.62 
 .08 
.03 
.11 
   Inhalants P90 
   Inhalants P14 
   Inhalants P14ce 
.036 (.191) 
0.00 (0.00) 
0.00 (0.00) 
.044 (.208) 
0.00 (0.00) 
0.00 (0.00) 
.029 (.169) 
0.00 (0.00) 
0.00 (0.00) 
-.370 
- 
- 
 .72 
- 
- 
   Heroin P90 
   Heroin P14 
   Heroin P14ce 
14.3 (28.6) 
1.92 (4.47) 
.662 (2.41) 
10.9 (23.7) 
1.24 (3.53) 
.867 (2.93) 
18.7 (33.7) 
2.8 (5.37) 
.400 (1.50) 
1.22 
1.48 
-.92 
 .23 
.14 
.36 
   Methadone P90  
   Methadone P14 
   MethadoneP14ce 
1.02 (4.59) 
.150 (1.14) 
.150 (1.14) 
.689 (3.74) 
0.00 (0.00) 
0.00 (0.00) 
1.43 (5.52) 
.342 (1.71) 
.343 (1.71) 
.710 
1.34  
1.18 
 .48 
.18 
.24 
   Pain killers P90 
   Pain killers P14 
   Pain killers P14ce 
11.1 (20.1) 
1.07 (2.67) 
.838 (2.34) 
11.7 (23.2) 
.933 (2.47) 
.756 (2.22) 
10.2 (15.5) 
1.23 (2.94) 
.943 (2.52) 
-.320 
.490 
.35 
 .75 
.63 
.73 
   PCP P90 
   PCP P14 
   PCP P14ce 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
0.00 (0.00) 
- 
- 
- 
 - 
- 
- 
   Hallucinogens P90 
   Hallucinogens P14 
   Hallucinogens P14ce 
1.03 (6.74) 
.150 (1.03) 
.125 (1.01) 
.267 (.963) 
.067 (.330) 
.022 (.149) 
2.00 (10.1) 
.257 (1.52) 
.257 (1.52) 
1.01 
.730 
.91 
 .32 
.47 
.37 
   Anti-anxiety drugs P90 
   Anti-anxiety drugs P14 
   Anti-anxiety drugs 
P14ce 
5.94 (15.0) 
.950 (2.96) 
.475 (1.81) 
3.56 (10.4) 
.489 (2.17) 
.178 (.683) 
9.00 (19.1) 
1.54 (3.70) 
.857 (.259) 
1.52 
1.50 
1.51 
 .14 
.14 
.14 
   Methamphetamine P90 
   Methamphetamine P14 
19.1 (28.4) 
2.90 (5.09) 
17.5 (27.7) 
2.82 (5.01) 
21.2 (29.4) 
3.00 (5.26) 
.580 
.150 
 .56 
.89 
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   Table 4 (cont.)      
   Methamphetamine Pce 1.13 (3.20) .778 (2.44) 1.57 (3.96) 1.04  .30 
   Ecstasy/Speed P90 
   Ecstasy/Speed P14 
   Ecstasy/Speed P14ce 
4.15 (14.5) 
.750 (2.88) 
.538 (2.49) 
3.29 (14.0) 
.778 (2.93) 
.400 (2.11) 
5.25 (15.3) 
.714 (2.86) 
.714 (2.86) 
.600 
-.10 
.56 
 .55 
.92 
.57 
   Barbiturates P90 
   Barbiturates P14 
   Barbiturates P14ce 
2.36 (11.1) 
.487 (2.07) 
.488 (2.07) 
3.11 (14.0) 
.400 (2.15) 
.400 (2.18) 
2.03 (5.65) 
.300 (1.98) 
.600 (1.99) 
-.430 
.430 
.430 
 .67 
.67 
.67 
   Other P90 f 
   Other P14 
   Other P14ce 
3.23 (11.9) 
.375 (2.20) 
.188 (1.57) 
4.49 (15.0) 
.644 (2.91) 
.311 (2.09) 
1.60 (5.78) 
.028 (.169) 
.029 (.169) 
-1.19 
-1.41 
-.900 
 .28 
.16 
.37 
    SFS P90 g 
    SFS P14 
    SFS P14ce 
16.1 (9.99) 
9.51 (9.73) 
8.65 (12.0) 
14.8 (9.29) 
7.74 (8.63) 
7.39 (10.4) 
17.7 (10.7) 
11.8 (10.7) 
10.3 (13.8) 
1.29 
1.88 
1.03 
 .21 
.07 
.31 
Self-help/social support       
    Num. self-help h 1.87 (3.78) 2.06 (3.47) 1.62 (4.19) -.510  .61 
Craving        
    Total Craving score  4.65 (2.78) 4.31 (2.89) 5.08 (2.59) 1.24  .22 
Mental Health i       
    Depression  19.4 (11.1) 19.6 (11.2) 19.0 (11.1) -.24  .81 
    Anxiety  17.3 (10.5) 17.8 (9.63) 16.7 (11.6) -.48  .63 
    Stress 22.6 (10.4) 22.4 (10.5) 22.8 (10.4) .17  .87 
Childhood Trauma        
    Age first abused  6.63 (3.13) 6.87 (3.42) 6.34 (2.73) -.74  .46 
    Total CTQ 50.3 (18.8) 48.1 (18.4) 53.0 (19.3) 1.17  .25 
    Emotional Abuse  12.2 (6.03) 11.6 (5.44) 13.1 (6.07) 1.07  .29 
    Physical Abuse 9.40 (5.43) 9.11 (5.39) 9.77 (5.54) .540  .59 
    Sexual Abuse  8.53 (6.07) 8.31 (5.94) 8.28 (6.31) .380  .71 
    Emotional Neglect  11.7 (5.46) 11.3 (5.14) 12.2 (5.90) .740  .46 
    Physical Neglect  8.36 (4.07) 7.76 (3.56) 9.14 (4.57) 1.53  .13 
Perceives Stress       
    Total Stress  33.7 (7.96) 34.9 (7.11) 32.2 (8.81) -1.49  .14 
Mindfulness       
    Total mindfulness  3.19 (.781) 3.19 (.689) 3.17 (.894) -.07  .95 
    Practice mindfulness 5.76 (13.9) 3.96 (9.70) 8.09 (17.9) 1.32  .19 
Note: MBRP = Mindfulness Based Relapse Prevention; TAU = Treatment as Usual (control condition). Items or 
measures followed by a P90 or P14 refer to past 90 days (P90) or past 2 weeks (P14). a. Adult education includes 
GED classes. b. Both mother and father education were dichotomized such that high school or less was the 
reference group.  c. Mother AOD and Father AOD are dichotomous indicators if their mother or father abused 
alcohol or other drugs. d. Substance use was measured in two ways. The first is represented by the first two 
values (P90 and P14). These values are for both the current recall period or if the participant had been in jail, 
prison, or other facility prior to entering treatment the recall period is the 90 days and 14 days prior to entering a 
facility. The values labeled P14ce is adjusted for the current past 14 days such that if a participant was in a 
facility for the entire 14 days prior to entering treatment they will have a value of 0 for days of substance use. If a 
participant reported being in a facility, for example, for 10 out of the prior 14 days the original value for each 
substance was used minus the number of days reported in a facility. e. cocaine included the sum of both cocaine, 
crack, and other forms of cocaine. f. Other includes bath salts and K2 (synthetic marijuana). g. SFS is a variable 
created to contain information on all substances and three substance problem items. The scale calculates the 
proportion of days each individual uses all 15 substances or experiences problems. These values are averaged and 
multiplied by 100.  h. Participants were asked how many days they attend any 12-step, self-help, or other social 
support group in the past 2 weeks. i. Subscales from the DASS-21 were multiplied by 2 to correspond to the 
larger scale, norms, and cut off scores. 
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 In terms of substance use, most participants (over 90%) were polysubstance users. On 
average participants were 12.7 (SD 2.8) years old when they first used any substance. Table 4 
also shows means for 15 different drugs for past 90 days and past 2 weeks. Substance use is 
displayed in two different ways. First, participants were asked on how many days they used each 
substance in the recall period (e.g., past 90 days, past 14 days) and if the participant reported 
being in jail, prison, or other facility where they could not use they were asked to refer to the 90 
days and 14 days prior to entering a facility. The second way substance use is presented 
(represented by a “ce” after each substance) is the controlled environment adjusted estimates – 
such that each participant was asked to report on how many days in the past 2 weeks (regardless 
of being in a facility) how often they used each substance. Values for each substance were 
subtracted from the number of days in a controlled environment. The most used substances were 
alcohol (past 90-day Mean = 17.5 days), getting drunk (past 90 day Mean = 14.3 days), cannabis 
(past 90 day Mean = 27.4 days), methamphetamine (past 90 day Mean = 19.1 days), and heroin 
(past 90 day Mean = 14.3 days). For controlled environment adjusted similar results were found 
such that alcohol use, getting drunk, cannabis use, opiate use (both heroin and pain killers), and 
methamphetamine were the most used drugs prior to entering the treatment facility. Figure 11 
displays overall means for past 90 days and past 14 days across the entire sample and Figures 12 
and 13 display means separated by treatment assignment. Across all substances one showed 
significant differences between MRBP and TAU groups (Crack/cocaine use, p = .03). Two 
variables (crack, cocaine) were averaged to obtain a single use variable for the two similar 
substances. However, this difference was no longer significant when assessing the controlled 
environment adjusted means (p = .11). The substance frequency scale was used to assess use of 
all substances and problems associated with substance use. No differences existed across the 
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substance frequency scale when comparing MBRP and TAU participants for the unadjusted and 
adjusted means. On average participants attended approximately 2 self-help or social support 
recovery meetings in the 30 days prior to entering treatment.  
  
Figure 11. Mean days of substance use for overall sample at baseline 
 
 
 
Note: Black bars represents past 90 day use and grey bars represents past 14 day use.  
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Figure 12. Mean days of substance use for participants assigned to MBRP at baseline 
 
 
Note: Black bars represents past 90 day use and grey bars represents past 14 day use.  
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Figure 13. Mean days of substance use for participants assigned to TAU at baseline  
 
 
Note: Black bars represents past 90 day use and grey bars represents past 14 day use.  
 
In terms of mental health the DASS-21 was used to assess depression, anxiety, and stress. 
Participants, on average scored 19.4 for depression, 17.3 for anxiety, and 22.6 for stress. To 
place this in context, the DASS-21 provide cut off scores for (normal, mild, moderate, severe, 
extremely severe). For example, for depression: normal (0-9), mild (10-13), moderate (14-20), 
severe (21-27), extremely severe (28+); anxiety: normal (0-7), mild (8-9), moderate (10-14), 
severe (15-19), extremely severe (20+); stress: normal (0-14), mild (15-18), moderate (19-25), 
severe (26-33), extremely severe (34+). No significant differences existed between those 
assigned to MBRP or TAU.  Figure 14 shows how the current sample compares two to 
normative samples and one clinical sample. Across all three comparison groups, the current 
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sample had higher scores on depression, anxiety, and stress. Specifically, if we compare the 
clinical sample to our current sample (both MBRP and TAU) depression scores have a 
standardized mean difference (Cohen’s d) of d = .91, anxiety d = .75, and stress d = .15. Figures 
15, 16, and 17 display DASS-21 counts by severity for the overall sample, MBRP, and TAU 
groups.  
 
Figure 14. DASS-21 Comparison across multiple samples at baseline  
 
Note: Normative 1 data are from Crawford & Henry (2003). Data were obtained from 1,771 
adults in the UK. Normative 2 data are from Henry & Crawford (2005). Data were obtained 
from 1,794 general adult UK population at two time points. Clinical data are from Brown et al. 
(1997). Data were from 678 participants presenting for assessment and treatment for depression, 
phobia, and anxiety disorders.   
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Figure 15. Counts of DASS-21 depression scores by severity for overall sample, MBRP, and 
TAU at baseline 
 
Figure 16. Counts of DASS-21 anxiety scores by severity for overall sample, MBRP, and TAU at 
baseline 
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Figure 17. Counts of DASS-21 stress scores by severity for overall sample, MBRP, and TAU at 
baseline  
 
 
 
To further assess stress, participants were also administered the perceived stress scale. On 
average, participants scored 33.7 (SD = 7.96). No significant differences existed between 
individuals assigned to MBRP or TAU. Figure 18 compares perceives stress scores in the current 
sample to three normative samples and one clinical sample. Similar to our comparisons across 
the DASS-21 scores participants in the current study have higher stress scores than the three 
normative samples and the clinical sample. Standardized mean difference between the clinical 
comparison study and the current sample result in d = .55. Figure 19 displays the means 
perceived stress scores for the overall sample, MRBP, and TAU groups.  
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Figure 18. Normative and current sample scores on the Perceived Stress Scale at baseline  
 
Note: Normative 1 & 2 data are from Cohen et al. (1983). Data are for a college sample (N = 
332;  normative 1) and a community sample (N = 64; normative 2) of individuals participating 
in a smoking cessation program. Normative 3 data are from Cohen & Janicki-Deverts (2013). 
Data are for a large normative US sample (n = 2,000). The clinical data are from Hewitt et al. 
(1992). Data are from 96 psychiatric patients. 
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Figure 19. Mean perceived stress scores for overall, MRBP, and TAU groups at baseline 
 
 
 
Data were also collected on childhood trauma using the childhood trauma questionnaire. At 
baseline, participants reported, on average, a score of 50.3 (SD = 18.8) across all subscales. 
When looking at each of the 5 subscales, specifically, participants averages 12.2 (SD = 6.0) for 
emotional abuse, 9.40 (SD = 5.4) for physical abuse, 8.53 (SD = 6.1) for sexual abuse, 11.7 (SD 
= 5.5) for emotional neglect, and 8.36 (SD = 4.1) for physical neglect. No significant differences 
existed between individuals assigned to MBRP or TAU.  Table 5 displays item level means for 
the current study sample compared to two large normative samples. In general, the current study 
sample has higher average scores across emotional abuse items, physical abuse items, and sexual 
abuse items. Comparison across emotional neglect and physical neglect are relatively 
comparable. 
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Table 5. Mean, Standard Deviations and Reliability of Measured Items for the CTQ. 
Comparison with Original Community Sample from Bernstein et al. (2003) and a larger 
Sample of emerging adults from Davis et al. (in press). 
 Current Study 
Sample 
 
Mean (SD) 
N = 80 
Davis, Dumas, & 
Roberts 
 
Mean (SD)a 
N = 832 
 
Bernstein et al. 
 
 
Mean (SD)b 
N = 579 
 
 
I. Emotional Abuse  (α = .90) 
   
   Called names by family  2.2 (1.4) 1.9 (1.2) 1.9 (1.2) 
   Parents wished was never born 1.9 (1.3) 1.6 (1.1) 1.4 (.90) 
   Felt hated by family  2.5 (1.6) 1.8 (1.2) 1.7 (1.1) 
   Family said hurtful things  2.7 (1.3) 2.1 (1.3) 2.1 (1.1) 
   Was emotionally abused  2.9 (1.6) 1.9 (1.4) 1.8 (1.3) 
Mean Subscale 12.2 (6.0) 9.3 (5.3)  
II. Physical Abuse (α = .92)    
   Hit hard enough to see doctor 1.6 (1.1) 1.3 (.72) 1.1 (.50) 
   Hit hard to leave bruises 1.8 (1.3) 1.5 (.96) 1.3 (.80) 
   Punished with hard object 2.7 (1.5) 1.9 (1.2) 2.2 (1.2) 
   Hit badly enough to be noticed  1.4 (1.1) 1.3 (.82) 1.1 (.50) 
   Was physically abused 1.9 (1.4) 1.5 (1.0) 1.4 (1.0) 
Mean Subscale 9.4 (5.4) 7.4 (3.9)  
III. Sexual Abuse (α = .95)    
   Was touched sexually  1.8 (1.4) 1.4 (.91) 1.6 (1.0) 
   Hurt if didn’t do something 
sexual 
1.4 (1.0) 1.2 (.76) 1.1 (.60) 
   Made me do sexual things  1.6 (1.2) 1.3 (.83) 1.4 (.90) 
   Was molested  1.8 (1.5) 1.3 (.90) 1.4 (1.0) 
   Was sexually abused 1.9 (1.5) 1.3 (.91) 1.4 (1.0) 
Mean Subscale 8.5 (6.1) 6.6 (4.0)  
IV. Emotional Neglect (α = .92)    
   Felt loved  2.0 (1.1) 2.0 (1.2) 1.8 (.90) 
   Made to feel important  2.0 (1.2) 2.2 (1.2) 2.0 (1.1) 
   Was looked out for 2.4 (1.3) 2.3 (1.2) 1.9 (1.0) 
   Family felt close 2.7 (1.3) 2.5 (1.3) 2.2 (1.1) 
   Family was source of strength 2.4 (1.4) 2.4 (1.3) 2.1 (1.1) 
Mean Subscale  11.7 (5.5) 11.3 (5.4)  
V. Physical Neglect (α = .79)    
   Not enough to eat 1.6 (1.0) 1.6 (.91) 1.2 (.60) 
   Got taken care of  1.9 (1.2) 1.9 (1.1) 1.7 (1.0) 
   Parents too drunk or high 2.0 (1.3) 1.4 (.91) 1.3 (.70) 
   Wore dirty clothes 1.4 (.93) 1.5 (.89) 1.2 (.50) 
84 
 
Table 5 (cont.)    
   Got taken to doctor 1.6 (1.0) 2.1 (1.5) 1.3 (.80) 
   Mean Subscale 8.4 (4.1) 8.4 (3.9)  
aData are from Davis, Dumas, & Roberts (in press). Normative sample of emerging adults recruited from 
Amazon’s MTurk.  
bData obtained from Bernstein et al. (2003) for sample of community members. 
Range of all variables is 1 – 5 where 1 = never true; 2 = rarely true; 3 = sometimes true; 4 = often true; 5 = very 
often true.  
Please note the original study (Bernstein et al., 2003) did not provide means for subscales.  
 
Treatment Fidelity  
 To assess treatment fidelity Dr. Christopher Menard sat in on 16 sessions over the course 
of the study period. During each session, Dr. Menard coded each therapist using the Mindfulness 
Based Relapse Prevention Adherence and Competence (MBRP-AC) scale. There are two 
adherence constructs (treatment components and key concepts) and two competence constructs 
(therapist style/approach and therapist performance). The treatment components adherence scale 
is assessed using a checklist of major topics assessed within each session. To make each session 
comparable in terms of the number possible components (each session differs based on if there 
are new participants, meditation, and activities within each session) we made the treatment 
components have 10 possible items. The average across all 16 observed sessions was 7.0 (SD = 
1.43) with a range of 4 to 9 components. Although we did not reach 100% in terms of adhering 
to treatment components this is likely due to sessions in which we did not have new participants 
(thus the component describing new participant orientation). The key components adherence 
scale is a count of behaviors used within each session that use the key concepts of MBRP to 
facilitate discussion and in-session exercises. Therapists averaged 20 (SD = 5.91) key concept 
behaviors per session (scores ranged from 8 to 30). In other words, therapists were able to 
administer 91% of the key components, on average, across each of the sessions. The therapist 
style/approach competence scale is assess overall ability to administer MBRP and mindfulness 
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based interventions (e.g., elicit feedback, clarifying expectations) and the overall therapist 
performance is the raters global impression of the sessions (e.g., therapists’ ability to work as a 
team. Overall therapists averaged 4.78 (SD = .176) on the style/approach scale and 4.72 (SD = 
.264) on the overall performance scale. Overall, fidelity across the adherence constructs were 
good with therapists averaging over 90% in both of the adherence categories. In terms of the 
competence scales, considering the scores for these scales ranged from 1 (low) to 5 (high), the 
scores indicated therapists in this study reached excellent levels of competence on both therapist 
style/approach and overall therapist performance. As a comparison, Chawla and colleagues 
(2010) reported Therapist/approach mean rating of 3.95 (SD = .50) and overall therapist 
performance mean rating of 3.92 (SD = .42).  
Treatment Completion and Mindfulness Practice  
 To assess treatment completion and engagement we tracked how many sessions each 
participant attended and how often they practiced mindfulness between each session. Session 
attendance ranged from 93% - 100% across the 8 sessions with 89% of participants receiving all 
8 sessions. The primary reason for non-attendance was early termination at the residential facility 
due to behavioral issues. Mindfulness practice was tracked by asking each participant how many 
times they practiced mindfulness since the last session. Sessions were held bi-weekly thus counts 
of mindfulness practice refer to the time between each session (3 – 4 days between sessions). A 
“weekly” count of mindfulness practice can be obtained by summing two adjacent sessions (e.g., 
session 1 and session 2 will give you the average number of times each person practiced 
mindfulness in week 1). In general participants assigned to the MBRP were practicing 
mindfulness at least once per day in between sessions. As participants became more engaged in 
the treatment process the number of times practiced per day increased over the course of the 8 
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sessions. These results indicate that the majority of participants assigned to MBRP attended 
sessions and nearly 90% received all 8 MBRP sessions. Further, engagement in mindfulness 
practice is evident by the near daily practice in between each of the sessions.  
 
Table 6. Participant treatment attendance and engagement in mindfulness practices  
 Session 
1 
Session 
2 
Session 
3 
Session 
4 
Session 
5 
Session 
6 
Session 
7 
Session 
8 
Attendance  100% 97.8% 95.6% 93.3% 93.3% 97.8% 93.3% 93.3% 
Mindfulness 
Practice  
3.8 
(3.0) 
3.8 
(3.1) 
5.0 
(4.2) 
6.3 
(6.9) 
6.4 
(6.5) 
6.5 
(5.2) 
6.7 
(5.9) 
6.5 
(5.6) 
Note: Sessions were held twice weekly, thus mindfulness practice refers to the Mean (SD) number of time 
participants practiced mindfulness between sessions (3-4 days between each session).   
 
Attrition Analysis  
 On average total attrition across the study period was 18% ranging from 0% - 29%. 
Among the individuals recruited for the study 17% (n = 14) did not have any data following 
discharge from the residential facility or provided assessments following discharge but were lost 
to follow up at various times throughout the follow-up period. Further, 95% completed follow-up 
assessments during the 1 month period, 91% completed follow-up assessments during the 3 
month period, and 75% completed follow-up assessments during the 5 month period. To assess if 
there are differences between individuals who were lost to follow up and those who completed 
the majority of follow up assessments an attrition analysis was conducted on the main variables 
of interest. There were no differences in terms of basic demographics such as age (t = 1.67, df = 
78, p = .10), sex (𝜒2 = 1.67, 𝑑𝑓 = 1, 𝑝 =  .20), or race (𝜒2 = .346, 𝑑𝑓 = 1, 𝑝 =  .55). There 
were no differences across all 15 substances: alcohol (t = -.92, df = 78, p = .36); binge drinking (t 
= -.89, df = 78, p = .37); cannabis (t = -1.14, df = 78, p = .26); crack/cocaine (t = .21, df = 78, p = 
.83); heroin  (t = -.13, df = 78, p = .89); methadone (t = .54, df = 78, p = .59); pain killers or other 
opiates (t = .87, df = 78, p = .39); hallucinogens (t = .60, df = 78, p = .55); anti-anxiety drugs (t 
87 
 
=.62, df = 78, p = .53); methamphetamine (t = .44, df = 78, p = .66); stimulants (t = 1.07, df = 78, 
p = .29); sedatives (t = .97, df = 78, p = .34); other drugs (t = .70, df = 78, p = .49); substance 
frequency scale past 90 days (t = .50, df = 78, p = .61); substance frequency scale past 14 days (t 
= -.07, df = 78, p = .94). Further, there were no differences when between those lost to follow-up 
versus those not lost to follow up in terms of childhood trauma scores: CTQ total (t = 1.77, df = 
78, p = .08); physical abuse (t = 1.45, df = 78, p = .15); emotional neglect (t = 1.35, df = 78, p = 
.18); emotional abuse (t = 1.80, df = 78, p = .08); physical neglect (t = .73, df = 78, p = .47); 
sexual abuse (t = .65, df = 78, p = .51). No differences emerged when assessing craving scores (t 
= .12, df = 78, p = .91) or perceived stress (t = 1.08, df = 78, p = .28).  
 
Stress: Basic Growth Models for Overall Sample  
 Table 7 displays fit statistics for a linear growth model for stress across the entire sample. 
Results indicate a model with random intercept, linear growth, quadratic growth fit the data best 
(𝛥 − 2𝑙𝑙 = 11.4, 𝑑𝑓 = 1, 𝑝 < .001). Table 8 displays parameter estimates and standard errors 
for all three models. Focusing on Model 3, we can see that there is an overall significant decrease 
in stress (linear slope b = -.158, SE = .29, p =.01; quadratic slope b = .061, SE = .02, p = .001). 
However, looking at Figure 20 which displays estimated and sample means for stress across the 
entire sample, we can see that the basic latent linear growth model does not capture the steep 
drop in stress during the first three time points (e.g., the treatment phase). To account for this a 
bilinear spline model was fit to the data. Table 9 displays fit statics for the bilinear spline model. 
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Table 7. Model fit statistics for overall stress linear latent growth model  
 Model 1 Model  
2 
Model  
3 
Parameters    
   -2LL 6567.8 6497.3 6356.3 
   AIC 6557.8 6509.3 6466.7 
   BIC 6589.7 6523.6 6514.4 
   df 5 6 10 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠    
   𝛥 − 2𝐿𝐿  70.5 241 
   𝛥 𝑑𝑓  1 4 
LRT  .000 .000 
Note: Model 1 is a random intercept and fixed slope model with constrained residual variances 
Model 2 is a random intercept, random linear slope and constrained residual variances  
Model 3 random intercept, random linear  slope, random quadratic slope, constrained  residual variance  
  
 
 
Table 8. Model parameters and standard errors for overall stress linear latent growth model 
 Model 1 Model 2 Model 3 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 28.4 (.662)* 28.3 (.727)* 26.9 (.760)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  .080 (.059) .111 (.104) -.671 (.260)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑   .061 (.019)* 
Residual (co) variance     
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 
.656 (.188)* -1.40 (.731) -2.24 (.1.96) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑   .062 (.131) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑with 𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝   -.150 (.061)* 
Variance     
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 20.5 (5.14)* 29.4 (6.63)* 25.6 (7.20)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  .000 (.000) .564 (.139)* 2.57 (.891)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑   .011 (.004)* 
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Figure 20. Estimates and sample means for stress across entire study sample.  
 
 Nested models were tested for the bilinear spline model to determine if a random slope was 
needed for the treatment phase and for the post-treatment phase. Results from likelihood ratio 
tests indicate a random slope is needed for both the treatment phase and the post-treatment phase 
(Table 9, Model 3). Table 10 displays parameter estimates and standard errors for the bilinear 
spline model. Focusing on model 3, there is a significant deceleration in stress during the 
treatment phase (𝑏 = −3.48, 𝑆𝐸 =  .883, 𝑝 <  .001) and a slight slowing of the deceleration 
during the post-treatment phase (𝑏 = .443, 𝑆𝐸 =  .106, 𝑝 <  .001). Significant variance existed 
across all parameters (intercept, treatment phase slope, and post-treatment phase slope). Figure 
21 displays the estimated and sample means for stress across the entire sample using a bilinear 
spline model.  
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Table 9. Model fit statistics for overall stress using a bilinear spline model 
 Model 1 Model  
2 
Model  
3 
Parameters    
   -2LL 6524.4 6470.6 6368.8 
   AIC 6534.4 6512.6 6416.8 
   BIC 6546.3 6562.6 6473.9 
   df 5 6 10 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠    
   𝛥 − 2𝐿𝐿  53.8 101.8 
   𝛥 𝑑𝑓  1 4 
LRT  .000 .000 
Note: Model 1 random intercept, fixed treatment slope, fixed follow up slope,  
Model 2 random intercept, random treatment slope, fixed follow up slope,  
Model 3 random intercept, random treatment slope, random follow up slope,  
 
Table 10. Model parameters and standard errors for overall stress. Bilinear spine latent growth 
model 
 Model 1 Model 2 Model 3 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 32.71 (.938)* 32.8 (.887)* 25.7 (.883)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝  -3.13 (.440) -3.11 (.574)* -3.48 (.532)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝐹𝑈𝑠𝑙𝑝 .368 (.070)* .385 (.067)* .443 (.106)* 
Residual (co) variance     
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝 
.000 (.000) -4.00 (7.97) 14.5 (5.1)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝐹𝑈𝑠𝑙𝑝 .000 (.000) .000 (.000) -1.89 (.939)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝with 𝑆𝑡𝑟𝑒𝑠𝑠𝐹𝑈𝑠𝑙𝑝 .000 (.000) .000 (.000) -.420 (.546) 
Variance     
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 32.4 (5.99)* 15.26 (15.2) 44.7 (9.96)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝  .000 (.000) 10.2 (4.85)* 9.04 (3.69)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝐹𝑈𝑠𝑙𝑝 .000 (.000)  .525 (.137)* 
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Figure 21. Estimated and sample means for stress for overall sample using bilinear spline model 
 
Stress: Treatment Effect on Stress Using Time Invariant Predictor Model  
 As an initial step in determining the effect of MBRP on stress over time, latent growth 
models with time a time invariant treatment predictor were estimated. Two sets of models were 
estimated: the first used a basic latent growth model with random linear and quadratic slopes, the 
second used a bilinear spline model with a random slope for the treatment phase and the post-
treatment phase. Both sets of models controlled for the number of days each participant spent at 
the inpatient facility. Table 11 presents results from the basic latent linear growth model. Results 
indicate a significant treatment effect on the linear (𝑏 = −2.05, 𝑆𝐸 =  .470, 𝑝 <  .001) and 
quadratic (𝑏 = .096, 𝑆𝐸 =  .036, 𝑝 =  .008) slope for stress. Put differently individuals assigned 
to MBRP had significant decreases in stress over the study period compared to individuals 
assigned to TAU.  Figure 22 displays mean stress scores for individuals assigned to MBRP and 
TAU. 
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Table 11. Treatment effects on latent stress trajectories. 
 B SE P 95% CI 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 29.6  1.17 .000 27.3, 31.8 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  .463 .358 .197 -.240,  1.17 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .008 .028 .764 -.046, .060 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 on MBRP .547  1.54 .718 -2.46, 3.57  
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 on MBRP -2.05 .470 .000 -2.97, -1.13 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 on MBRP .096 .036 .008 .025, .166 
Residual (co) variance      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 
-2.11  1.78 .236 -5.60, 1.38 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .050 .124 .689 -.194, .294 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑with 𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 -.10 .050 .048 -.197, -.001 
Variance      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 25.9 7.24 .000 11.7, 4.1 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  1.51 .688 .028 .168, 2.86 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .009 .004 .027 .001, .017 
Fit Statistics      
   -2LL 6315.5    
   AIC 6341.5    
   BIC 6372.3    
   df  13    
   CFI .722    
  TLI .769    
   RMSEA .12    
   𝜒2 356.7    
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Figure 22. Mean stress scores for individuals assigned to MBRP, TAU, and the total mean 
scores. 
 
To assess the treatment effect during the treatment phase and the post-treatment phase a model 
was estimated using a bilinear spline specification. Table 12 presents results for the bilinear 
spline growth model. Results indicate a significant treatment effect for stress during the 
treatment phase (𝑏 = −3.70, 𝑆𝐸 =  .947, 𝑝 <  .001) and post treatment phase (𝑏 = −.582, 𝑆𝐸 =
 .233, 𝑝 =  .013). Put differently individuals assigned to MBRP had significant decreases in 
stress during both the treatment and post-treatment phases compared to individuals assigned to 
TAU.  
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Table 12. Treatment effects on latent stress trajectories for the bilinear spline model 
 B SE P 95% CI 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 31.4  1.24 .000 30.0, 33.8 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  -1.06 .718 .157 -2.42, .392 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .775 .180 .000 .423, 1.13 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 on MBRP 2.09 1.65 .205 -1.14, 5.31 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑡𝑥 𝑠𝑙𝑝 on MBRP -3.70 .947 .000 -5.60, -1.85 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 on MBRP -.582 .233 .013 -1.04, -.198 
Residual (co) variance      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑡𝑥 𝑠𝑙𝑝 
-2.55 4.05 .529 -10.5, 5.38 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 -.963 .809 .234 -2.55, .623 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑡𝑥 𝑠𝑙𝑝with 𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 -.767 .545 .159 -2.17, .300 
Variance      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 22.3 2.86 .009 5.63, 38.9 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  5.52 2.86 .054 -.094, 11.1 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 .615 .164 .000 .293, .937 
Fit Statistics      
   -2LL 6267.7    
   AIC 6293.7    
   BIC 6324.5    
   df  13    
   CFI .714    
  TLI .770    
   RMSEA .13    
   𝜒2 308.9    
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Stress: Treatment Effect on Stress Using Multi-Group Modeling   
 While the prior models (e.g., time invariant predictor) indicate a significant effect for 
individuals assigned to the experimental group, these models cannot determine if the slopes are 
actually different for experimental and control groups. To test differences in slopes across 
randomized groups, a series of multi-group models were estimated. In particular, a taxonomy of 
models were estimated for the overall trajectory (e.g., across both treatment and post-treatment 
phases) as well as for a bilinear spline model. Within both of these growth models five separate 
models (Model 1 – Model 5) were estimated to determine invariance across groups (e.g., 
invariance model, means model, means and co-variances model, means, co-variances, and 
residual variances, and the final model). Model fit was estimated using LRT test. The final model 
(Model 5) employs and constraints needed based on LRT tests across the first four models. The 
MODEL TEST command was used to assess differences in stress slopes across groups (MRBP 
and TAU). Table 13 displays results of the multi-group model for overall stress trajectories. 
There was significantly better model fit (𝛥 − 2𝐿𝐿 = 39.4, 𝛥 𝑑𝑓 = 3, 𝑝 =  .001) for Model 2 
(means model) compared to Model 1 (invariance model) indicating are significant differences in 
average trajectories. The non-significant LRT results in Model 3 (𝛥 − 2𝐿𝐿 = 8.4, 𝛥 𝑑𝑓 = 6, 𝑝 =
 .212) indicates limited between person variability and co-variability in the growth parameters. 
However, the significant LRT result in Model 4 (𝛥 − 2𝐿𝐿 = 72.7, 𝛥 𝑑𝑓 = 1, 𝑝 =  .000) 
indicates significant unexplained within person variability in stress over time. Model 5 represents 
the final model with variances and co-variances constrained to be equal across groups. Results 
from the LRT test indicate the model was not significantly worse fitting compared to Model 5, 
thus constraining variances and co-variances to be equal across groups does not result in a worse 
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fitting model. Results indicate a significant linear decrease in stress for individuals assigned to 
MRBP (𝑏 = −.842, 𝑆𝐸 =  .356, 𝑝 =  .018) and a significant deceleration for the quadratic term 
(𝑏 = .060, 𝑆𝐸 =  .026, 𝑝 =  .018). Conversely, there was a significant linear increase in stress 
for individuals assigned to TAU (𝑏 = .921, 𝑆𝐸 =  .402, 𝑝 =  .022) and a non-significant 
quadratic effect (𝑏 = −.027, 𝑆𝐸 =  .029, 𝑝 =  .353). Results from the Wald test of parameter 
constraints indicate a significant difference between groups for the linear slope (𝑊𝑎𝑙𝑑 𝜒2 =
10.7 , 𝑑𝑓 =  1, 𝑝 =  .001) and quadratic slope (𝑊𝑎𝑙𝑑 𝜒2 = 10.7 , 𝑑𝑓 =  1, 𝑝 =  .001). Figure 23 
displays means and estimated trajectories for overall stress across individuals assigned to MRBP 
and TAU.  
In addition to assessing differences in slopes (change), model testing was also assessed 
on mean differences at four distinct time points: 1) baseline, 2) treatment completion, 3) mid-
point (3 months), and 4) end of study (6 months). To assess mean differences at these time points 
from a modeling perspective the intercept was set at each of the above mentioned time points. 
The MODEL TEST option was used to assess mean differences for the intercept at each phase of 
the study. For stress, no significant differences were found between individuals assigned to 
MRBP and TAU at baseline (𝑊𝑎𝑙𝑑 𝜒2 = .367 , 𝑑𝑓 =  1, 𝑝 =  .545). In terms of standardized 
mean differences (Cohen’s d) results for baseline mean differences resulted in small, but non-
significant, difference (𝑑 = −.14, 95%𝐶𝐼 [−.58, .31] , 𝑑𝑓 =  1, 𝑝 =  .545).   However, 
significant mean differences were found across groups at treatment completion (𝑊𝑎𝑙𝑑 𝜒2 =
9.45 , 𝑑𝑓 =  1, 𝑝 =  .002; 𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −.70, 95% 𝐶𝐼[−1.16,−.25]), mid-point (𝑊𝑎𝑙𝑑 𝜒2 =
40.8 , 𝑑𝑓 =  1, 𝑝 <  .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −1.5, 95% 𝐶𝐼[−2.03,−1.02]), and at study 
completion (𝑊𝑎𝑙𝑑 𝜒2 = 12.5 , 𝑑𝑓 =  1, 𝑝 <  .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −.80, 95% 𝐶𝐼[−1.26, −.33]). 
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Figure 23. Means and estimated trajectories for multi-group growth modeling  
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Table 13. Multi-group model parameters and standard errors for stress trajectories by treatment assignment  
 Model 1 Model 2 Model 3 Model 4 Model 5 
MRBP      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 29.9 (.757)* 30.1 (1.01)* 30.07 (.948)* 27.1 (1.26)* 27.3 (1.21)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  -.672(.257)* -1.57 (.303)* -1.59 (.269)* -.802 (.373)* -.842 (.356)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .060 (.018)* .103 (.023)* .104 (.020)* .059 (.027)* .060 (.026) 
Residual (co) variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 
-.207 (1.96) -2.10 (1.77) -1.99 (2.06) -6.28 (3.82) -2.58 (2.35) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .041 (.130) .038 (.124) .079 (.143) .349 (.262) .036 (.154) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑with 𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 -.144 (.061)* -.094 (.049)* -.036 (.047) -.127 (.084) -.086 (.054) 
Variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 25.5 (7.18)* 25.9 (7.24)* 20.6 (8.47)* 37.2 (14.1)* 31.1 (9.89)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  2.46 (.875)* 1.46 (.676)* .689 (.672) 2.03 (1.22) 1.41 (.786) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .011 (.004)* .008 (.004)* .004 (.004) .010 (.006) .008 (.004)* 
TAU      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 29.9 (.757)* 27.7 (1.15)* 29.7 (1.24)* 28.5 (1.39)* 28.5 (1.43)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  -.672 (.257)* .430 (.352) .507 (.405) .939 (.388)* .921 (.402)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .060 (.018)* .006 (.027) -.002 (.031) -.028 (.027) -.027 (.029)* 
Residual (co) variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 
-.207 (1.96) -2.098 (1.77) -2.64 (3.21) -6.29 (3.80) -2.58 (2.35) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .041 (.130) .038 (.124) .014 (.226) .349 (.262) .036 (.154) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑with 𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 -.144 (.061)* -.094 (.049)* -.193 (.106) -.127 (.084) -.086 (.054) 
Variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 25.5 (7.18)* 25.9 (7.24)* 33.3 (12.7)* 37.3 (14.1)* 31.1 (9.89)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  2.46 (.875)* 1.42 (.676)* 2.776 (1.41)* 2.03 (1.22) 1.41 (.786) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .011 (.004)* .008 (.004)* .016 (.008) .010 (.006) .008 (.004)* 
Fit Indices       
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Table 13. (cont.)      
   -2LL 6455.7 6416.296 6407.9 6335.2 6342.0 
   AIC 6475.7 6442.3 6445.9 6431.2  
   BIC 6499.5 6473.3 6491.2 6545.6  
   df 10 13 19 48 42 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠      
   𝛥 − 2𝐿𝐿  39.4 8.4 72.7 6.8 
   𝛥 𝑑𝑓  3 6 29 6 
LRT  .001 .212 .000 .34 
Note:  
Model 5 is the final model with variances and co-variances constrained to be equal across groups (based on  
Results from LRT M3 versus M2) and group varying intercepts, slopes, and residuals. Results of the LRT  
Indicate a non-significant increase in -2LL, indicating model fit is not significantly worse than a model with  
Group varying variances and co-variances.  
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Table 14 displays results of the multi-group model for the bilinear spline model for stress 
trajectories. There was significantly better model fit (𝛥 − 2𝐿𝐿 = 40.5, 𝛥 𝑑𝑓 = 3, 𝑝 =  .001) for 
Model 2 (means model) compared to Model 1 (invariance model) indicating are significant 
differences in average trajectories. The non-significant LRT results in Model 3 (𝛥 − 2𝐿𝐿 =
10.5, 𝛥 𝑑𝑓 = 6, 𝑝 =  .105) indicates limited between person variability and co-variability in the 
growth parameters. However, the significant LRT result in Model 4 (𝛥 − 2𝐿𝐿 = 5.5, 𝛥 𝑑𝑓 =
1, 𝑝 =  .019) indicates significant unexplained within person variability in stress over time. 
Model 5 represents the final model with variances and co-variances constrained to be equal 
across groups. Results from the LRT test indicate the model was not significantly worse fitting 
compared to Model 5, thus constraining variances and co-variances to be equal across groups 
does not result in a worse fitting model. Results indicate a significant decrease in stress for 
individuals assigned to MRBP during the treatment phase (𝑏 = −4.72, 𝑆𝐸 =  .571, 𝑝 <  .001) 
but a non-significant effect during the post-treatment phase (𝑏 = .194, 𝑆𝐸 =  .146, 𝑝 =  .186). 
Conversely, there was a non-significant decrease in stress for individuals assigned to TAU 
during the treatment phase (𝑏 = −1.02, 𝑆𝐸 =  .733, 𝑝 =  .163) and a significant increase in 
stress during the post-treatment phase (𝑏 = .763, 𝑆𝐸 =  .183, 𝑝 <  .001). Results from the Wald 
test of parameter constraints indicate a significant difference between groups during the 
treatment phase (𝑊𝑎𝑙𝑑 𝜒2 = 15.7 , 𝑑𝑓 =  1, 𝑝 <  .001) and during the post-treatment phase 
(𝑊𝑎𝑙𝑑 𝜒2 = 5.94 , 𝑑𝑓 =  1, 𝑝 =  .015). Figure 24 displays means and estimated trajectories for 
overall stress across individuals assigned to MRBP and TAU.  
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Table 14. Multi-group model parameters and standard errors for bilinear spline stress trajectories by treatment assignment  
 Model 1 Model 2 Model 3 Model 4 Model 5 
MRBP      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 32.68 (.819)* 33.5 (1.08)* 33.5 (.932)* 33.1 (1.03)* 33.5 (1.03)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝  -3.12 (.506)* -4.72 (.614)* -4.73 (.488)* -4.51 (.556)* -4.72 (.571)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 .455 (.120)* .194 (.152) .206 (.147) .176 (.149) .194 (.149) 
Residual (co) variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝 
-3.78 (4.40) -2.245 (4.01) 3.73 (3.36) 12.8 (7.27) -.866 (3.89) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 
-1.46 (.861) -1.17 (.827) -.901 (.856) -.899 (.853) -1.19 (.798) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋 𝑠𝑙𝑝with    𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋𝑠𝑙𝑝 .091(.588) -.696 (.545) -.223 (.529) -.419 (.536) -.636 (.525) 
Variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 22.90 (8.62)* 22.2 (8.50)* 8.33 (8.42) -9.24 (14.0) 19.9 (8.32)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝  8.43 (3.36)* 5.14 (2.82)* -1.11 (2.36) -4.83 (3.95) 4.03 (2.75) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 .680 (.177)* .648 (.170)* .572 (.209)* .629 (.211)* .633 (.168)* 
TAU      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 32.68 (.819)* 31.7 (1.23)* 31.6 (1.42)* 31.8 (1.44)* 31.7 (1.26)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝  -3.12 (.506)* -1.07 (.704) -.989 (.853) -1.05 (.874) -1.08 (.722) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 .455 (.120)* .718 (.181)* .689 (.190)* .709 (.211)* .703 (.184)* 
Residual (co) variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝 
-3.78 (4.40) -2.245 (4.01) -9.88 (8.42) -6.08 (13.5) -.866 (3.89) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 
-1.46 (.861) -1.17 (.827) -1.48 (1.56) -1.12 (1.70) -1.19 (.798) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋𝑠𝑙𝑝with    𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝 .091(.588) -.696 (.545) -1.33 (1.06) -1.79 (1.16) -.636 (.525) 
Variance       
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 22.90 (8.62)* 22.2 (8.50)* 39.6 (16.8)* 29.81 (25.9) 19.9 (8.32)* 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑇𝑋𝑠𝑙𝑝  8.43 (3.36)* 5.14 (2.82)* 13.1 (6.15)* 11.7 (8.35) 4.03 (2.75) 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 .680 (.177)* .648 (.170)* .720 (.278)* .997 (.331)* .633 (.168)* 
Fit Indices       
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Table 14. (cont.)      
   -2LL 6409.6 6369.1 6358.6 6353.4 6362 
   AIC 6429.6 6395.1 6396.6 6395.4 6390.5 
   BIC 6453.4 6426.0 6441.8 6442.6 6423.9 
   df 10 13 19 20 14 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠      
   𝛥 − 2𝐿𝐿  40.5 10.5 5.5 9 
   𝛥 𝑑𝑓  3 6 1 6 
LRT  .000 .105 .019 .174 
 
Model 5 is the final model with variances and co-variances constrained to be equal across groups (based on  
Results from LRT M3 versus M2) and group varying intercepts, slopes, and residuals. Results of the LRT  
Indicate a non-significant increase in -2LL, indicating model fit is not significantly worse than a model with  
Group varying variances and co-variances. 
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Figure 24. Stress means and estimated trajectories for the multi-group bilinear spline model  
 
Stress: Multi-Level Modeling  
 As a robustness check the effect of treatment on stress was also assessed using a multi-
level modeling framework. Unconditional growth models revealed an Intraclass Correlation of 
36.0% indicating that 36% of the variance in stress is retained in the between-person level and 
64% at the within-person level. An LRT test was conducted to determine if a random slope was 
needed. Results indicate a significant reduction in -2 log likelihood (𝛥 − 2𝐿𝐿 = 605, 𝛥 𝑑𝑓 =
2, 𝑝 <  .001), indicating a random slope fits the data better than a model with a fixed slope. In 
the final model, treatment assignment, days in residential facility, and days not in the community 
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were entered into the model. Results indicate a significant effect of treatment on the slope of 
stress (𝑏 = −.907, 𝑆𝐸 =  .140, 𝑝 < .001). This means individuals assigned to MBRP had 
significantly lower stress over the study period compared to individuals assigned to TAU.  
Craving: Basic Growth Models for Overall Sample  
 Table 15 displays fit statistics for a linear growth model for craving across the entire 
sample. Results indicate a model with random intercept, linear growth, quadratic growth fit the 
data best (𝛥 − 2𝑙𝑙 = 11.4, 𝑑𝑓 = 1, 𝑝 < .001). Table 16 displays parameter estimates and 
standard errors for all three models. Focusing on Model 3, we can see that there is an overall 
significant decrease in craving (linear slope b = -.189, SE = .094, p =.045; quadratic slope b = 
.015, SE = .007, p = .034). However, looking at Figure 25 which displays estimated and sample 
means for craving across the entire sample, we can see that the basic latent linear growth model 
does not capture the steep drop in craving during the first three time points (e.g., the treatment 
phase). To account for this a bilinear spline model was fit to the data. Table 17 displays fit statics 
for the bilinear spline model. 
Table 15. Model fit statistics for overall craving linear latent growth model  
 Model 1 Model  
2 
Model  
3 
Parameters    
   -2LL 4429.8 4357.8 4269.4 
   AIC 4439.8 4369.8 4289.4 
   BIC 4435.9 4365.2 4281.7 
   df 5 6 10 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠    
   𝛥 − 2𝐿𝐿  71.9 88.4 
   𝛥 𝑑𝑓  1 4 
LRT  .000 .000 
Note: Model 1 is a random intercept and fixed slope model with constrained residual variances 
Model 2 is a random intercept, random linear slope and constrained residual variances  
Model 3 random intercept, random linear  slope, random quadratic slope, constrained  residual variance  
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Table 16. Model parameters and standard errors for overall craving linear latent growth model 
 Model 1 Model 2 Model 3 
   𝐶𝑟𝑎𝑣𝑖𝑛𝑡 2.97 (.255)* 2.92(.267)* 3.35 (.241)* 
   𝐶𝑟𝑎𝑣𝑠𝑙𝑝  .007 (.019) .016 (.035) -.189 (.094)* 
   𝐶𝑟𝑎𝑣𝑞𝑎𝑑   .015 (.007)* 
Residual (co) variance     
   𝐶𝑟𝑎𝑣𝑖𝑛𝑡with  
𝐶𝑟𝑎𝑣𝑠𝑙𝑝 
.073 (.025)* -,088 (.087) -.023 (.209) 
   𝐶𝑟𝑎𝑣𝑖𝑛𝑡with 𝐶𝑟𝑎𝑣𝑞𝑎𝑑   -.009 (.015) 
   𝐶𝑟𝑎𝑣𝑞𝑎𝑑with 𝐶𝑟𝑎𝑣𝑠𝑙𝑝   -.029 (.008)* 
Variance     
   𝐶𝑟𝑎𝑣𝑖𝑛𝑡 23.74 (.802)* 4.45 (.915)* 2.78 (.743)* 
   𝐶𝑟𝑎𝑣𝑠𝑙𝑝  .000 (.000) .063 (.016)* .437 (.113)* 
   𝐶𝑟𝑎𝑣𝑞𝑎𝑑   .002 (.001)* 
 
 
 
Figure 25. Estimates and sample means for craving across entire study sample.  
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 Nested models were tested for the bilinear spline model to determine if a random slope was 
needed for the treatment phase and for the post-treatment phase. Results from likelihood ratio 
tests indicate a random slope is needed for both the treatment phase and the post-treatment phase 
(Table 17, Model 3). Table 18 displays parameter estimates and standard errors for the bilinear 
spline model. Focusing on model 3, there is a significant deceleration in craving during the 
treatment phase (𝑏 = −1.15, 𝑆𝐸 =  .172, 𝑝 <  .001) and a slight slowing of the deceleration 
during the post-treatment phase(𝑏 = .124, 𝑆𝐸 =  .038, 𝑝 <  .001). Significant variance existed 
across all parameters (intercept, treatment phase slope, and post-treatment phase slope). Figure 
26 displays the estimated and sample means for craving across the entire sample using a bilinear 
spline model.  
 
Table 17. Model fit statistics for overall craving using a bilinear spline model 
 Model 1 Model  
2 
Model  
3 
Parameters    
   -2LL 4340.9 4336.6 4256.6 
   AIC 4356.9 4354.6 4276.6 
   BIC 4350.7 4347.6 4300.4 
   df 8 9 10 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠    
   𝛥 − 2𝐿𝐿  4.29 80.0 
   𝛥 𝑑𝑓  1 1 
LRT  .038 .000 
Note: Model 1 random intercept, fixed treatment slope, fixed follow up slope,  
Model 2 random intercept, random treatment slope, fixed follow up slope,  
Model 3 random intercept, random treatment slope, random follow up slope,  
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Table 18. Model parameters and standard errors for overall craving. Bilinear spine latent 
growth model 
 Model 1 Model 2 Model 3 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 2.10 (.282)* 2.12 (.294)* 2.08 (.318)* 
  𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝  -1.12 (.142)* -1.11 (.163)* -1.15 (.172)* 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 .099 (.020)* .098 (.020)* .124 (.038)* 
Residual (co) variance     
  𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝 
.597 (.245)* -1.57 (.471)* 1.77 (.587)* 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 .078 (.028)* .068 (.029)* -.199 (.118) 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝with 𝑆𝑡𝑟𝑒𝑠𝑠𝑃𝑇𝑋 𝑠𝑙𝑝 .056 (.013)* .048 (.016)* -.086 (.061) 
Variance     
  𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 4.41 (.872)* 5.02 (1.05)* 6.41 (1.31)* 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝  .000 (.000) .564 (.325) 1.07 (.378) 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 .000 (.000) .000 (.000) .077 (.019)* 
 
 
 
Figure 26. Estimated and sample means for craving for overall sample using bilinear spline 
model 
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Craving: Treatment Effect on Craving Using Time Invariant Predictor Model  
 As an initial step in determining the effect of MBRP on craving over time, latent growth 
models with a time invariant treatment predictor were estimated. Two sets of models were 
estimated: the first used a basic latent growth model with random linear and quadratic slopes, the 
second used a bilinear spline model with a random slope for the treatment phase and the post-
treatment phase. Both sets of models controlled for the number of days each participant spent at 
the inpatient facility. Table 19 presents results from the basic latent linear growth model. Results 
indicate a significant treatment effect on the linear (𝑏 = −.778, 𝑆𝐸 =  .169, 𝑝 <  .001) and 
quadratic (𝑏 = .048, 𝑆𝐸 =  .013, 𝑝 <  .001) slope for craving. Put differently, individuals 
assigned to MBRP had significant decreases in craving over the study period compared to 
individuals assigned to TAU.  Figure 27 displays mean craving scores for individuals assigned to 
MBRP and TAU. 
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Table 19. Treatment effects on latent craving trajectories. 
 B SE P 95% CI 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 3.56 .518 .000 27.3, 31.8 
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝  .291 .177 .101 -.240,  1.17 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 -.019 .014 .169 -.046, .060 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 on MBRP -.425   .487 .383 -2.46, 3.57  
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝 on MBRP -.778 .013 .000 -2.97, -1.13 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 on MBRP .048 .013 .008 .025, .166 
Residual (co) variance      
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝 
-.080  .191 .676 -5.60, 1.38 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with 𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 -.003 .014 .825 -.194, .294 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑with 𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝 -.020 .006 .001 -.197, -.001 
Variance      
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 2.77 .743 .000 11.7, 4.1 
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝  .290 .085 .001 .168, 2.86 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 .002 .0001 .001 .001, .017 
Fit Statistics      
   -2LL 4237.5    
   AIC 4269.5    
   BIC 4307.6    
   df  16    
   CFI .729    
  TLI .764    
   RMSEA .16    
   𝜒2 470.1    
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Figure 27. Mean craving scores for individuals assigned to MBRP, TAU, and the total mean 
scores. 
 
To assess the treatment effect during the treatment phase and the post-treatment phase a model 
was estimated using a bilinear spline specification. Table 20 presents results for the bilinear 
spline growth model. Results indicate a significant treatment effect for craving during the 
treatment phase (𝑏 = −.802, 𝑆𝐸 =  .325, 𝑝 =  .014) but a non-significant effect during the post 
treatment phase(𝑏 = −.150, 𝑆𝐸 =  .087, 𝑝 =  .085). Put differently individuals assigned to 
MBRP had significant decreases in craving during the treatment phase compared to individual 
assigned to TAU, however a non-significant effect during the post-treatment phase indicates that 
although individual assigned to MBRP had lower craving scores, these slopes were not 
significantly different from each other. 
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Table 20. Treatment effects on latent craving trajectories for the bilinear spline model 
 B SE P 95% CI 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 4.64 .697 .000 3.45, 5.83 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  -.446 .347 .199 -1.27, .235 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 .136 .091 .133 -.042, .314 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 on MBRP -.676 .571 .237 -1.80, .446 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑡𝑥 𝑠𝑙𝑝 on MBRP -.802 .325 .014 -1.4, -.165 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 on MBRP -.150 .087 .085 -.320, .020 
Residual (co) variance      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with  
𝑆𝑡𝑟𝑒𝑠𝑠𝑡𝑥 𝑠𝑙𝑝 
-.552 .474 .244 -1.48, .377 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 -.077 .150 .465 -.282, .129 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑡𝑥 𝑠𝑙𝑝with 𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 -.097 .064 .129 -.223, .028 
Variance      
   𝑆𝑡𝑟𝑒𝑠𝑠𝑖𝑛𝑡 3.54 1.04 .001 1.51, 5.57 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝  .943 .330 .004 .295, 1.59 
   𝑆𝑡𝑟𝑒𝑠𝑠𝑝𝑡𝑥 𝑠𝑙𝑝 .098 .024 .000 .050, .145 
Fit Statistics      
   -2LL 4223.0    
   AIC 4255.0    
   BIC 4293.1    
   df  16    
   CFI .746    
  TLI .779    
   RMSEA .16    
   𝜒2 455.6    
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Craving: Treatment Effect on Craving Using Multi-Group Modeling   
 While the prior models (e.g., time invariant predictor) indicate a significant effect for 
individuals assigned to the experimental group, these models cannot determine if the slopes are 
actually different for experimental and control groups. To test differences in slopes across 
randomized groups, a series of multi-group models were estimated. In particular, a taxonomy of 
models were estimated for the overall trajectory (e.g., across both treatment and post-treatment 
phases) as well as for a bilinear spline model. Within both of these growth models five separate 
models (Model 1 – Model 5) were estimated to determine invariance across groups (e.g., 
invariance model, means model, means and co-variances model, means, co-variances, and 
residual variances, and the final model). Model fit was estimated using LRT test. The final model 
(Model 5) employs and constraints needed based on LRT tests across the first four models. The 
MODEL TEST command was used to assess differences in craving slopes across groups (MRBP 
and TAU). Table 21 displays results of the multi-group model for overall craving trajectories. 
There was significantly better model fit (𝛥 − 2𝐿𝐿 = 30.8, 𝛥 𝑑𝑓 = 3, 𝑝 <  .001) for Model 2 
(means model) compared to Model 1 (invariance model) indicating significant differences in 
average trajectories. The significant LRT results in Model 3 (𝛥 − 2𝐿𝐿 = 34.0, 𝛥 𝑑𝑓 = 6, 𝑝 <
 .001) indicates significant between person variability and co-variability in the growth 
parameters. Finally, the significant LRT result in Model 4 (𝛥 − 2𝐿𝐿 = 65.5, 𝛥 𝑑𝑓 = 1, 𝑝 <
 .001) indicates significant unexplained within person variability in craving over time. Model 5 
represents the final model, which is simply replicated from model 4 as all parameters were 
allowed to be freely estimated. Results indicate a significant linear decrease in craving for 
individuals assigned to MRBP (𝑏 = −.556, 𝑆𝐸 =  .087, 𝑝 <  .001) and a significant 
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deceleration for the quadratic term (𝑏 = .038, 𝑆𝐸 =  .007, 𝑝 <  .001). Conversely, there was a 
non-significant linear slope in craving for individuals assigned to TAU (𝑏 = .231, 𝑆𝐸 =
 .148, 𝑝 =  .119) and a non-significant quadratic effect (𝑏 = −.010, 𝑆𝐸 =  .011, 𝑝 =  .377). 
Results from the Wald test of parameter constraints indicate a significant difference between 
groups for the linear slope (𝑊𝑎𝑙𝑑 𝜒2 = 20.9 , 𝑑𝑓 =  1, 𝑝 <  .001) and quadratic slope 
(𝑊𝑎𝑙𝑑 𝜒2 = 13.3 , 𝑑𝑓 =  1, 𝑝 <  .001). Figure 28 displays means and estimated trajectories for 
overall craving across individuals assigned to MRBP and TAU.  
Mean differences across the four time points (baseline, treatment completion, mid-point 
(3 months), and study completion (6-months) were also assessed. For craving, no significant 
differences were found between individuals assigned to MRBP and TAU at baseline 
(𝑊𝑎𝑙𝑑 𝜒2 = .734 , 𝑑𝑓 =  1, 𝑝 =  .392; 𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −.06, 95% 𝐶𝐼 [−.50, .39]). However, 
significant mean differences were found across groups at treatment completion (𝑊𝑎𝑙𝑑 𝜒2 =
15.1 , 𝑑𝑓 =  1, 𝑝 <  .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −.94, 95% 𝐶𝐼 [−1.40,−.47]), mid-point (𝑊𝑎𝑙𝑑 𝜒2 =
32.7 , 𝑑𝑓 =  1, 𝑝 <  .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −1.52, 95% 𝐶𝐼 [−2.02, −1.01]), and at study 
completion (𝑊𝑎𝑙𝑑 𝜒2 = 4.41 , 𝑑𝑓 =  1, 𝑝 =  .036;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −.50, 95% 𝐶𝐼 [−950,−.05]). 
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Figure 28. Craving means and estimated trajectories for multi-group growth modeling  
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Table 21. Multi-group model parameters and standard errors for craving trajectories by treatment assignment  
 Model 1 Model 2 Model 3 Model 4 Model 5 
MRBP      
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 3.35 (.241)* 3.18 (.320)* 3.18 (.336)* 3.19 (.333)* 3.19 (.333)* 
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝  -.189 (.094)* -.541 (.110)* -.557 (.090)* -.556 (.087)* -.556 (.087)* 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 .015 (.007)* .037 (.008)* .038 (.007)* .038 (.007)* .038 (.007)* 
Residual (co) variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝 
.023 (.209) -.082 (.192) -.513 (.257)* -.619 (.244)* -.619 (.244)* 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with 𝑆𝑡𝑟𝑒𝑠𝑠𝑞𝑎𝑑 -.009 (.015) -.003 (.014) .034 (.019) .039 (.018)* .039 (.018)* 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑with 𝑆𝑡𝑟𝑒𝑠𝑠𝑠𝑙𝑝 -.029 (.008)* -.020 (.006)* -.009 (.005) -.013 (.005)* -.013 (.005)* 
Variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 2.77 (.743)* 2.77 (.743)* 3.62 (1.07)* 3.79 (1.05)* 3.79 (1.05)* 
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝  .437 (.113)* .291 (.086)* .129 (.074) .181 (.069)* .181 (.069)* 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 .002 (.001)* .002 (.001)* .002 (.001)* .001 (.0001)* .001 (.0001)* 
TAU      
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 3.35 (.241)* 3.60 (.365)* 3.61 (.353)* 3.60 (.350)* 3.60 (.350)* 
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝  -.189 (.094)* .244 (.127) .235 (.148) .231 (.148) .231 (.148) 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 .015 (.007)* -.012 (.010) -.010 (.011) -.010 (.011) -.010 (.011) 
Residual (co) variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝 
.023 (.209) -.082 (.192) .328 (.308) .587 (.307) .587 (.307) 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with 𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 -.009 (.015) -.003 (.014) -.043 (.023) -.057 (.022)* -.057 (.022)* 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑with 𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝 -.029 (.008)* -.020 (.006)* -.031 (.013)* -.023 (.013) -.023 (.013) 
Variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 2.77 (.743)* 2.77 (.743)* 2.54 (1.06)* 1.44 (1.06) 1.44 (1.06) 
   𝐶𝑟𝑎𝑣𝑒𝑠𝑙𝑝  .437 (.113)* .291 (.086)* .481 (.179)* .369 (.178)* .369 (.178)* 
   𝐶𝑟𝑎𝑣𝑒𝑞𝑎𝑑 .002 (.001)* .002 (.001)* .002 (.012)* .002 (.001)* .002 (.001)* 
Fit Indices       
116 
 
Table 21. (cont.)      
   -2LL 4269.4 4269.4 4204.7 4139.3 4139.3 
   AIC 4289.4 4264.7 4242.7 4179.3 4179.3 
   BIC 4313.3 4295.6 4288.0 4226.9 4226.9 
   df 10 13 19 20 20 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠      
   𝛥 − 2𝐿𝐿  30.8 34.0 65.5 6.8 
   𝛥 𝑑𝑓  3 6 1 6 
LRT  .000 .000 .000 .34 
Note:  
Model 5 is the final model with variances and co-variances constrained to be equal across groups (based on  
Results from LRT M3 versus M2) and group varying intercepts, slopes, and residuals. Results of the LRT  
Indicate a non-significant increase in -2LL, indicating model fit is not significantly worse than a model with  
Group varying variances and co-variances.  
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Table 22 displays results of the multi-group model for the bilinear spline model for craving 
trajectories. There was significantly better model fit (𝛥 − 2𝐿𝐿 = 27.9, 𝛥 𝑑𝑓 = 3, 𝑝 =  .001) for 
Model 2 (means model) compared to Model 1 (invariance model) indicating significant 
differences in average trajectories. The non-significant LRT results in Model 3 (𝛥 − 2𝐿𝐿 =
38.4, 𝛥 𝑑𝑓 = 6, 𝑝 =  .000) indicates limited between person variability and co-variability in the 
growth parameters. However, the significant LRT result in Model 4 (𝛥 − 2𝐿𝐿 = 63.0, 𝛥 𝑑𝑓 =
1, 𝑝 =  .019) indicates significant unexplained within person variability in craving over time. 
Model 5 represents the final model which is a replication of Model 4 as all parameters were 
allowed to vary freely across groups. Results indicate a significant decrease in craving for 
individuals assigned to MRBP during the treatment phase (𝑏 = −1.42, 𝑆𝐸 =  .178, 𝑝 <  .001) 
but a non-significant (slowing of the deceleration) effect during the post-treatment phase (𝑏 =
.065, 𝑆𝐸 =  .041, 𝑝 =  .114). Conversely, there was a significant decrease in craving for 
individuals assigned to TAU during the treatment phase (𝑏 = −.585, 𝑆𝐸 =  .288, 𝑝 =  .042) and 
a significant increase in craving during the post-treatment phase (𝑏 = .212, 𝑆𝐸 =  .087, 𝑝 <
 .014). Results from the Wald test of parameter constraints indicate a significant difference 
between groups during the treatment phase (𝑊𝑎𝑙𝑑 𝜒2 = 6.14 , 𝑑𝑓 =  1, 𝑝 =  .013) however a 
non-significant difference during the post-treatment phase (𝑊𝑎𝑙𝑑 𝜒2 = 2.34 , 𝑑𝑓 =  1, 𝑝 =
 .127). Figure 29 displays means and estimated trajectories for overall craving across individuals 
assigned to MRBP and TAU.  
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Table 22. Multi-group model parameters and standard errors for bilinear spline craving trajectories by treatment assignment  
 Model 1 Model 2 Model 3 Model 4 Model 5 
MRBP      
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 4.34 (.285)* 4.05 (.377)* 4.05 (.394)* 4.05 (.395)* 4.05 (.395)* 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝  -1.04 (.167)* -1.40 (.214)* -1.45 (.177)* -1.42 (.178)* -1.42 (.178)* 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 .132 (.044)* .062 (.056) .071 (.041) .065 (.041) .065 (.041) 
Residual (co) variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝 
-.421 (.484) -.555 (.474) -1.08 (.607) -1.56 (.604)* -1.56 (.604)* 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 
-.042 (.108) -.075 (.10) -.013 (.103) -.018 (.105) -.018 (.105) 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋 𝑠𝑙𝑝with    𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋𝑠𝑙𝑝 -.068 (.067) -.098 (.065) .002 (.046) -.029 (.048) -.029 (.048) 
Variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 3.64 (1.05)* 3.54 (1.04)* 4.15 (1.49)* 5.17 (1.49)* 5.17 (1.49)* 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝  1.11 (.357)* .940 (.331)* .315 (.293) .760 (.298)* .760 (.298)* 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 .103 (.026)* .099 (.024)* .038 (.015)* .048 (.016)* .048 (.016)* 
TAU      
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 4.34 (.285)* 4.74 (.428)* 4.72 (.406)* 4.71 (.403)* 4.71 (.403)* 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝  -1.04 (.167)* -.585 (.245)* -.606 (.288)* -.585 (.288)* -.585 (.288)* 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 .132 (.044)* .204 (.067)* .240 (.092)* .212 (.087)* .212 (.087)* 
Residual (co) variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝 
-.421 (.484) -.555 (.474) -.018 (.744) -.787 (.759) -.787 (.759) 
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡with  
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 
-.042 (.108) -.075 (.10) -.150(.216) -.155 (.199) -.155 (.199) 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋𝑠𝑙𝑝with    𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝 -.068 (.067) -.098 (.065) -.242 (.164) -.176 (.152) -.176 (.152) 
Variance       
   𝐶𝑟𝑎𝑣𝑒𝑖𝑛𝑡 3.64 (1.05)* 3.54 (1.04)* 2.89 (1.40)* 1.32 (1.43) 1.32 (1.43) 
   𝐶𝑟𝑎𝑣𝑒𝑇𝑋𝑠𝑙𝑝  1.11 (.357)* .940 (.331)* 1.74 (.695)* 1.14 (.699) 1.14 (.699) 
   𝐶𝑟𝑎𝑣𝑒𝑃𝑇𝑋 𝑠𝑙𝑝 .103 (.026)* .099 (.024)* .226 (.075)* .169 (.065)* .169 (.065)* 
Fit Indices       
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Table 22. (cont.)      
   -2LL 4252.1 4224.2 4185.8 4122.8 4122.8 
   AIC 4272.1 4250.2 4223.8 4162.8 4162.8 
   BIC 4295.9 4281.2 4269.0 4210.4 4210.4 
   df 10 13 19 20 20 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠      
   𝛥 − 2𝐿𝐿  27.9 38.4 63.0  
   𝛥 𝑑𝑓  3 6 1  
LRT  .000 .000 .000  
 
Model 5 is the final model with variances and co-variances constrained to be equal across groups (based on  
Results from LRT M3 versus M2) and group varying intercepts, slopes, and residuals. Results of the LRT  
Indicate a non-significant increase in -2LL, indicating model fit is not significantly worse than a model with  
Group varying variances and co-variances. 
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Figure 29. Craving means and estimated trajectories for the multi-group bilinear spline model  
 
Craving: Multi-Level Modeling  
 As a robustness check the effect of treatment on craving was also assessed using a multi-
level modeling framework. Unconditional growth models revealed an Inter Class Correlation of 
.488 indicating that 49% of the variance in craving is retained in the between-person level and 
51% at the within-person level. An LRT test was conducted to determine if a random slope was 
needed. Results indicate a significant reduction in -2 log likelihood (𝛥 − 2𝐿𝐿 = 78.5, 𝛥 𝑑𝑓 =
2, 𝑝 <  .001), indicating a random slope fits the data better than a model with a fixed slope. In 
the final model, treatment assignment, days in residential facility, and days not in the community 
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
To
ta
l C
ra
vi
n
g 
Sc
o
re
Time
Sample TAU Estimated TAU Sample MBRP Estimated MBRP
121 
 
were entered into the model. Results indicate a significant effect of treatment on the slope of 
craving (𝑏 = −.277, 𝑆𝐸 =  .064, 𝑝 < .001). This means individuals assigned to MBRP had 
significantly lower craving over the study period compared to individuals assigned to TAU, thus 
replicating our latent growth model results.  
 
Substance Use 
 Because participants were in a controlled facility during the first four weeks of the study 
(treatment phase) it was assumed there would be little to no variance in the substance use 
variables. While some participants did report substance use within these time points (n = 3), our 
assumption was confirmed when attempting to model substance use using the first two time 
points following the baseline assessment. Specifically, an error indicating a zero variance was 
displayed for both time points 1 and 2. Thus, our analyses for substance use when using latent 
growth modeling assessed post-treatment substance use only. However, when assessing 
substance use using a survival function, all time points after the initial baseline assessment were 
used. Each model in the latent growth and survival models controlled for the number of days 
each participant spent in the residential facility as well as number of days not in the community 
over time. No bilinear spline models were run for substance use given data from post-treatment 
are being analyzed.  
Substance use: Basic Growth Models for Overall Sample  
 Table 23 displays fit statistics for a linear growth model for substance use across the 
entire sample. Results indicate a model with random intercept, linear growth, quadratic growth 
fit the data best (𝛥 − 2𝑙𝑙 = 66.2, 𝑑𝑓 = 4, 𝑝 < .001). Table 24 displays parameter estimates and 
standard errors for all three models. Focusing on Model 3, we can see that there is an overall 
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significant increase in substance use (linear slope b = 2.09, SE = .436, p < .000) and a significant 
slowing of the acceleration (quadratic slope b = -.130, SE = .043, p = .002).  
Table 23. Model fit statistics for overall substance use linear latent growth model  
 Model 1 Model  
2 
Model  
3 
Parameters    
   -2LL 5066.0 4977.8 4911.6 
   AIC 5076.0 4989.8 4931.6 
   BIC 5087.8 5003.9 4955.1 
   df 5 6 10 
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠    
   𝛥 − 2𝐿𝐿  88.3 66.2 
   𝛥 𝑑𝑓  1 4 
LRT  .000 .000 
Note: Model 1 is a random intercept and fixed slope model with constrained residual variances 
Model 2 is a random intercept, random linear slope and constrained residual variances  
Model 3 random intercept, random linear  slope, random quadratic slope, constrained  residual variance  
  
 
 
Table 24. Model parameters and standard errors for overall substance use linear latent growth 
model 
 Model 1 Model 2 Model 3 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 5.45 (1.07)* 4.99 (1.07)* 3.42 (.919)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  .721 (.091)* .903 (.182)* 2.09 (.436)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑   -.130 (.043)* 
Residual (co) variance     
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with  
𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 
1.26 (.491)* -1.20 (1.86) 7.45 (3.76)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with 𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑   -.973 (.362)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑with 𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝   -.757 (.243)* 
Variance     
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 68.3 (14.5)* 71.8 (14.8)* 40.8 (11.2)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  .000 (.000) 1.68 (.438)* 8.63 (2.52)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑   .079 (.025)* 
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Figure 30. Estimates and sample means for substance use across entire study sample.  
 
Substance use: Treatment Effect on Substance use Using Time Invariant Predictor Model  
 As an initial step in determining the effect of MBRP on substance use over time, latent 
growth models with a time invariant treatment predictor were estimated. This model controlled 
for the number of days each participant spent at the inpatient facility, baseline substance use 
scores, and no community time. Table 25 presents results from the basic latent linear growth 
model for the effect of treatment on substance use during the post-treatment phase.  Results 
indicate a significant treatment effect on the linear (𝑏 = −3.28, 𝑆𝐸 =  .768, 𝑝 <  .001) and 
quadratic (𝑏 = .257, 𝑆𝐸 =  .080, 𝑝 <  .001) slope for substance use. Put differently, individuals 
assigned to MBRP had significant decreases in substance use over the study period compared to 
individuals assigned to TAU.  Figure 31 displays mean substance use scores for individuals 
assigned to MBRP and TAU. 
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Table 25. Treatment effects on latent substance use trajectories. 
 B SE P 95% CI 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 10.4 2.26 .000 5.98, 14.8 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  3.08 .984 .002 1.15, 5.00 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 -.255 .101 .011 -.452, -.057 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 on MBRP -6.34 1.73 .000 -9.72, -2.98 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 on MBRP -3.28 .768 .000 -4.79, -1.78 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 on MBRP .257 .080 .001 .101, .414 
Residual (co) variance      
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with  
𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 
.717 3.10 .817 -5.35, 6.79 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with 𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 -.437 .301 .147 -1.03, .154 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑with 𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 -.462 .172 .007 -.799, -.125 
Variance      
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 28.8 9.01 .001 11.2, 46.5 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  4.94 1.71 .005 1.50, 8.19 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 .056 .019 .003 .018, .093 
Fit Statistics      
   -2LL 4838.4    
   AIC 4882.4    
   BIC 4864.8    
   df  22    
   CFI .747    
  TLI .751    
   RMSEA .14    
   𝜒2 290.8    
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Figure 31. Mean substance use scores for individuals assigned to MBRP, TAU, and the total 
mean scores. 
 
Substance use: Treatment Effect on Substance use Using Multi-Group Modeling   
 While the prior models (e.g., time invariant predictor) indicate a significant effect for 
individuals assigned to the experimental group, these models cannot determine if the slopes are 
actually different for experimental and control groups. To test differences in slopes across 
randomized groups, a series of multi-group models were estimated. In particular, a taxonomy of 
models was estimated for the overall trajectory (e.g., post-treatment phases). Five separate 
models (Model 1 – Model 5) were estimated to determine invariance across groups (e.g., 
invariance model, means model, means and co-variances model, means, co-variances, and 
residual variances, and the final model). Model fit was estimated using LRT test. The final model 
(Model 5) employs any constraints needed based on LRT tests across the first four models. The 
MODEL TEST command was used to assess differences in substance use slopes across groups 
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(MRBP and TAU). Table 26 displays results of the multi-group model for substance use 
trajectories. There was significantly better model fit (𝛥 − 2𝐿𝐿 = 60.4, 𝛥 𝑑𝑓 = 3, 𝑝 <  .001) for 
Model 2 (means model) compared to Model 1 (invariance model) indicating are significant 
differences in average trajectories. The significant LRT results in Model 3 (𝛥 − 2𝐿𝐿 =
103.9, 𝛥 𝑑𝑓 = 6, 𝑝 <  .001) indicates significant between person variability and co-variability in 
the growth parameters. Finally, the significant LRT result in Model 4 (𝛥 − 2𝐿𝐿 = 90. ,8, 𝛥 𝑑𝑓 =
1, 𝑝 <  .001) indicates significant unexplained within person variability in substance use over 
time. Model 5 represents the final model, which is simply replicated from model 4 as all 
parameters were allowed to be freely estimated. Results indicate a non-significant linear increase 
in substance use for individuals assigned to MRBP (𝑏 = .406, 𝑆𝐸 =  .388, 𝑝 =  .295) and a non-
significant acceleration for the quadratic term (𝑏 = .003, 𝑆𝐸 =  .042, 𝑝 =  .945). Conversely, 
there was a significant linear increase in substance use for individuals assigned to TAU (𝑏 =
4.10, 𝑆𝐸 =  .784, 𝑝 <  .001) and a significant deceleration in substance use from the quadratic 
effect (𝑏 = −.292, 𝑆𝐸 =  .078, 𝑝 <  .001). Results from the Wald test of parameter constraints 
indicate a significant difference between groups for the linear slope (𝑊𝑎𝑙𝑑 𝜒2 = 17.8 , 𝑑𝑓 =
 1, 𝑝 <  .001) and quadratic slope (𝑊𝑎𝑙𝑑 𝜒2 = 11.0 , 𝑑𝑓 =  1, 𝑝 <  .001). Figure 32 displays 
means and estimated trajectories for substance use across individuals assigned to MRBP and 
TAU during the post-treatment phase.  
Mean differences across the three of the four selected time points (treatment completion, 
mid-point (3 months), and study completion (6-months)) were also assessed. Baseline was not 
assessed as it is used as a control variable in the growth models given the first two time points 
have zero variance and cannot be modeled. For substance use, significant mean differences were 
found across groups at treatment completion (𝑊𝑎𝑙𝑑 𝜒2 = 11.3 , 𝑑𝑓 =  1, 𝑝 <
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 .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −.81, 95% 𝐶𝐼 [−1.28,−.35]), mid-point (𝑊𝑎𝑙𝑑 𝜒2 = 11.2 , 𝑑𝑓 =  1, 𝑝 =
 .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −2.1, 95% 𝐶𝐼 [−2.7, −1.59]), and at study completion (𝑊𝑎𝑙𝑑 𝜒2 =
11.5 , 𝑑𝑓 =  1, 𝑝 =  .001;  𝐶𝑜ℎ𝑒𝑛′𝑠 𝑑 =  −1.80, 95% 𝐶𝐼 [−2.3, 1.27]). 
 
 
Figure 32. Substance use means and estimated trajectories for multi-group growth modeling  
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Table 26. Multi-group model parameters and standard errors for substance use trajectories by treatment assignment  
 Model 1 Model 2 Model 3 Model 4 Model 5 
MRBP      
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 3.42 (.919)* .604 (1.11) .538 (.667) .557 (.512) .557 (.512) 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  2.09 (.436)* .426 (.489) .357 (.502) .406 (.388) .406 (.388) 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 -.130 (.043)* -.002 (.050) .012 (.054) .003 (.042) .003 (.042) 
Residual (co) variance       
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with  
𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 
7.45 (3.76)* 1.20 (3.21) -5.85 (1.81)* -2.72 (1.07)* -2.72 (1.07)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with 𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 -.973 (.362)* -.529 (.313) .786 (.228)* .368 (.133)* .368 (.133)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑with 𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 -.757 (.243)* -.502 (184)* -.721 (.255)* -.428 (.042)* -.428 (.042)* 
Variance       
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 40.8 (11.2)* 31.3 (9.46)* 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  8.63 (2.52)* 5.27 (1.83)* 6.49 (2.33)* 3.87 (1.32)* 3.87 (1.32)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 .079 (025)* .061 (.020)* .081 (.029)* .050 (.017)* .050 (.017)* 
TAU      
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 3.42 (.919)* 7.03 (1.32)* 6.85 (.1.98)* 6.96 (1.98)* 6.96 (1.98)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  2.09 (.436)* 4.08 (.598)* 4.33 (.828)* .4.10 (784)* .4.10 (784)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 -.130 (.043)* -.295 (.063)* -.319 (.084)* -.292 (078)* -.292 (078)* 
Residual (co) variance       
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with  
𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 
7.45 (3.76)* 1.20 (3.21) 5.50 (10.3) .548 (9.94) .548 (9.94) 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡with 𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑 -.973 (.362)* -.529 (.313) -.908 (.964) -1.25 (.905) -1.25 (.905) 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑞𝑎𝑑with 𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝 -.757 (.243)* -.502 (184)* 1.34 (.588)* -.791 (.475) -.791 (.475) 
Variance       
   𝑆𝑢𝑏𝑈𝑠𝑒𝑖𝑛𝑡 40.8 (11.2)* 31.3 (9.46)* 102.9 (32.2)* 85.3 (32.8)* 85.3 (32.8)* 
   𝑆𝑢𝑏𝑈𝑠𝑒𝑠𝑙𝑝  8.63 (2.52)* 5.27 (1.83)* 15.4 (5.84)* 9.60 (5.00) 9.60 (5.00) 
𝑆𝑢𝑏𝑈𝑠𝑒 .079 (025)* .061 (.020)* .147 (.065)* .091 (.051) .091 (.051) 
Fit Indices       
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Table 26. (cont.)      
   -2LL 4911.6 4851.1 4747.2 4656.4  
   AIC 4931.6 4877.1 4783.2 4696.4  
   BIC 4955.1 4907.8 4825.6 4680.5  
   df 10 13 18 20  
𝛥𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟𝑠      
   𝛥 − 2𝐿𝐿  60.4 103.9 90.8  
   𝛥 𝑑𝑓  3 5 2  
LRT  .000 .000 .000  
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Substance use: Multi-Level Modeling  
 As a robustness check the effect of treatment on substance use was also assessed using a 
multi-level modeling framework. Unconditional growth models revealed an Intraclass 
Correlation of .561 indicating that 56% of the variance in substance use is retained in the 
between-person level and 44% at the within-person level. An LRT test was conducted to 
determine if a random slope was needed. Results indicate a significant reduction in -2 log 
likelihood (𝛥 − 2𝐿𝐿 = 94.6, 𝛥 𝑑𝑓 = 2, 𝑝 <  .001), indicating a random slope fits the data better 
than a model with a fixed slope. In the final model, treatment assignment, days in residential 
facility, and days not in the community were entered into the model. Results indicate a 
significant effect of treatment on the slope of substance use (𝑏 = −1.85, 𝑆𝐸 =  .365, 𝑝 < .001). 
This means individuals assigned to MBRP had significantly lower substance use over the study 
period compared to individuals assigned to TAU, thus replicating our latent growth model 
results. 
Substance Use: Survival Analysis 
 To assess relapse (e.g., time to first use after entering treatment) a survival model was 
estimated. Specifically, data were set up to assess time to first use following baseline assessment 
using a continuous time survival analysis. Three separate models were estimated: 1) time to use 
across all substances, 2) time to first alcohol or heavy drinking episode, and 3) time to first illicit 
drug use. The model controlled for baseline levels of use, number of days spent in the inpatient 
facility, and number of days each participant was not residing in the community. Figure 33 
displays the failure curves for time to first use across all substances, Figure 34 for alcohol or 
heavy/binge drinking, and Figure 35 illicit drug use. While both groups have increasing rates of 
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relapse over time, those assigned to TAU (compared to MRBP) have a much steeper incline in 
risk of relapse following baseline assessment. For example, failure trends were significantly 
different between those assigned to MRBP versus TAU based on the log-rank chi-square statistic 
for any substance use (𝑙𝑜𝑔 − 𝑟𝑎𝑛𝑘 𝜒2 = 23.9, 𝑑𝑓 = 1, 𝑝 < .001), alcohol or heavy/binge 
drinking (𝑙𝑜𝑔 − 𝑟𝑎𝑛𝑘 𝜒2 = 31.5, 𝑑𝑓 = 1, 𝑝 < .001), and illicit drug use (𝑙𝑜𝑔 − 𝑟𝑎𝑛𝑘 𝜒2 =
27.6, 𝑑𝑓 = 1, 𝑝 < .001). This trend was replicated in the multivariate Cox proportional hazard 
regression model. In particular, individuals assigned to MBRP had a 64% (Hazard Ratio = .351, 
95% CI[.190, .645]) decrease in the risk of relapse to drug or alcohol use, 54% (Hazard Ratio = 
.456, 95% CI[.235, .687]) decrease in the risk of relapse to alcohol or heavy (binge) drinking, 
and a 56% (Hazard Ratio = .436, 95% CI[.238, .797]) decrease in the risk of relapse to illicit 
drug use compared to individuals assigned to TAU.  
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Figure 33. Failure curves from survival analysis across all substances. MBRP = mindfulness 
based relapse prevention. TAU = treatment as usual 
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Figure 34. Failure curves from survival analysis for alcohol or binge drinking episode.  
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Figure 35. Failure curves for survival analysis for illicit drug use. 
Mediation Models 
To assess if reductions in stress mediated the association between treatment assignment 
(MBRP vs. TAU) and craving or substance use a series of models were estimated. First, a model 
based approach was used where the slopes for both stress and substance use or craving were 
estimated using latent growth models. Specifically, the exogenous variable for treatment 
assignment was regression both stress (a path) and substance use and craving (c path). Further, 
the stress slope was regressed on the slope for substance use and craving (b path). All intercepts 
were allowed to covary. The MODEL INDIRECT function was used to assess if there was a 
significant indirect effect from treatment assignment to the outcome of interest (e.g., substance 
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use or craving) through changes in stress.  Second, latent growth models were estimated for 
stress, substance use, and craving. Using the SAVEDATA command, the factor scores were 
saved and used in a bootstrapped mediation model (Preacher & Hayes, 2004). This method is 
parallel to a Sobel test (Hayes, 2009), but has the advantage of using bootstrapped confidence 
intervals. Models were estimated using standardized factor scores.  
 Table 27 presents results for the model based latent growth mediation model for craving 
and substance use. Results for craving indicate a significant indirect effect for stress between 
treatment assignment and craving (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.126, 𝑆𝐸 =
 .065, 95% 𝐶𝐼 [−.254,−.001]). Using the standardized results 
(𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑖𝑧𝑒𝑑 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.288, 𝑆𝐸 =  .146, 95% 𝐶𝐼 [−.537,−.003]) we can 
conclude that craving is expected to decrease by .28 standard deviations for individuals assigned 
to MBRP (compared to TAU) via decreases in stress. Figure 36 depicts the model based indirect 
effect for craving.  
Table 27. Model based approach for mediation  
 Model 1 
Craving 
Model 2 
Substance Use 
 Parameter 
(SE) 
p- 
value 
95% CI Parameter 
(SE) 
p-
value 
95% CI 
  A path -.422 (.193) .022 -.820, -.064 -.608 (.180) .001 -.961, -.256 
  B path .285 (.103) .006 .082, .487 1.28 (.409) .002 .480, 2.09 
  C’ path -.053 (.081) .510 -.212, .105 .314 (.338) .353 -.348, .967 
Total effect -.179 (.066) .007 -.309, -.050 -.467 (.398) .241 -1.24, .313 
Indirect effect  -.126 (.065) .050 -.254, .001 -.780 (.340) .022 -1.45, -.114 
 
Results were replicated in the bootstrapped approach using extracted factor scores. Table 28 
displays parameter estimates and 95% confidence intervals for the bootstrapped approach. For 
craving, a significant indirect effect was found (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.560, 𝑆𝐸 =
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 .143, 95% 𝐶𝐼 [−.892,− .316]) indicating craving is expected to decrease by .56 standard 
deviations for individuals assigned to MBRP (versus TAU) via decreases in perceived stress. 
Figure 37 displays the bootstrapped mediation model. Results for substance use revealed a  
Table 28. Bootstrapped factor score approach for mediation  
 Model 1 
Craving 
Model 2 
Substance Use 
 Parameter 
(SE) 
p- 
value 
95% CI Parameter 
(SE) 
p-
value 
95% CI 
  A path -1.07 (.189) .000 -1.43, -.717 -1.07 (.189) .000 -.143, -.717 
  B path .523 (.097) .000 .351, .740 .011 (.132) .933 -.239, .280 
  C’ path -.187 (.229) .415 -.621, .286 -.484 (.265) .067 -.994, .037 
Total effect -.746 (.223) .001 -1.14, -.299 -.496 (.227) .029 -.943, -.064 
Indirect effect  -.560 (.143) .000 -.892, -.316 -.012 (.143) .933 -.343, .229 
 
Significant indirect effect (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.780, 𝑆𝐸 =  .340, 95% 𝐶𝐼 [−1.45,− .113]). 
Using the standardized parameters (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.449, 𝑆𝐸 =
 .173, 95% 𝐶𝐼 [−.788,− .110]) this indicates that substance use is expected to decrease by .45 
standard deviations for individuals assigned to MRBP (versus TAU) via decreases in perceived 
stress (see Figure 38). These results were not replicated in the bootstrapped model (see Figure 
39) such that a non-significant indirect effect was found (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.012, 𝑆𝐸 =
 .143, 95% 𝐶𝐼 [−.343, .229]).  
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Figure 36. Model based latent growth mediation model for craving. Solid lines indicate significant path, dashed lines indicate non-
significant path. Parameter (Standard Error) estimates that are not bold are unstandardized, bold parameter estimates (Standard 
Error) are in standardized units. Not all time points are displayed for ease of reading – all 15 time points were estimated in the model.
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Figure 37. Factor score bootstrapped mediation model for craving. Solid lines indicate 
significant path, dashed lines indicate non-significant path. Parameter (Standard Error) 
estimates are in standardized units are factor scores were standardized prior to model 
estimation.  
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Figure 38. Model based latent growth mediation model for substance. Solid lines indicate significant path, dashed lines indicate non-
significant path. Parameter (Standard Error) estimates that are not bold are unstandardized, bold parameter estimates (Standard 
Error) are in standardized units. Not all time points are displayed for ease of reading – all 15 time points were estimated in the model.
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Figure 39. Factor score bootstrapped mediation model for substance use. Solid lines indicate 
significant path, dashed lines indicate non-significant path. Parameter (Standard Error) 
estimates are in standardized units are factor scores were standardized prior to model 
estimation. .  
 
 Given the preliminary results found above, that changes in stress act as a mechanism 
between treatment assignment and changes in substance use, several robustness checks were run. 
This was done because the mediation tested above ignores temporal order. That is, the 
measurement of stress, substance use, and craving are simultaneous making it difficult to 
determine if stress is actually a mechanism of change. Thus, additional models were run to assess 
the stability of stress as a mechanism.  
First, the mediator and outcome variables were switched such that changes in substance use and 
craving were the acting mechanisms and changes in stress the outcome. Second, the centering 
point was moved for stress as the mechanism to the end of treatment and the mid-point of the 
study. Third, a bilinear spline approach was taken such that stress was split into change during 
MBRP 
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the treatment phase and change during the post treatment phase. The knot point remains at the 
end of treatment (same modeling approach as the bilinear spline models above). The indirect 
effects of interest are the effect of treatment on changes in stress during the treatment phase (a 
path) and the effect of changes in stress during the treatment phase on changes in both substance 
use and craving during the post-treatment phase (b path).  
 Results for models where the mediator and outcome were switched can be found in Table 
29. When placing change in craving as the mediating construct, no evidence was found for an 
indirect effect between treatment assignment and changes in stress (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =
 −.163, 𝑆𝐸 =  .093, 95% 𝐶𝐼 [−.345, .020]). Similar results were found in the second model 
where changes in substance use was the mediating construct. That is, no indirect effect was 
found for substance use as the mechanism between treatment assignment and changes in stress 
(𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.012, 𝑆𝐸 =  .143, 95% 𝐶𝐼 [−.343, .229]). 
Table 29. Model based approach for mediation with substance use and craving as mediator 
 Model 1 
Craving Mediator 
Model 2 
Substance Use Mediator 
 Parameter 
(SE) 
p- 
value 
95% CI Parameter 
(SE) 
p-
value 
95% CI 
  A path -.179 (.060) .003 -.296, -.062 -.467 (.398) .241 -1.25, .331 
  B path .908 (.436) .038 .052, 1.76 .381 (.109) .000 .167, .595 
  C’ path -.279 (.145) .054 -.563, .005 -.431 (.197) .029 -.817, -.044 
Total effect -.442 (.144) .002 -.725, -.160 -.608 (.180) .001 -.817, -.293 
Indirect effect  -.163 (.093) .080 -.345, .020 -.178 (.172) .302 -.458, .134 
 
 As a second check, stress was placed as the mediating construct but the centering point (the 
zero point) was placed at the end of treatment and the mid-point of the study. Results from the 
indirect effect models can be found in Table 30. When stress was centered at the mid-point, 
evidence of an indirect effect between treatment assignment and substance use via stress 
142 
 
remained (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.529, 𝑆𝐸 =  .270 95% 𝐶𝐼 [1.066,−.008]). Looking at the 
standardized indirect effect (𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑖𝑧𝑒𝑑 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.219) individuals assigned to 
MBRP (versus TAU) are expected to reduce their substance use by .22 standard deviations via 
decreases in stress. When stress was centered at the end of treatment results were replicated such 
there was a significant indirect effect between treatment assignment and substance use via stress 
(𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.998, 𝑆𝐸 =  .355, 95% 𝐶𝐼 [−1.69, −.302]). Looking at the standardized 
indirect effect (𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑖𝑧𝑒𝑑 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.359) substance use is expected to decrease 
by .36 standard deviations via decreases in stress during the treatment phase for individuals 
assigned to MBRP versus TAU.  
Table 30. Indirect effects for variations in centering slope of stress for substance use outcome 
 Model 1 
End of treatment 
 
Model 2 
Mid-point of study 
 
 Parameter 
(SE) 
p- 
value 
95% CI Parameter 
(SE) 
p-
value 
95% CI 
  A path -.947 (.187) .000 -1.31, -.581 -.832 (.185) .000 -1.19, -.465 
  B path 1.05 (.304) .001 .459 1.65 .636 (.291) .029 .065, 1.20 
  C’ path -.509 (.393) .195 -1.28, .261 -.758 (.368) .039 -1.48, -.037 
Total effect -1.51 (.336) .000 -.725, -.160 1.29 (.306) .000 -1.89, -.688 
Indirect effect  -.998 (.355) .005 -.345, .020 -.529 (.270) .049 -1.07, -.008 
 
Results were consistent for craving when assessing variations in the centering point for stress. 
Table 31 displays results for craving. When stress was centered at the mid-point, there remained 
evidence of an indirect effect between treatment assignment and craving use via stress 
(𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.166, 𝑆𝐸 =  .051 95% 𝐶𝐼 [−.267,−.066]). Looking at the standardized 
indirect effect (𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑖𝑧𝑒𝑑 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.540) individuals assigned to MBRP (versus 
TAU) are expected to reduce their craving use by .54 standard deviations via decreases in stress. 
When stress was centered at the end of treatment results were replicated such there was a 
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significant indirect effect between treatment assignment and substance use via stress 
(𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.151, 𝑆𝐸 =  .060 95% 𝐶𝐼 [−.268,−.064]).  Looking at the standardized 
indirect effect (𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑖𝑧𝑒𝑑 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  −.511) substance use is expected to decrease 
by .51 standard deviations via decreases in stress during the treatment phase for individuals 
assigned to MBRP versus TAU.  
Table 31. Indirect effects for variations in centering slope of stress for craving outcome 
 Model 1 
End of treatment 
 
Model 2 
Mid-point of study 
 
 Parameter 
(SE) 
p- 
value 
95% CI Parameter 
(SE) 
p-
value 
95% CI 
  A path -.868 (.168) .000 -1.20, -.539 -.830 (.186) .000 -1.20, -.464 
  B path .174 (.061) .004 .055, .292 .200 (.043) .000 .117, .284 
  C’ path .092 (.067) .195 -.038, .223 .074 (.052) .159 -.029, .177 
Total effect -.058 (.050) .224 -.156, -.040 -.092 (.049) .059 -.188, .003 
Indirect effect  -.151 (.060) .0012 -.268, -.034 -.166 (.051) .001 -.267, -.066 
 
 Results from the bilinear spline model, again, replicated prior mediation results. For 
substance use, there was a significant indirect effect for treatment assignment and changes in 
substance use. That is, for those assigned to MBRP changes in stress during the treatment phase 
fully mediated the association between treatment assignment and changes in substance use 
during the post-treatment phase (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  1.35, 𝑆𝐸 =  .585 95% 𝐶𝐼 [.206, 2.50]). 
For craving, there was a significant indirect effect for treatment assignment and changes in 
craving. That is, for those assigned to MBRP changes in stress during the treatment phase fully 
mediated the association between treatment assignment and changes in craving during the post-
treatment phase (𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 =  .676, 𝑆𝐸 =  .344 95% 𝐶𝐼 [.002, 1.35]). 
Mediated Moderation by Early Childhood Trauma  
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  There was no support for the fifth hypothesis (H5) across both substance use and craving. 
That is, no evidence was found for a moderated mediation by childhood trauma. Given the two 
models tested above assessed latent change over the course of the study, secondary set of models 
were estimated using the bilinear spline modeling approach. Similar to the additional models run 
for the mediation results, the same models were used here with the addition of the latent variable 
and latent variable interaction for childhood trauma. In both of the bilinear spline models, again, 
no evidence for moderated mediation existed for substance use (𝐵𝑙𝑎𝑡𝑒𝑛𝑡 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 = .597, 𝑆𝐸 =
 .600, 95% 𝐶𝐼 [−1.77, .578]) or craving (𝐵𝑙𝑎𝑡𝑒𝑛𝑡 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 = −.406, 𝑆𝐸 =
 .557, 95% 𝐶𝐼 [−1.50, .685]). 
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Chapter 4: Discussion  
 Emerging adults represent about 10% (30,474,600) of the population in the United States 
(U.S. Census Bureau, 2016). While only comprising a small subset of individuals in the United 
States, emerging adults have the highest prevalence rate of alcohol use (58.3%), binge drinking 
(39%), and illicit drug use (22.3%) compared to adolescents and young adults (NSDUH, 2015). 
Naturally, this high prevalence rate also corresponds to high treatment admissions (10.5%) for 
substance use disorders (NSDUH, 2016). Not surprisingly, trajectories of lifetime use and misuse 
peak in emerging adulthood, to 49% among 19 – and 20- year-olds and 72% by age 27 
(Johnston, O’Malley, Bachman, & Schulenberg, 2013; SAMHSA, 2015). Prior research has 
identified a myriad of risk factors associated with substance use and substance problems. For 
example, Stone and colleagues (2012) found that most of the risk factors in the adolescent 
substance use literature also pertain to emerging adulthood. Other researchers have assessed 
predictors of treatment entry across adolescence and young adulthood. For example, Davis and 
colleagues (2016) found youth with a diagnosis of PTSD had a 67% increase in the risk of 
entering treatment across adolescence and emerging adulthood. Over the past several decades 
stress has been posited to be one of the most prominent risk factors for substance use. Given 
emerging adulthood is a period of life riddled with change, transitions, and decision making – it 
is primed to be one of the most stressful periods of life. This may be particularly true for 
emerging adults who have experienced early life traumas such as childhood physical abuse, 
neglect, and emotional abuse.  
Until recently, while emerging adults maintain the highest prevalence rate of substance 
use and substance related problems, few studies have focused on treatment outcomes among 
emerging adults (Davis, Smith, & Briley, 2017). This is particularly true for mindfulness based 
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interventions. In a recent meta-analysis investigating mindfulness interventions, only one study 
used an emerging adult population (Li et al., 2017), however this sample was comprised of 
college students. This is unfortunate as mindfulness based interventions have shown relatively 
strong effects for individuals with substance use disorders (Li et al., 2017). Further, mindfulness 
based interventions have been shown to influence both physiological and psychological stress (Li 
et al., 2017).  
 This randomized controlled trial represents the first study to investigate the effect of 
MBRP among a sample of emerging adults in residential substance use disorder treatment. 
Specifically, this study investigated the effect of MBRP on substance use, stress, and craving 
over a six month period. In line with recommendations from the Institute of Medicine, this trial 
also investigated treatment effects among at risk, or marginalized, emerging adults. For example, 
the median yearly salary among individuals in this study was $5,500 with the majority of 
participants reporting being unemployed (65%) and spending, on average, 40 days (out of the 
past 90) in jail prior to entering treatment. In addition to low income, participants in this sample 
also reported relatively high childhood trauma (average childhood trauma questionnaire score 
~50) and an average age of 6.5 when the abuse/trauma began. Needless to say, our sample 
clearly fits the definition of being marginalized and meets several criteria outlined by the IOM.  
Over the course of the study we found support for several of the proposed hypotheses. In 
particular, we found that assignment to MBRP (compared to TAU) was associated with lower 
rates of substance use (H1) during the post-treatment phase. Further, partial support was found 
for the second hypothesis (H2) such that individuals assigned to MBRP had significantly lower 
craving scores during the treatment phase, however no group differences were found during the 
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post-treatment phase (e.g., change trajectories) but significant differences were found at the level 
(e.g., mean differences across time at post treatment, midpoint of follow up, and end of follow 
up). In regards to the third hypothesis (H3) individuals assigned to MRBP had significantly 
lower stress trajectories during the treatment phase and post-treatment phase compared to 
individuals assigned to TAU. We found full support for our mediation hypotheses (H4) such that 
reductions in stress mediated the association between treatment assignment and both craving and 
substance use. Finally, no significant results were found for a moderated mediation (H5) by 
childhood trauma.  
Substance Use and Craving Main Effects 
 This is the first study to assess the effect of MBRP on substance use and craving 
outcomes in a high-risk sample of emerging adults. In line with the first hypothesis (H1) results 
from this study found evidence for significant reductions in substance use for individuals 
assigned to MBRP. In particular, emerging adults assigned to MBRP had significant decreases in 
substance use during the post-treatment phase. However, individuals assigned to TAU did show 
a significant slowing of acceleration in substance use (significant quadratic effect) indicating that 
given enough time (e.g., measuring substance use over a year) the two groups may become more 
similar in substance use outcomes. These results echo findings from a recent meta-analysis that 
found small effects (d = -.28) for mindfulness interventions on substance use [when compared to 
control conditions (e.g., TAU)] (Li et al., 2017). More importantly, given our sample was 
primarily illicit drug users (e.g., heroin and methamphetamine) our results also echo findings 
from Li and colleague’s (2016) which found a Cohen’s d of -.51 for mindfulness interventions in 
reducing opiate abuse. While results from the current study cannot be directly compared to prior 
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studies in terms of sample (e.g., marginalized emerging adults), results from the current study are 
parallel to previous studies investigating the effect of MBRP on substance use outcomes with 
adult populations. Taking results from the current study’s survival analysis, individuals assigned 
to MBRP had a 64% decrease in the risk for relapse across both alcohol and drug use (results 
also showed a 54% decrease in risk for relapse to alcohol or heavy alcohol use and 56% decrease 
in risk of relapse for illicit drug use). Bowen and colleagues (2014) found that, compared to 
individuals assigned to TAU, adults assigned to MBRP or Relapse Prevention had a 54% 
decrease in risk for relapse to drug use and a 59% decrease in risk for relapse to heavy alcohol 
use. However, when comparing individuals assigned to MRBP or Relapse Prevention, adults 
assigned to MRBP had a 21% increase in the risk for relapse to drug use. Participants from the 
Bowen and colleagues (2014) sample were primarily older adults (average age 38 years old) with 
an average of high school education. Further, participants in the Bowen study were primarily 
poly substance users (average 82.3%). Thus, while the current study investigated a younger 
population compared to Bowen and colleagues, from a demographic perspective the samples 
were relatively comparable.  Witkiewitz and colleagues (2014) assessed MBRP versus Relapse 
Prevention among a sample of female offenders in a residential treatment facility. While the 
Witkiewitz’s sample was all female offenders results indicated a 96% decrease in the risk for 
relapse for individuals assigned to MBRP compared to individuals assigned to Relapse 
Prevention. This estimate is much larger than the effect found in the current study (55% 
decrease). However, it was noted that a small proportion of participants actually relapsed during 
the follow up period (10%), thus these results may be biased due to a high frequency of 
abstainers. Further, Witkiewitz and colleagues were unable to track vital information regarding 
MBRP implementation such as number of sessions attended and participants were allowed to 
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switch treatment groups, making the study design relatively weak, compared to a randomized 
controlled trial.  
The current study results also follow prior studies investigating the relative efficacy of 
12-step/self-help meetings on substance use among emerging adults. For example, Davis and 
colleagues (2016) found that emerging adults in Project MATCH assigned to 12-step/self-help 
had significantly worse drinking and drug outcomes compared to emerging adults (and older 
adults) assigned to either Motivational Enhancement Therapy or Cognitive Behavioral Therapy. 
Given individuals in the current study that were assigned to TAU received 8 -12 additional hours 
of 12-step/self-help (e.g., alcoholics anonymous), our results are in line with conclusions drawn 
by Davis and colleagues (2014) that only receiving 12-step based help as a treatment may not be 
effective in reducing substance use among emerging adults.  
In line with our second hypothesis (H2), individuals assigned to MBRP had significantly 
lower craving scores during the treatment phase. However, while individuals assigned to MBRP 
still had lower craving scores during the post-treatment phase the group differences were no 
longer significant during the post-treatment phase. That is, simple slopes were not significantly 
different from each other, however when assessing mean differences across time differences did 
emerge at three critical time points: post-treatment, mid-follow up, and end of follow-up. Our 
results follow suit with prior studies investigating the effect of mindfulness based interventions 
on craving across a variety of samples. For example, Garland and colleagues (2016) found that 
individuals assigned to Mindfulness Oriented Recovery Enhancement (MORE) had significantly 
lower craving scores 10 weeks post-treatment compared to individuals assigned to Cognitive 
Behavioral Therapy. Further, Witkiewitz and colleagues (2010) reported significant effects on 
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craving for female offenders in residential substance use disorder treatment assigned to MBRP 
compared to female offenders assigned to Relapse Prevention only. Our results extend the 
literature in several ways. First, this is the first study to find effects of MBRP on long term 
craving scores for a sample of at-risk emerging adults. Second, our study assessed craving scores 
over a 6-month period of time every two weeks – thus we were better able to assess nuanced 
change in craving during the treatment phase and post-treatment phase. Third, our results also 
maintain clinical significance. For example, in the multi-group bilinear spline model significant 
within-person variability was found for craving over time. This translated to an overall decrease 
in craving for both groups (though significantly different for those assigned to MBRP) during the 
treatment phase and a significant increase in craving for individuals assigned to TAU and a 
relatively flat slope for craving for individuals assigned to MBRP during the post treatment 
phase. However, when assessing mean differences across the study (e.g., end of treatment, 
middle of post-treatment phase, and end of study) significant differences were found at all three 
time points, indicating MBRP is associated with mean decreases in craving during the post-
treatment phase. When looking at the standardized results assignment to MRBP was associated 
with a 38% decrease in craving during the treatment phase and a 23% decrease during the post-
treatment phase. These results are in line with a recent meta-analysis that found a significant 
effect (d = -.65) of mindfulness on craving outcomes across 42 studies.  
MBRP provides several modules throughout the 8 session curriculum to aid in dealing 
with craving or coping with craving symptomology. For example, participants are instructed to 
deconstruct their experience of craving (or negative thoughts) into both a cognitive and affective 
component. When their experience becomes too overwhelming (e.g., craving and negative 
thoughts become rumination) participants are instructed to return to the sensory experience of 
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noticing the breath. Mindfulness has been posited to be an effective way for individuals with 
substance use disorders to deal with craving (Brewer, Elwafi, & Davis, 2013).  It is thought that 
when individuals experience craving, the automatic reaction is to rid themselves of the sensations 
(e.g., emotional, physiological, psychological) associated with craving. However, mindfulness 
teaches individuals to sit with the uncomfortable feelings (both physical and psychological) 
associated with craving. The ability to sit with this uncomfortable sensation has been posited to 
do two things: first, it teaching individuals that cravings are physical sensations that happen 
within the body and not necessarily a moral imperative that must be acted upon immediately. 
Second, it allows individuals to experience, first hand, the impermanent nature of the sensation 
of craving. That is, the feelings and sensations will not last forever. This experience is directly 
replicated in session 2 of the MBRP curriculum in which participants are asked to sit with a 
difficult experience or memory and taught (during the meditation portion) that they are able to sit 
with uncomfortable and unpleasant experiences without reacting in a typical (e.g., using) way.  
Stress Main Effects  
 In line with the third hypothesis (H3) individuals assigned to MBRP had significantly 
lower stress scores during both the treatment phase and the post-treatment phase. In particular, 
when looking at the standardized effects individuals assigned to MBRP had a 62% decrease in 
stress during the treatment phase and a 35% decrease in stress during the post-treatment phase. 
Li and colleagues (2017) reported that reductions in stress had the largest effect size across all 
studies assessing effectiveness of mindfulness interventions for substance use disorders. 
Specifically, they found a Cohen’s d of -1.12 for stress indicating a large effect of mindfulness 
based interventions on stress.  
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 It is well known that prolonged or repeated exposure to stress can increase one’s health 
risks (Cohen et al., 2002; Cohen, Janicki-Deverts, & Miller, 2007; Flier, Underhill, & McEwen, 
1998). Given stress is one of the most well-known contributors to initiation and continuation of 
substance use (Sinha, 2008; Shonkoff & garner, 2012) – assessing how a treatment, mindfulness, 
that targets reduction in stress is vital for understanding recovery processes. The stress response 
system consists of two major components: 1) physiological stress response and 2) psychological 
stress response. From a physiological perspective stress response has been associated with a 
variety of neuroendocrine responses (e.g., cortisol production) and activation of neurological 
pathways associated with increased risk for drug use (Gordon, 2002). For example, in nonhuman 
primate studies high stress environments are associated with heightened corticotropin releasing 
factor (CRF) concentrations and lower cerebrospinal fluid (CSF) cortisol indicating a lack of 
feedback inhibition for the release of the stress hormone cortisol (see Andersen & Teicher, 2009 
for review). Similar results have been found in human studies which has been extensively 
reviewed by Sinha (2008), Shonkoff & Garner (2012) and Holzel and colleagues (2011).  
While the stress response system remains an important aspect in understanding addiction, 
stress is also a common denominator for psychological stress – which can make an individual 
more vulnerable to drug or alcohol use. Stress is typically consequent from events or 
environmental conditions and manifested by acute psychological reactions where individuals 
seek a mollifying escape from the event which is typically achieved through psychoactive 
substances. However, mindfulness has been posited to alleviate some of this psychological strain 
and aid in reductions in stress. For example, Creswell and colleagues (2014) found that exposure 
to a brief mindfulness intervention (compared to cognitive training) resulted in buffered self-
reported psychological stress reactivity and increased cortisol reactivity in a lab based stress test. 
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In general, when under stress our body activates an automatic or “auto pilot” response typically 
in the form of rumination, negative thoughts, assumptions about what will happen, and 
impulsivity (Esch, 2014). The MBRP curriculum has a strong focus on acknowledging when we 
enter ‘auto pilot’ and attempts to offer alternatives to remaining in this state. For example, one 
way MRBP may mitigate effects of stress is through the practice of reducing rumination and 
enhancing emotional regulation. Through practices such as the “SOBER breathing space” and 
allowing “thoughts to be thoughts” MBRP teaching individuals not to push negative thought 
processes aside (which can activate a stress response via neglecting internal emotionality), but to 
sit with the negative thoughts in a safe space. Prior research has shown mindfulness to enhance 
positive emotional regulation strategies, self-compassion, increase trait (or state) mindfulness, 
and decrease rumination and experiential avoidance (Chiesa et al., 2014). The current study 
provides further support for the effects of mindfulness based interventions on psychological 
stress.  
Mechanisms of Behavior Change 
In the past five years researchers have become interested in the potential mechanisms 
(both behavioral and physiological) that may aid in explaining the effect of mindfulness based 
interventions on substance use problems and related behaviors (e.g., craving; Witkiewitz et al., 
(2013)). Mindfulness based interventions have been associated with changes in brain structure 
and brain functioning.  Recent studies have found individuals assigned to mindfulness based 
interventions (compared to control) show significant increases in gray-matter in brain regions 
associated with learning and memory, emotional regulation, perspective taking, and impulsivity 
(Hölzel, Carmody et al., 2011), similar areas which drug and alcohol use inhibit. There seems to 
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be evidence that mindfulness works through neoplastic changes in brain areas (e.g. anterior 
cingulate cortex, insula, temporo-parietal junction, fronto-limbic network) associated with 
establishing a more enhanced self-regulation system (Hölzel et al., 2011). Because of this recent 
evidence, Witkiewitz et al. (2013) outlined several mechanisms though which MBRP may work, 
one being stress response systems such as the HPA axis (e.g., stress response system), in relation 
to craving and subsequent substance use. Two pathways have been proposed: 1) a “top down” 
approach in which individuals exhibit executive control over craving and stressful experiences 
(e.g., rumination from stress) and 2) a “bottom up” approach in which individuals actually 
change their subjective experiences of stress and craving (Westbrook et al., 2013; Witkiewitz et 
al., 2013). Prior research has found that greater mindful acceptance and nonjudgement partially 
explained differences in craving and negative affect affecting substance use for individuals 
assigned to MBRP versus Relapse Prevention (Witkiewitz & Bowen, 2010). Thus, prior research 
has shown support for the utility of mindfulness based interventions (specifically MBRP) to aid 
participants in reducing initial reactivity to negative or stressful experiences (e.g., thoughts, 
direct experience) - indicating a potential “top down” conditioned response. Results from the 
current study provide further support for this top down hypothesis. Specifically, we found full 
support for the fourth hypothesis (H4) such that reductions in stress mediated the association 
between treatment assignment and craving and substance use. These results support the notion 
that reducing one’s stress can act as an important mechanism in the recovery loop. 
Similar pathways have been proposed for stress experience and exposure. Sinha (2001) 
proposed a model in which maladaptive stress response (e.g. higher or lower 
reactivity/sensitivity to stress followed by slow recovery to baseline stress levels) mediate the 
increased frequency and chronic drug use among vulnerable individuals after exposure to a 
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stressful situation. For example, in a review by Sinha (2008) several have found that lab based 
stress induction is associated with increased craving (or desire to use; Chaplin, Hong, Bergquist, 
& Sinha, 2008; Fox, Bergquist, Hong, & Sinha, 2007; Hyman, Fox, Hong, Doebrick, & Sinha, 
2007; Sinha, Easton, Renee‐Aubin, & Carroll, 2003), salivary cortisol, and heart rate variability 
(both are known proxy’s for stress; Sinha, 2003). Others have found that among recently 
abstinent drug users, brief exposure to stress and drug cures activated the HPA axis (increases in 
ACTH, cortisol and prolactin levels) – and interestingly, little evidence of return to baseline 
stress levels nearly 2 hours after the brief (5 min) stress exposure (Sinha, 2003). When 
comparing stress response and craving across treatment-engaged participants and a matched 
social drinking group – treatment-engaged participants had higher levels of emotional distress 
and physiological arousal (e.g., drug craving and stress) compared to controls (Fox, Hong, 
Siedlarz, & Sinha, 2008). In essence, one of the key constructs for individuals in substance use 
disorder treatment is the ability to appropriately assess stressful events or negative emotion 
states. That is, when an individual experiences an acute stressor and they have a dysfunctional 
stress response system – that maladaptation may mediate the relationship between treatment and 
subsequent substance use outcomes. By attempting to reduce stress among individuals in 
substance use disorder treatment we have shown this process can be reversed and actually lead to 
reduced long-term problem behaviors.  
Both of these proposed models indicate various ways in which the stress response system 
can be activated and regulated. Findings from the current study indicate that mindfulness, 
specifically MBRP, significantly reduced the stress response which ultimately led to reduced 
craving and days of alcohol and drug use over a six month period.  
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MBRP teaches individuals to practice acceptance (accepting their current craving as just 
craving), being nonjudgmental (noncritical of themselves and craving), and changing the way 
they react to negative stimuli. While the current study is unable to determine any physiological 
effects– it is possible that reduced perceived stress is associated with changes in the stress 
response system. That is, it may be that the skills learned in MBRP influence neurological (HPA 
axis) aspects of the stress response systems which aid in reduced craving and return to use.  
Sinha and colleagues (2006) found that stress-induced cocaine craving during laboratory tests 
(e.g., prior to treatment entry) was predictive of shorter time to relapse after inpatient treatment. 
It may be that individuals assigned to MBRP have successfully mitigated the effects of 
dysregulated stress response systems thus leading to decreased desire (craving) and substance 
use. This falls in line with Witkiewitz et al., (2013) who hypothesized that long-term effects of 
MBRP may be observable through changes in physiological processes (e.g. alterations in stress 
response systems such as HPA axis) and perceived stress which may improve long-term 
treatment outcomes.  
Clinical Implications  
 Results from this study have specific clinical implications. In a recent meta-
analysis Davis and colleagues (2017) reported an average treatment effect of d = .17 for 
emerging adults in substance use disorder treatment in non-college settings. While this effect is 
in line with prior studies investigating the meta-analytic effects of interventions for college 
students, Davis and colleagues called for more research on emerging adults treated in non-
college settings, especially among ‘at risk’ or marginalized emerging adults. The current study 
fills this gap in the literature and provides evidence for long-term treatment effects using MBRP 
among a sample of marginalized emerging adults. In the current study treatment fidelity was 
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high and the clinicians had extensive training in mindfulness based interventions. Thus, 
clinicians wishing to implement MRBP or similar protocol may need extensive training to see 
similar results. While this may appear to be a limitation – it implies that with correct training and 
implementation clinicians may see similar results. This would, however, include extensive 
supervision and, again, opens the door to future research on implementation and dissemination of 
MBRP in the context of treatment centers.  
One of the more meaningful clinical implications from this study is the effect MBRP has 
on stress. Results indicate that by reducing stress, clinicians can expect significant decreases in 
craving and substance use. Given the extensive literature on the negative effects of chronic stress 
on both behavioral and physiological outcomes – results from the current study are promising 
and provides a potential ‘entry point’ to reducing participants’ substance use and craving. This is 
important as many studies (including large scale intervention studies such as Project MATCH) 
have found treatments, in general, work to reduce substance use. Results from the current study 
indicate that by simply reducing one’s stress acts as a mechanism between reductions in craving 
and substance use. Extrapolating these results open future research to explore dynamic processes 
involved within the treatment phase (e.g, does reductions in stress lead to reductions in craving 
during treatment) which may have implications for longer-term processes (e.g., substance use 
during the post-treatment phase).   
Further, while the MBRP curriculum does not directly address trauma or trauma 
symptoms, the current study provides marginal support for utilizing MBRP among samples with 
relatively high rates of past trauma. That is, we did not find evidence of a moderated mediated 
indirect effect for early childhood trauma, likely due to low power. Probing that interaction, it 
did show that for individuals in MBRP (compared to TAU) with high. Future research may wish 
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to investigate the effects of a trauma-informed MBRP to specifically address trauma, however it 
appears the current curriculum may be useful for emerging adults with or without a history of 
trauma. Prior research has found that a diagnosis of Post-traumatic stress disorder increases the 
risk of substance use disorder treatment entry by 67% (Davis et al., 2016). Earlier reviews have 
noted rates of victimization of 50% - 100% among individuals entering inpatient substance use 
disorder treatment (Najavits, Weiss, & Shaw, 1997). Others have noted that among individuals 
entering substance use disorder treatment nearly 25%-50% meet criteria for Post-traumatic stress 
disorder (Ellason, Ross, & Fuchs, 1996). While the current study did not asses post-traumatic 
stress disorder symptoms it is likely that these prevalence rates are similar in the current sample 
of emerging adults.  
In addition to being useful for trauma exposed clients, clinicians may also note that the 
current study found moderate to large treatment effects among a sample of polysubstance users. 
Specifically, 33% of participants were in treatment for heroin use and 25% for 
methamphetamine. The current study provides further evidence for clinicians treating emerging 
adults for illicit drug use. Unfortunately, the prevalence rate of co-occurring mental health 
diagnoses was not available given the treatment facility does not conduct mental health 
diagnostic interviews. However, future research and clinicians may wish to investigate the 
efficacy of MBRP among a sample of co-morbid emerging adults. Prior research has found 
mindfulness based interventions (MORE) to be effective in treating adults with co-morbid 
substance use and post-traumatic stress (Garland et al., 2016). However, more research is needed 
for samples of emerging adults.  
Limitations and Strengths 
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 Numerous limitations to the study warrant caution when interpreting results. First, the 
small sample size and attrition rates may have influenced the power to detect effects of interest. 
For example, while mean differences for craving existed at various time points across the post-
treatment phase, no significant differences in the slopes were found. Further, results for the 
moderated mediation were not powered to find an effect. Thus, with a larger sample size a more 
accurate estimate of how early childhood trauma influences treatment effects (e.g., stress, 
craving, substance use) may have been possible. Second, the present study was limited by a lack 
of biochemical measures of abstinence. While it would have been ideal to assess the effects of 
the intervention on drug and alcohol use using biochemical verification, this was not possible 
due to the population being studied. That is, biochemical analyses were conducted at random 
when individuals were at the residential facility (100% corroboration with self-report), however 
over 75% of the participants returned home after discharge to different communities than where 
the treatment facility was located. Prior studies have found that self-reported substance use is 
highly correlated with biochemical results and a reliable way to assess treatment effects (Chan, 
2009; Digiusto, Seres, Bibby, & Batey, 1996; Jain, 2004). Third, with respect to the study design 
the treatment facility provided ample opportunity for participants to share their treatment 
experience across conditions. While the program at the residential facility did provide some 
mindfulness based activities within the treatment program (e.g., yoga, mindfulness session 
separate from MBRP curriculum) we did ask each participant at each time point to indicate how 
often they practiced mindfulness in the past two weeks. Individuals assigned to MBRP reported 
significantly higher number of times practicing mindfulness during the treatment phase (t(51.3) = 
-2.31, p = .023). Further, participants assigned to MBRP were given explicit instructions not to 
share the material being learned in the MBRP sessions with their peers. No participant could 
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switch treatment assignments after randomization was completed. Related to this is our 
adaptation to the original manualized MBRP workbook. The original format is a closed group 
and 8, 2 hour sessions. We used a rolling admissions framework and only 1.5 hours per session. 
While the classes were shorter (given time constraints at the residential facility) no aspect of the 
curriculum was not completed. However, to address the different time constraints several of the 
modules were shortened (e.g., some meditations were shortened). Fourth, the examination of 
mediation may not lend itself to an actual temporal effect. For example, the indirect effect was 
assessing changes in stress and changes in substance use that were measures simultaneously 
(over time). While our post-hoc models did show consistent results with the mediation effect of 
stress, temporal order can only be established using lagged effects. Future research may wish to 
examine temporal lags (e.g., autoregressive latent trajectory (ALT) models, or latent change 
models). This would also allow researchers to examine within-person change process. The 
current study only assessed between person differences. Assessing within-person changes across 
treatment groups would allow for a better understanding of the cross lagged relationship 
between, say, stress and substance use over the study period.  
Finally, the current study may not be generalizable to other populations. The current sample 
consisted of emerging adults only entering a public not-for-profit residential substance use 
disorder treatment facility. The majority of participants were referred by the criminal justice 
system, had low education attainment, and high prevalence rate of early childhood trauma. Thus, 
results found here may only be generalizable to a similar sample of emerging adults and may not 
extend to adolescents or older adults.  
 While the current study had a number of limitations, it also had numerous strengths. First, 
this is the first randomized controlled trial investigating the effect of MBRP on multiple 
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outcomes among a sample of marginalized emerging adults. Successful recruitment of 79 
emerging adults entering residential care indicates that studying this population may not only be 
a possibility, but within the reach of most researchers. Further, retention rates were relatively 
high for this type of sample (average 82% retention). Given the transient nature of this 
population and the frequency of contact with the criminal justice system, retaining the large 
majority of participants throughout the 6-month study period is a major strength. Further, the 
current study controlled for a variety of factors that may influence treatment outcomes such as 
number of days participants stayed in the residential facility as well as how many days (at each 
time point) each participant was in jail or other facility. Finally, the current study used a 
continuous measurement approach to assess changes in stress, craving, and substance use over 
the study period. The current study assessed each participant 15 times over the study period with 
a total of 1,185 time points across the 79 participants. This is a strength as many researchers 
assess participants quarterly (3 month intervals) and potentially missing important changes in 
stress, craving, or other constructs that change based on experiencing an event.  
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Chapter 5: Conclusion 
 This is the first study to provide evidence and support for the use of MBRP among high 
risk, marginalized emerging adults in residential substance use disorder treatment. The current 
study showed modest, yet statistically significant therapeutic effects on factors that are integral to 
reducing relapse among a sample of individuals with low abstinence rates. Further, this study 
provided further support that MBRP can be used as an active treatment, and not just as an 
aftercare protocol. This is also the second study to investigate the use of MBRP using a rolling 
group admission processes (Witkiewitz et al., 2010) which is more likely to be disseminated in 
community based settings compared to the closed group format. This study also showed that 
MBRP is effective in reducing perceived stress during the treatment phase and – more 
importantly maintaining lower stress throughout the post-treatment phase. This study is the first 
to provide support for changes in stress as an active mechanism contributing to lower craving 
and substance use. Overall, this study suggests that MBRP is an appropriate and integrative 
therapy designed to reduce stress, negative emotion, and substance use among a sample of 
marginalized young adults.  
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Appendix A: Study Materials  
 
Are you: 
 
 
• 18-29 years old? 
• Interested in psychology? 
o Personality 
o Stress 
o Coping with stress 
o Mindfulness 
• Willing to be in a longitudinal Study? 
• Want to earn money by answering questions 
about personality, stress, and mindfulness? 
 
If you answered yes to all of these questions, you may be 
eligible to participate in a research project through the 
University of Illinois. 
Participants in this project will participate in a yearlong study 
and receive compensation for each follow-up. 
For more information or to enroll, please contact: 
Research Team 
(217) 333-4187 
jdavis37@illinois.edu 
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Demographics and Interest Sheet 
Thank you for expressing interest in our study! We are very excited about this research and are 
ready to answer any questions you might have. First, we want to get a little information about 
you. This information will be used to get to know you a little and keep in contact with you after 
you leave the Prairie Center. We will not share this information with anyone, the only people 
who will see it are our research staff. Simply place this filled out sheet into the locked cabinet 
labeled “University of Illinois”, and one of our research staff will meet with you in the next one 
to two days. Thanks again, we look forward to meeting you! 
 
Name: ________________________________________________________________________ 
  First                                Last  
 
 
Address: __________________________________________________________________________ 
 
                 ________________________________________________________________________ 
 
 
E-mail address: ___________________________________________ 
 
 
Home Phone number:  _______________________________ 
 
 
Cell Phone Number: ________________________________ 
 
 
Any medications? Yes  No   
If yes, what medications are you taking?  _______________________________________________ 
_________________________________________________________________________________ 
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Appendix B: IRB Letter 
 
 
 
 
 
 
 
Informed Consent 
Study Name: Impact of Mindfulness Based Relapse Prevention on Stress and 
Developmental Trends among Emerging Adults in Residential Substance Use Treatment 
 
Principle Investigator: Brent Roberts, PhD, Professor, Psychology 
Other Investigators:  Jordan Davis, MSW 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
You are eligible to be in a research study about developmental changes among people your age 
entering residential substance use treatment. That is, we want to find out what life is like for 
people your age after leaving treatment, including: whether personality changes, how stress 
changes over time, and how you feel you are progressing in adulthood. Whether or not you 
participate is entirely up to you, and the purpose of this consent is to help you make a decision 
about whether or not to participate. If you decide to participate, we will give you a copy of this 
form so you can go back to it later.  
HOW LONG WILL I BE IN THIS STUDY? 
If you agree to participate in this study, you will receive an initial assessment that will last 
approximately 1 hour.  In addition, we will meet with you or call you 2-3 times per month for 
much shorter (20-25 min) assessments for about one year. Your participation in this study is 
voluntary and you can decide to drop out at any time.  
WHAT WILL HAPPEN DURING THIS STUDY? 
If you decide to participate, we will ask you to do an initial assessment and several follow up 
assessments. The initial assessment will take place in person at the Prairie Center. All follow up 
assessments will take place in person or over the phone. If we are able to schedule a follow-up 
UNIVERSITY OF ILLINOIS  
AT URBANA-CHAMPAIGN 
DEPT. OF PSYCHOLOGY 
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assessment in person we will work with you to determine a safe, quiet, and private location. 
Typically locations such as our University office/lab or local libraries are used for in person 
follow-up assessments. In both cases, quiet and private rooms will be available for assessments 
to ensure confidentiality is not breeched.  We expect each of the follow up assessments to take 
approximately 20-25 minutes each.  During these assessments, we will ask you questions about 
your behaviors, including: your use of alcohol and drugs, your mental and physical health, your 
use of services for mental health or substance use problems, and illegal behaviors (i.e., substance 
use, money earned from illegal behaviors).  We will also ask you about your family and friends’ 
use of alcohol or drugs, personality, stress, ways of dealing with stress, and what stressful life 
events you have had.  A table has been provided for you at the end of this document that explains 
what will happen at each of the assessments/time points.  
We will help you to remember your follow up appointments by giving you reminder calls 
between each assessment.  We will also ask you to give us the names of up to three people and 
your consent to contact them in case we lose touch with you during the follow up period.  
We will audiotape your initial assessment to help us supervise our research team and make sure 
we have recorded your answers correctly.  Willingness to be audio recorded is not a requirement 
for participating in this study.    
It should be noted that you will be asked to sign separate consents for the collection of hair and 
blood samples (bottom of this document).  
If you are placed in a prison or jail setting we will still attempt to get follow up data on you. This 
will require a research staff member coordinating with prison or jail staff a safe and quiet place 
to conduct the assessment. You will still be compensated for your time at the regular rate of $5 
per follow up.  
It should be noted that you are able to remove yourself from the study at any time and your 
choice to remove yourself will not impact the treatment or services you will receive from the 
Prairie Center or any other agency.  
 BLOOD AND HAIR SAMPLING 
As part of our study we would like to collect hair and blood samples. The hair and blood that you 
provide us will allow our research team to investigate how stress impacts your life. Further, the 
blood samples will allow our research team to investigate genetic changes that occur as a result 
of stress. It should be noted participation in this study is completely voluntary and declining to 
give blood samples will not have an impact on the treatment you receive or your participation 
eligibility in our study. 
WHAT ARE THE BENEFITS OF THIS STUDY? 
Although we cannot be sure, you may benefit from participating in this study gaining a better 
understanding of psychological processes that are important to persons leaving substance use 
treatment. Also, you may gain a better understanding of your drug and alcohol use, stressors, and 
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ways you cope with stress.  Further, this study may help researchers improve treatments for 
young adults with alcohol and drug problems, which might make you feel good.   
WHAT ARE THE RISKS OF THIS STUDY? 
There may be some risks from participation, including: 
• Discomfort.  You may feel uncomfortable at times as you talk about sensitive topics in 
the treatment sessions, as well as during your follow up appointments. Discomfort may 
also occur during the collection of hair and blood samples.  
• Physical risks. You may experience physical risk during the collection of hair and blood. 
These risks are minimal and are not more than one would experience during a routine 
doctor visit.  
• Mandatory reporting/Duty to warn.  If you share information with us about child abuse 
or neglect, we must report this to proper authorities.  We are also required to report 
someone who may seriously injure themselves or others. 
• Confidentiality.  Although very unlikely, there is a chance that information that you 
provide in confidence will be shared with others or will allow you to be identified, or that 
others may attempt to access data or audio recording files that are transferred via the 
internet between treatment staff and research staff.   
 HOW WILL WE MINIMIZE THESE RISKS? 
It is important that you not disclose information from this study to other people in order to 
protect your privacy and your friend’s privacy.   
Identifying information like your name, contact information and birth date will not be attached to 
the information gathered. We are committed to keeping your participation in this study both safe 
and confidential.  However, it is possible that other people may become aware of your 
participation in this study. To keep this risk low we will keep your signed consent form and any 
other materials with your name on them in a locked file cabinet away from the forms with your 
answers to our questions (i.e., data collection forms).  Instead of putting your name on the data 
collection forms, we will put a made up number (i.e. code number) that allows only the 
researchers to identify your responses.  All audio recordings and answers to questions will be 
stored by your code number only, and they will be stored in a password protected computer 
network. Please remember that we will not tell your counselor, other members of the Prairie 
Center staff, or other residents any of your answers to the questions we ask you.  Finally, all of 
your biological material (e.g. blood and hair samples) will be given the same unique ID. All 
samples of blood will be stored in a locked deep freezer in the Psychology building. All hair 
samples will be stored in a locked cabinet in at the University of Illinois.  
We do not anticipate that you will experience any physical injuries as a result of participation in 
this study. However, during the course of hair and blood sampling you may become injured. 
Risks of hair and blood collection include potential cut (hair extraction), soreness or bruising 
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(blood collection). When taking hair and blood samples we do not believe this is any more risk 
than would be expected form a routine medical visit. Prairie Center staff are trained and 
equipped to deal with any issues that arise during the collection of hair and blood samples such 
as feeling uncomfortable or agitated from the act of giving blood or hair and involuntary 
triggering of drug use from the blood drawing. The University of Illinois does not provide 
medical or hospitalization insurance coverage for participants in this research study, nor will the 
University of Illinois provide compensation for any injury sustained as a result of participation in 
this research study, except as required by law.  
All information gathered in this study will be kept confidential.  We will not disclose your 
answers, blood, or hair test results to treatment providers, law enforcement agencies, or any 
others not listed on this sheet.  Furthermore, if we write a report on this study’s findings, the 
readers will not be able to identify you or your individual responses.  There are, however, two 
exceptions to confidentiality.  Researchers will voluntarily disclose your identity under the 
following situations: in the case of child abuse or if you are contemplating seriously injuring 
another individual or yourself (i.e., murder, suicide, serious attack). The only time your data will 
be used is to help researchers understand problems faced by persons your age. In order to further 
protect the confidentiality of your information research staff and anyone authorized to use the 
combined data set or review audio recordings must sign an agreement to respect your 
confidentiality by: 
 
a) agreeing never to try to figure out who you are 
b) not to report any information on you as an individual, and  
c) to abide by federal regulations that protect the privacy of your treatment records 
and their use in program evaluation and research (42 C.F.R., Part 2,  HIPAA).  
 
IS BEING IN THIS STUDY VOLUNTARY? 
Taking part in this study is completely voluntary.  If you decide not to participate in this 
developmental study, you may stop participating at any time and you won’t be penalized or lose 
any benefits for which you otherwise qualify.  You may decline to answer any question that you 
do not want to answer, and you may request that we turn off the tape recorder if there is 
something you would like to say without being taped.   
WHAT IF I HAVE QUESTIONS? 
Please contact Jordan Davis at (217) 333-4187 or jdavis37@illinois.edu with any questions or 
concerns about the research.  You may also call Jordan Davis if you feel you have been injured 
or harmed by this research.  If you have any questions about your rights as a participant in this 
study or any concerns or complaints, please contact the University of Illinois Institutional 
Review Board at (217) 333-2670 or via email at irb@illinois.edu.  
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?  
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It will not cost you anything to participate in this study.   
WILL I BE PAID FOR PARTICIPATING? 
If you choose to participate in this study, you will receive compensation. You will receive $5 for 
completing the initial assessment. You will also receive $10 per month if you complete both (2) 
monthly assessments. Finally, for every month you complete both assessments you will have an 
added chance of winning a lottery to be drawn every 6 months for a $100 gift card. The total 
cash compensation possible per person is $144. With the additional 2 lotteries the total cash 
compensation possible (if you win both lotteries) is $344.  The approximate odds of winning are 
1/35 for the first six months of the study, 1/70 for the second six months. Your odds, however, 
will go up or down based on how many assessments you complete. 
Information in this study will be presented at professional conferences and submitted for 
publication in scientific journals.  We may assign your quotation a fake name so people will not 
know it is you.  Again, your individual responses will not be identifiable.  Further, the audio 
recordings of your sessions will not be shared with anyone outside of the research team.   
 
GENERAL CONSENT 
Your signature below indicates: 
• I am 18 years of age or older. 
• I have read and understand the above consent form and voluntarily agree to participate in 
this study. 
• I understand my assessment will be audio recorded for quality assurance purposes.  
• I understand that I will be given a copy of this consent form for my records.   
 
____________________________________________  ____________________ 
Participant Signature      Date 
BLOOD CONSENT 
By signing this document:  
a) You will have given members of our research team permission draw blood samples 
b) You will give members of our research team permission to analyze blood samples  
c) You will give permission to use your blood samples in future analyses if funding is 
acquired. 
d) You understand that you may rescind consent to analyze your blood samples at any time. 
  
__ I hereby allow the research team to use blood samples for genetic testing and stress testing 
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__ I do not allow the research team to use blood samples for genetic testing and stress testing 
 
 
_____________________________________________ 
Participant Signature                                  Date 
 
HAIR CONSENT 
 
By signing this document:  
a) You will have given members of our research team permission collect hair samples. 
b) You will give members of our research team permission to analyze hair samples.  
c) You understand that you may rescind consent to analyze your hair samples at any time.  
 
__ I hereby allow the research team to use hair samples for stress testing 
__ I do not allow the research team to use hair samples for stress testing 
 
 
_____________________________________________ 
Participant  Signature                                  Date 
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Process and Procedures of Study Follow Ups 
 
 Intake Residential 
Stay 
Discharge Monthly 
Follow-up 
3,6,12 Month 
Follow-Up 
 
 Assessment
s:  
Initial 
assessment 
Assessments: 
Maximum of 
1 follow-up 
assessment 
per week 
 
Assessments:  
Final follow 
up 
assessment. 
 
Assessments:  
2-3 
assessments 
per month via 
telephone or 
in person  
 
Assessments:  
Same shorter 
follow up 
assessment 
plus hair 
samples 
collected 
 
 
Procedures 
Time:  
Approximat
ely 1-1.5 
hours 
 
Time:  
Approximatel
y 20-25 min 
Time:  
Approximatel
y 20-30 min 
 
Time:  
Approximatel
y 20-25 min 
 
Time:  
Approximatel
y 20-30 min 
 
 Measures:  
All 
 
Measures:  
Shorter subset 
 
Measures:  
Shorter subset  
 
Measures:  
Shorter subset  
 
Measures:  
Shorter subset  
 
 Biological 
Material 
Collection:  
Hair and 
Blood  
 
Biological 
Material 
Collection:  
None 
Biological 
Material 
Collection:  
Hair and 
Blood 
Biological 
Material 
Collection:  
See next 
panel 
Biological 
Material 
Collection:  
Hair samples 
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Appendix C: Class handouts  
Introduction to Mindfulness Handout 
 
What is mindfulness?  
Mindfulness is the ability to bring full awareness to the present moment. It means to be attentive and 
conscious about what's happening both around us and inside of us.  
What are mindfulness practices/exercises?  
Mindfulness practices involve different ways of practicing mindfulness and paying attention to what is 
happening in the present moment. Some practices are focused on noticing particular aspects of our 
experience such as inner experience (body sensations, thoughts, emotions) or things around us (sounds, 
sights, smells).  
Do I have to stop my thoughts?  
No, but that is a common misconception. People often think that meditating correctly means clearing all 
thought from the mind. We are not trying to stop or control our thoughts, we’re simply noticing them.  
Where should I practice mindfulness?  
You can practice mindfulness almost anywhere. One option is to set aside time to practice. It is ideal to 
create a supportive environment for practice, one that is comfortable, quiet and uncluttered. Another 
option is to practice throughout the day and do brief “on-the-go” practices. 
Is mindfulness a religion?  
No, mindfulness is not a system of beliefs. It is a practice that brings full awareness to the present 
moment.  
What position or posture should I be in when I practice mindfulness?  
Choose the position that works best for you. In choosing a position, it is important to think about what 
position will help you feel both comfortable and alert at the same time. Here are some common 
positions for meditation: 
Sitting in a chair: You can sit at the edge of the seat with your feet flat on the floor and with a straight, upright 
posture. You can also sit back in the chair to support your lower back with the option of placing a cushion or pillow 
behind your lower back. 
Lying on your back on the floor or on a cushioned surface: You can lie on your back with your feet flat on the floor 
and knees pointing towards the ceiling. Or you can lie on your back with the legs fully extended with the option of 
placing a pillow or cushion under your knees relieve any strain in the lower back. 
Sitting cross-legged on the floor: You can sit cross-legged on the floor with a rolled up blanket or towel or one or 
more cushions or pillows under your butt. Placing support under your butt lifts your hips above your knees and 
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support your upright sitting posture. If your knees are lifted high off the ground while sitting cross-legged, you can 
also place cushions under your knees to support them, so you can sit more comfortably. 
Kneeling on the floor: Another option for sitting on the floor is to sit on your knees with a pillow or cushion placed 
under your butt. Your feet can be on either side of the cushion. In a kneeling position, it is often helpful to have a 
soft surface under your knees for comfort. 
Standing: You can also meditate in an upright standing position with both feet firmly placed on the floor 
about hip’s width apart. 
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Mindful Check-In Handout 
The Mindful Check-In Practice involves setting aside a brief amount of time to check-in with yourself and 
notice what you are experiencing in that moment. The amount of time you take is up to you. For 
example you can take 1-2 minutes to do the practice or you can take 5-10 minutes, or more if you like. 
You can close your eyes, you can have your eyes half open and softly gaze at something in front of you, 
or you can have you eyes open. Whatever works for you. Here are the basic steps for doing the practice: 
Step 1: Check-in/notice what’s happening with your body 
 
• Notice sensations in your body in the present moment 
• You can notice where your body is touching the chair or cushion.  
• You can feel the weight of your body.  
• You can scan your body starting from the top of your head and slowly moving 
down noticing sensations in different parts of your body. 
  
Step 2: Check-in/notice thoughts 
 
• Notice thoughts you are having from moment to moment.  
• You can notice what’s going on in your mind. Is it busy with thoughts?  Are your 
thoughts fast or slow or somewhere in between.  
• No need to do anything special with your thoughts but just stepping back and 
noticing your own thoughts, almost like you are watching your own mind. 
 
Step 3: Check-in/notice emotions 
 
• Notice any emotions you may be experiencing or your overall mood. 
• Just acknowledging what you are feeling allowing any emotions to be present. 
 
Step 4: Anchoring attention on the breath 
 
• Gather your attention and shift your focus to your breathing. 
• Use your breath as an anchor for your attention. 
• Allow your attention to settle on the breath and simply notice sensations of the 
breath from moment to moment. 
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SOBER Breathing Space Handout 
 
This is an exercise that you can do almost anywhere, anytime because it is very brief and 
quite simple. It can be used in the midst of stressful situation, if you are upset about 
something, or when you are experiencing urges or impulses to engage in unwanted 
behavior. It can help you step out of “automatic pilot”, becoming less reactive, and more 
aware and mindful in your response. 
 
A way to help remember these steps is the acronym SOBER. 
 
• S – Stop. When you are in a stressful or risky situation, or even just random times 
throughout the day, remember to stop and do this exercise. This is the first step in 
stepping out of automatic pilot. 
 
• O– Observe. Observe the sensations that are happening in your body. Also 
observe any emotions, moods or thoughts you are having. Just notice as much as 
you can about your experience. 
 
• B – Breath. Allow your attention to settle on your breath. 
 
• E – Expand. Expand your awareness to include the rest of your body, to your 
experience, and to the situation, seeing if you can gently hold it all in awareness. 
 
• R – Respond. Respond (versus react) mindfully, with awareness of what is truly 
needed in the situation and how you can best take care of yourself. 
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MINDFULNESS BASED RELAPSE 
PREVENTION ADHERENCE AND 
COMPETENCE SCALE 
 
Adherence: MBRP Treatment Components 
Session One Check if Completed 
1. Introductions  
2. Expectations for group and rules 
for confidentiality and privacy 
 
3. Discussion of group structure and 
format 
 
4. Raisin exercise/discussion of 
automatic pilot 
 
5. What is mindfulness?  
6. Body scan practice  
7. Home practice for the week  
 
 
Adherence: Discussion of Key Concepts 
Key Concept  Behavior Counts 
1. Noticing/awareness of current 
experience: 
 
To what extent do therapists encourage 
noticing and being aware of 
present-moment experience? 
 
This includes pointing out and 
validating client behaviors, if the 
client is already paying attention to 
his/her experience (e.g., ‘‘So you 
noticed the thought that. . .’’; ‘‘So 
you noticed a judging thought’’; ‘‘So 
you noticed your mind wandering’’; 
‘‘Seems like you were aware of the 
craving’’), as well as encouraging 
client to pay attention to his/her 
 
 
 
____________________ 
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experience (e.g., ‘‘What would happen if you 
just tried to notice that as a thought?’’; 
‘‘Could you pay attention to the sensation?’’). 
2. Acceptance of current experience:  
 
To what extent do therapists encourage 
bringing curiosity and a nonjudgmental 
attitude to whatever arises in the present 
moment, regardless of whether it is 
pleasant, unpleasant, or neutral? 
 
For example, paying attention to the 
experience of sleepiness, 
restlessness, peacefulness, calm, 
anger, an itch, etc., with curiosity 
and nonjudgment: ‘‘Can you just 
notice what the experience of anger 
is like?’’; ‘‘What does an itch really 
feel like*Is it burning, is it hot, 
pulsing, throbbing?’’ 
 
 
 
____________________ 
3. Acceptance versus aversion: 
 
To what extent do therapists introduce 
the differences between relating to one’s 
experiences from a standpoint of 
acceptance as opposed to aversion? 
 
For example, allowing and being 
with difficult emotional and physical 
states instead of trying to get rid of 
them, fight them, fix them, or 
manipulate one’s experience in 
some way: ‘‘Can you just stay with 
the itch for a moment and get to 
know it before scratching it, or 
immediately getting rid of it and 
having to make it go away?’’ 
 
 
 
____________________ 
 
4. Acceptance and action: 
 
To what extent do therapists discuss the 
importance of stepping out of auto-pilot 
(pausing, taking a breathing space, 
evaluating one’s choices etc.) as a 
means of engaging in mindful action 
(responding vs. reacting, making 
 
 
 
 
 
____________________ 
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choices that are in one’s best interest), 
and/or to what extent do therapists 
describe the relationship between 
acceptance and skillful/mindful action? 
 
 
 
Competence: Therapist Style/Approach 
Inquiry Therapists’ ability to elicit and respond to 
both verbal and nonverbal feedback 
(this may be demonstrated through eliciting 
reactions to exercises, asking open questions, 
validating the clients’ experience and 
summarizing/making reflections). 
1 2  3  4  5 
     Low           High  
Attitude Therapists’ ability to model and embody the 
spirit of mindfulness (respond to participants 
in a way that is curious, focused in the 
present moment, and 
nonjudgmental/accepting of whatever 
participants bring up). 
1 2  3  4  5 
     Low           High 
Use of Key 
Questions 
The overall extent to which the therapists 
used key questions in eliciting discussion 
about exercises and home practice. 
(1) Highlighting the participant’s raw 
experience in the moment: What did you 
experience in this exercise? What body 
sensations did you experience during the 
exercise? Making a distinction between 
thoughts, feelings, and body sensations. 
(2) Distinguishing from typical way of 
experiencing things: How is this different 
from how you usually experience things? 
(3) Relationship to purpose of program: How 
does it relate to relapse? 
1 2  3  4  5 
     Low           High 
Clarifying 
Expectations  
The extent to which the therapist addresses 
and clarifies ideas and misconceptions 
about mindfulness meditation (e.g., ‘‘I’m not 
doing it right’’;’’ I’m just in a different 
zone when I practice’’; ‘‘This practice is 
great because it makes me feel so relaxed and 
blissful’’). 
1 2  3  4  5 
     Low           High 
 
 
 
216 
 
Competence: Overall Therapist Performance 
1. How would you rate the overall quality of the therapy in this session? 
           1                              2                             3                      4                  5 
Not Satisfactory          Mediocre           Satisfactory           Good          Excellent 
2. How would you rate the ability of the therapists to work as a team? 
           1                              2                             3                      4                  5 
Not Satisfactory          Mediocre           Satisfactory           Good          Excellent 
3. How would you rate the ability of the therapists to keep the session focused and on topic? 
           1                              2                             3                      4                  5 
Not Satisfactory          Mediocre           Satisfactory           Good          Excellent 
4. Please rate the overall quality of delivery of the meditation exercises. 
           1                              2                             3                      4                  5 
Not Satisfactory          Mediocre           Satisfactory           Good          Excellent 
*These items vary based of the content of each of the eight sessions. 
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Appendix D: Measures  
DEMOGRAPHICS  
 
1. Enter participant ID    ___________________ 
2. What is today’s date?   (MM/DD/YYYY)   ___________________ 
3. What is the Assessment Number?   _______________________ 
4. What Is your gender? 
a. Male 
b. Female 
c. Transgender (male to female) 
d. Transgender (female to male) 
5. What is your date of birth? (MM/DD/YYY)   ___________________ 
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6. How old are you today?   ______________________ 
 
7. Which race, ethnicities, nationalities or tribes best describe you? 
a. Alaskan native 
b. Asian 
c. African American/black 
d. Caucasian/white 
e. Hispanic, Latino, Chicano 
f. Native American 
g. Native Hawaiian 
h. Pacific islander 
i. Some other group _____ 
8. Which of the following best describes your current relationship status? 
a. Single 
b. Married 
c. Divorced 
d. In a serious relationship (boyfriend/girlfriend) 
9. How many children, if any, do you have? ______________ 
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10. Which of the following best describes your present school situation? 
a. IN a 4 year university full time? 
b. In a 4 year university part time 
c. In a 2 year college full time 
d. In a 2 year college part time 
e. Adult education (e.g. GED classes) 
f. Not in college /university 
11. What was the last grad you completed in school? (NOTE: use 12 for high school, 16 for 
BA/BS, and 17+ for graduate school years) 
_____________________  
12. What is your current job status? 
a. Employed full time, 35 hours per week 
b. Employed part time, less than 35 hours per week 
c. Unemployed 
13. How much do you earn per year from your job? _________________ 
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Substance Frequency 
The next questions deal with problems associated with drug and alcohol use. 
In the past 2 weeks how often have you experienced the following problems associated with 
alcohol and drug use? 
 
Substance  90 days  2 weeks  
  
 
Used any kind of alcohol    
Gotten drunk or had 5 or more 
drinks?   
  
Used marijuana, hashish, 
blunts, THC  
  
Used crack, smoked crack    
Used other forms of cocaine    
Used inhalants or huffed    
Used heroin (alone or mixed)    
Used nonprescription or street 
methadone?  
  
Used pain killers, opiates, or 
other analgesics?   
  
Uses PCP or angel dust    
Used acid, LSD, ketamine, 
mushrooms, or other 
hallucinogens  
  
Used anti-anxiety drugs or 
tranquilizers   
  
Used methamphetamine, 
crystal, ice glass, or other forms  
  
Used speed, uppers, 
amphetamines, ecstasy, 
MDMA, or other stimulant  
  
Used downers, sleeping pills, 
barbiturates or other sedatives  
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Used any other drug?    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
222 
 
Substance Problems Scale 
The next questions deal with problems associated with drug and alcohol use. 
In the past 2 weeks how often have you experienced the following problems 
associated with alcohol and drug use? 
1  2  3  4 
Never  Once  Twice  Multiple Times 
1. Get hurt of injured?  ________ 
2. Argue with friends and family? ________ 
3. Get into a physical fight? ________ 
4. Become physically sick or unable to take care of yourself? ________ 
5. Not used protection when you had sex? ________ 
6. Forget where you were or what you did? ________ 
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 CRS. Craving Scale  
(Mazza, 2011) 
The next questions are about the extent to which you currently crave alcohol or other 
drugs. 
 
Please answer the next questions using yes or no.  
Yes No 
CRS1. If I were using alcohol or other drugs, I would feel less nervous................ 1 0 
CRS2. I have an urge for alcohol or other drugs..................................................... 1 0 
CRS3. I crave alcohol or other drugs right now...................................................... 1 0 
CRS4. Using alcohol or other drugs would make things seem just perfect............ 
CRS5. I would not be able to control how much alcohol or other drugs I used if 
I 
1 0 
had some...................................................................................................... 1 0 
CRS6. Nothing would be better than using alcohol or other drugs right now........ 1 0 
CRS7. My desire for alcohol or other drugs seems overwhelming. 
....................... 
CRS8. I want to use alcohol or other drugs so badly that I can't think of anything 
1 0 
else............................................................................................................... 
CRS9. Right now, I want to use alcohol or other drugs so badly I can almost 
1 0 
taste 
it........................................................................................................... 
1 0 
CRS10.All I want to do is use alcohol or other 
drugs.............................................. 
1 0 
CRS11.I would do almost anything to use alcohol or other 
drugs........................... 
1 0 
CRS12.I am going to use alcohol or other drugs as soon as I possibly 
can............. 
1 0 
CRS13.It has been uncomfortable for me to answer these questions. 
..................... 1 0 
CRS14.Which substance were you thinking of most when you answered these 
questions? v.  
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 Never 
True  
Rarely 
True  
Sometimes 
True  
Often 
True  
Very  
Often  
True  
1. I didn’t have enough to eat. 1  2  3  4  5  
2. I knew there was someone to take 
care of me and protect me (R).  
1  2  3  4  5  
3. People in my family called me 
“stupid,” 
“lazy,” or “ugly.”  
1  2  3  4  5  
4. My parents were too drunk or high 
to take care of the family.  
1  2  3  4  5  
5. Someone in my family helped me 
feel important or special. (R)  
1  2  3  4  5  
6. I had to wear dirty clothes 1  2  3  4  5  
7. I felt loved. (R) 1  2  3  4  5  
8. I thought that my parents wished I 
had never been born.  
1  2  3  4  5  
9. Got hit so hard that I had to see a 
doctor or go to the hospital.  
1  2  3  4  5  
10. Family hit me so hard that it left 
me with bruises or marks.  
1  2  3  4  5  
11. I was punished with a 
belt/board/cord/other hard object  
1  2  3  4  5  
12. People in my family looked out 
for each other. (R)  
1  2  3  4  5  
13. People in my family said hurtful 
or insulting things to me  
1  2  3  4  5  
14. I believe that I was physically 
abused 
1  2  3  4  5  
15. Beaten so badly it was noticed by 
a Teacher/neighbor/doctor.  
1  2  3  4  5  
16. I felt that someone in my family 
hated me  
1  2  3  4  5  
17. People in my family felt close to 
each other. (R)  
1  2  3  4  5  
18. Someone tried to touch me in a 
sexual way/ Made me touch them.  
1  2  3  4  5  
19. Someone threatened me unless I 
did something sexual.  
1  2  3  4  5  
20. Someone tried to make me 
do/watch sexual things  
1  2  3  4  5  
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Perceived Stress Scale  
The questions in this scale ask you about your feelings and thoughts during the 
last month. In each case, you will be asked to indicate how often you felt or 
thought a certain way. Although some of the questions are similar, there are 
differences between them and you should treat each one as a separate question. 
The best approach is to answer each question fairly quickly. That is, don't try to 
count up the number of times you felt a particular way, but rather indicate the 
alternative that seems like a reasonable estimate.   
For each question choose from the following alternatives.  
 0  1  2  3  4  
 Never  Almost Never  Sometimes  Fairly Often  Very Often  
1. In the last month, how often have you been upset because of something 
that 
 happened unexpectedly?  ________  
2. In the last month, how often have you felt that you were unable to control 
the ________ important things in your life?  
3. In the last month, how often have you felt nervous and "stressed"?
 ________  
 4.a In the last month, how often have you dealt successfully with irritating 
life hassles?  ________    
 5.a  In the last month, how often have you felt that you were effectively 
coping with ________ important changes that were occurring in your life?  
6.a In the last month, how often have you felt confident about your ability to 
handle your personal problems   ________  
 7.a In the last month, how often have you felt that things were going your way?  ________  
21. Someone Molested me 1  2  3  4  5  
      
22. I believe that I was emotionally 
abused 
1  2  3  4  5  
23. There was someone to take me to 
the doctor if I needed it. (R).  
1  2  3  4  5  
24. I believe I was sexually abused 1  2  3  4  5  
25. My family was a source of 
strength and support. (R)  
1  2  3  4  5  
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8. In the last month, how often have you found that you could not cope with 
all the ________ things that you had to do?   
9.a In the last month, how often have you been able to control irritations in 
your life? ________    
 10.a In the last month, how often have you felt that you were on top of things   ________  
11. In the last month, how often have you been angered because of things 
that ________ happened that were outside of your control?  
12. In the last month, how often have you found yourself thinking about 
things that you have to accomplish?   ________   
13.a In the last month, how often have you been able to control the way you 
spend your time?     ________  
14. In the last month, how often have you felt difficulties were piling up so high that 
you could not overcome them?  _____ 
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Brief COPE 
These items deal with ways you've been coping with the stress in your life 
since you found out you were going to have to have this operation.  There are 
many ways to try to deal with problems.  These items ask what you've been 
doing to cope with this one.  Obviously, different people deal with things in 
different ways, but I'm interested in how you've tried to deal with it.  Each 
item says something about a particular way of coping.  I want to know to 
what extent you've been doing what the item says.  How much or how 
frequently.  Don't answer on the basis of whether it seems to be working or 
not—just whether or not you're doing it.  Use these response choices.  Try to 
rate each item separately in your mind from the others.  Make your answers 
as true FOR YOU as you can.   
1 = I haven't been doing this at all   
2 = I've been doing this a little bit   
3 = I've been doing this a medium amount  
4 = I've been doing this a lot   
1. I've been turning to work or other activities to take my mind off things. ______ 
2. I've been concentrating my efforts on doing something about the situation I'm in. 
______ 
3. I've been saying to myself "this isn't real.". ______ 
4. I've been using alcohol or other drugs to make myself feel better. ______ 
5. I've been getting emotional support from others. ______ 
6. I've been giving up trying to deal with it. ______ 
7. I've been taking action to try to make the situation better. ______ 
8. I've been refusing to believe that it has happened. ______ 
9. I've been saying things to let my unpleasant feelings escape. ______ 
10. I’ve been getting help and advice from other people. ______ 
11. I've been using alcohol or other drugs to help me get through it. ______ 
12. I've been trying to see it in a different light, to make it seem more positive. ______ 
13. I’ve been criticizing myself. ______ 
14. I've been trying to come up with a strategy about what to do. ______ 
15. I've been getting comfort and understanding from someone. ______ 
16. I've been giving up the attempt to cope. ______ 
17. I've been looking for something good in what is happening. ______ 
18. I've been making jokes about it. ______ 
19. I've been doing something to think about it less, such as going to movies, watching 
TV, reading, daydreaming, sleeping, or shopping. ______ 20. I've been accepting the 
reality of the fact that it has happened. 
228 
 
21. I've been expressing my negative feelings. ______ 
22. I've been trying to find comfort in my religion or spiritual beliefs. ______ 
23. I’ve been trying to get advice or help from other people about what to do. ______ 
24. I've been learning to live with it. ______ 
25. I've been thinking hard about what steps to take. ______ 
26. I’ve been blaming myself for things that happened. ______ 
27. I've been praying or meditating. ______ 
28. I've been making fun of the situation. ______ 
 
 
MAAS 
Instructions: Below is a collection of statements about your everyday experience.  
Using the 1-6 scale below, please indicate how frequently or infrequently you 
currently have each experience.  Please answer according to what really reflects 
your experience rather than what you think your experience should be. Please 
treat each item separately from every other item.  
 1 2 3 4 5 6 
 Almost  Very  Somewhat  Somewhat  Very  Almost  
 Always  Frequently  Frequently  Infrequently  Infrequently  Never  
I could be experiencing some emotion and not be 
conscious of  it until some time later.   1       2       3       4       5       6   
I break or spill things because of carelessness, not paying  
attention, or thinking of something else.  
1       2       3       4       5       6   
I find it difficult to stay focused on what’s happening in 
the  present.  
1       2       3       4       5       6   
I tend to walk quickly to get where I’m going without 
paying  attention to what I experience along the way.  
1       2       3       4       5       6   
I tend not to notice feelings of physical tension or 
discomfort  until they really grab my attention.  
1       2       3       4       5       6   
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I forget a person’s name almost as soon as I’ve been 
told it  for the first time.  
1       2       3       4       5       6   
It seems I am “running on automatic,” without much 
awareness  of what I’m doing.  
1       2       3       4       5       6   
I rush through activities without being really attentive to 
them.  
1       2       3       4       5       6   
I get so focused on the goal I want to achieve that I lose 
touch  with what I’m doing right now to get there.  
1       2       3       4       5       6   
I do jobs or tasks automatically, without being aware of 
what  I'm doing.  
1       2       3       4       5       6   
I find myself listening to someone with one ear, doing  
something else at the same time.  
1       2       3       4       5       6   
I drive places on ‘automatic pilot’ and then wonder why I 
went  there.   1       2       3       4       5       6   
I find myself preoccupied with the future or the past.  1       2       3       4       5       6   
I find myself doing things without paying attention.  1       2       3       4       5       6   
I snack without being aware that I’m eating.  1       2       3       4       5       6   
  
In the past 2 weeks how many times have you practiced any type of mindfulness 
activity?  
Enter number of times here ______________ 
